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Summary
Malaria is a vector-transmitted disease caused by unicellular parasites of the Plasmodium
species and resulted in over 400,000 deaths in 2015, most of them in African children below
the age of five. Plasmodium parasites are transmitted to a vertebrate intermediate host
during blood-meals of female Anopheles mosquitoes, the definitive host of the parasite.
Infections with P. falciparum are responsible for the severest form of malaria in hu-
mans, cerebral malaria (CM). CM is thought to be a multi-factorial process, where se-
questration of infected erythrocytes and immune cells in the cerebral microvasculature
and overwhelming pro-inflammatory immune responses result in severe cerebral damage.
Previous research using experimental models revealed that T cells that have been primed
in the spleens of infected individuals and migrated to the brain, play an important role in
the development of experimental CM. However, the exact mechanisms that lead to CM
in some cases of P. falciparum infection remain elusive.
Cross-presenting dendritic cells (DCs) have been shown to be the major cell subset
in priming cytotoxic CD8+ T cells during Plasmodium infection. Batf3-/- mice, which
genetically lack cross-presenting DCs, are completely protected from experimental CM.
We demonstrated here, that the protection was accompanied by reduced immune cell
migration to the brain and impaired cytotoxic T lymphocyte (CTL) responses in the
spleens of Batf3-/- mice after P. berghei ANKA-infection. Additionally, we found elevated
expression of immune regulating factors in these mice, which could further contribute to
the ECM-resistance in Batf3-/- mice.
In summary, these results underlined the importance of cross-presenting DCs in the
pathogenesis of ECM. Furthermore, they improved our understanding of the disease de-
i
SUMMARY
velopment by adding important details about the alterations in the immune responses
that result from the lack of cross-presenting DCs.
Another important question in understanding ECM pathology is how these immune
responses can be modified later in Plasmodium infection, before cerebral symptoms occur,
in order to prevent brain inflammation.
The lack of specific treatment of cerebral malaria and increasing drug resistance of Plas-
modium species requires new approaches to fight this disease. Here, we demonstrated that
the antibiotic doxycycline did not only reduce the parasitemia in P. berghei ANKA infected
mice but also generally dampened the pro-inflammatory milieu and antigen-specific cyto-
toxicity of immune cells in the spleens and brains of infected animals. Different approaches
in our experimental setup suggest that the reduced inflammation in doxycycline-treated
mice was not exclusively dependent on doxycycline’s anti-plasmodial effect. Thus, a com-
bined treatment of doxycycline, which is relatively well-tolerated with few side effects,
and another fast-acting anti-parasitic drug might offer a reasonable therapeutic option to
target parasite load and cerebral inflammation at the same time.
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Zusammenfassung
Malaria ist eine durch Vektoren u¨bertragene Krankheit, die allein im Jahr 2015 u¨ber
400.000 Leben gefordert hat; die meisten davon in Afrika bei Kindern unter fu¨nf Jahren.
Die Krankheit wird durch eine Infektion mit einzelligen Parasiten der Gattung Plasmod-
ium ausgelo¨st, die wa¨hrend der Blutmahlzeit ihres Endwirtes, der Anopheles Mu¨cke, auf
ein Wirbeltier als Zwischenwirt u¨bertragen werden.
Die schwerwiegendste Form der Malaria in Menschen ist die sogenannte zerebrale
Malaria (ZM), deren Ursache eine Infektion mit P. falciparum ist. ZM wird als eine
Krankheit mit multi-faktoriellen Ursachen angesehen, bei der sowohl die Sequestration
infizierter Erythrozyten und Immunzellen in den zerebralen Blutgefa¨ßen als auch eine
u¨berschießende Entzu¨ndungsreaktion zum Schaden im Gehirn beitragen.
Fru¨here Studien in Tierversuchen haben gezeigt, dass T Zellen, die nach einer Infektion
in der Milz aktiviert werden und dann ins Gehirn einwandern, eine wichtige Rolle in
der Entwicklung der experimentellen ZM einnehmen. Der genaue Mechanismus der in
manchen Fa¨llen der P. falciparum Infektion zur Entstehung von ZM fu¨hrt, konnte bisher
allerdings nicht vollsta¨ndig aufgekla¨rt werden.
Da Erythrozyten keine MHC Klasse I Moleku¨le exprimieren, u¨bernehmen sogenan-
nte kreuz-pra¨sentierende dendritische Zellen (DZs) das Priming von zytotoxischen CD8+
T Zellen in einer Plasmodium Infektion. Batf3-/- Ma¨use, denen kreuz-pra¨sentierende
DZs genetisch bedingt fehlen, sind vor der Entstehung von experimenteller zerebraler
Malaria (EZM) im Mausmodell vollsta¨ndig geschu¨tzt. Dieser Schutz vor EZM ging ein-
her mit einer deutlich eingeschra¨nkten Migration der Immunzellen ins Gehirn sowie einer
beeintra¨chtigten zytotoxischen T Zell (CTL) Immunantwort in der Milz der Plasmod-
ium berghei ANKA infizierten Batf3-/- Ma¨use. Zudem fanden wir in diesen Ma¨usen eine
iii
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erho¨hte Expression von immun-regulierenden Faktoren, die zusa¨tzlich zum Schutz vor
EZM beitragen ko¨nnten.
Zusammengefasst unterstreichen diese Ergebnisse die zentrale Bedeutung kreuz-pra¨sen-
tierender DZs in der Entwicklung von EZM in Ma¨usen und verbessern damit unser Ver-
sta¨ndnis des Krankheitsablaufes auf immunologischer Ebene und die vera¨nderten Immu-
nantworten, die durch das Fehlen dieser Zellen hervorgerufen werden.
Untersuchungen humaner Erkrankungen, wie ZM, in knock-out Ma¨usen lassen uns
A¨nderungen der Immunantwort charakterisieren, die durch das Fehlen einzelner Faktoren
hervorgerufen werden. Eine weitere wichtige Frage ist, ob die Immunantworten auch
im spa¨teren Krankheitsverlauf, kurz vor dem Auftreten neurologischer Symptome, noch
beeinflusst werden ko¨nnen.
Der Mangel an spezifischen Behandlungsmo¨glichkeiten der zerebralen Malaria und das
vermehrte Auftreten von Resistenzen der Plasmodien gegenu¨ber herko¨mmlichen Medika-
menten erfordert neue Lo¨sungen im Kampf gegen die Krankheit. Wir konnten zeigen,
dass eine Behandlung mit dem Antibiotikum Doxycyclin nicht nur die Parasita¨mie in
PbA-infizierten Ma¨usen verringerte, sondern auch insgesamt die Entzu¨ndungsreaktion
sowie vor allem die antigen-spezifische Zytotoxizita¨t der Immunzellen in Milz und Gehirn
verringerte. Mithilfe unterschiedlicher experimenteller Behandlungsansa¨tze konnten wir
zeigen, dass der Schutz vor EZM in Doxycyclin-behandelten Ma¨usen nicht nur auf den an-
tiparasita¨ren Effekt des Medikaments zuru¨ckzufu¨hren war, sondern ho¨chstwahrscheinlich
auch zum großen Teil auf dessen entzu¨ndungshemmende Eigenschaften.
Da Doxycyclin sehr gut vertragen wird und nur geringe Nebenwirkungen auftreten,
bietet die Behandlung mit Doxycyclin in Kombination mit einem weiteren, schneller wirk-
enden Medikament gegen die Plasmodien, eine Mo¨glichkeit bei Malaria-Patienten mit neu-
rologischen Symptomen gleichzeitig den Parasiten und die Entzu¨ndungsreaktion im Gehirn
zu beka¨mpfen.
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Chapter 1
Introduction
1.1 General introduction to Malaria
Malaria is a vector-transmitted disease that is known for over 4,000 years, but it took
several centuries before the actual parasite and the transmitting vector, the Anopheles
mosquito, were discovered in the late 19th century [Centers for Disease Control and Pre-
vention, 2016b]. Today we know, that human malaria can be caused by five different
unicellular Plasmodium species: P. falciparum, P. vivax, P. ovale, P. malariae and P.
knowlesi. These species share the general life cycle but lead to different clinical mani-
festations, that might progress to life-threatening complications such as severe anemia or
cerebral malaria. Malaria occurs in tropical and subtropical countries, mostly in Africa
and South-East Asia and currently half of the world population lives at risk of Plasmod-
ium infection. In 2015, 214 Mio. people were infected with Plasmodium parasites and
438,000 died from following complications; most of them being African children under the
age of five [WHO, 2016]. Despite enormous progress regarding prevention of fatality in
the last decade, with a drop of mortality rates of almost 47%, Plasmodium infection still
remains a big burden in tropical and sub-tropical countries [WHO, 2014]. Not only does
the tropical climate in these countries promote parasite replication within its definitive
host, the Anopheles mosquito, but also incomplete comprehension and limited availabil-
ity of convenient treatment options are important factors that make these countries more
vulnerable to the disease. Luckily, in most regions of the world, treatment for Plasmodium
infections is available today and malaria death’s have been decreasing constantly.
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Figure 1.1: Life cycle of Plasmodium spp. in humans and mosquitoes. Sporozoites of Plasmodium spp.
are injected into the human host during the blood meal of an infected female Anopheles mosquito. Thereafter the
parasite enters the liver through the blood stream and develops there before entering the erythrocytic cycle; in case
of P.vivax or P. ovale infection hypnozoites can form and remain in the liver before starting the blood stage cycle
at a later time point. The parasite further replicates in the red blood cells and finally forms gametocytes which
are taken up by Anopheles mosquitoes with their next blood meal. The Plasmodium gametocytes undergo sexual
reproduction in the mosquito and develop till they reach sporozoite stage in the salivary glands from where a new
cycle starts [Picture ©Johns Hopkins Bloomberg School of Public Health].
However, an unsolved problem is the development of cerebral malaria, that accounts
for almost all deaths after P. falciparum infection. Till today, neither the reason why
this disease form develops in only 1% of P. falciparum infections nor the mechanisms
responsible for disease progression are completely understood. An estimated 5 - 20%
of people who present themselves at hospitals with severe neurological symptoms like
convulsion or coma will still succumb to the disease despite immediate anti-plasmodial
treatment [de Souza et al., 2010]. Therefore, profound research is needed to understand
disease development and consequential prevent and treat cerebral malaria.
1.1.1 Plasmodium life cyle
The life cycle of all Plasmodium species (Fig. 1.1) starts when an infected female Anophe-
les mosquito takes a blood meal and transfers sporozoites from its salivary glands to a
vertebrate host. Here, sporozoites enter the blood stream and are transported to the liver
where they infect hepatocytes. During exo-erythrozytic schizogony, schizonts containing
thousands of merozoits are formed. In this clinically silent phase, the parasite replicates
for 6 - 30 days before single merozoites are released to the blood stream and start the ery-
throcytic cycle. In P. vivax and P. ovale infections, schizonts can develop into so-called
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hypnozoites which remain dormant in the liver for up to several years before they are
reactivated and enter the erythrocytic cycle.
In the blood stream, merozoites infect erythrocytes where they develop into tropho-
zoites and start the erythrocytic schizogony. Multiplication of parasites within erythro-
cytes finally leads to rupture of the cells and another release of merozoites that infect other
red blood cells and can either start another asexual replication or mature into gametocytes
of both sexes.
Gametocytes are then taken up by a female Anopheles during its next blood meal.
Sexual reproduction takes place in the mosquito gut when microgametes (male) penetrate
macrogametes (female) which leads to the formation of zygotes. In the midgut, the zygote
matures into an ookinete and then into an oocyst. In the oocyst, up to thousand sporozoits
develop which are released and then migrate into the salivary gland from where they can
start another infection cycle with the next blood meal [Centers for Disease Control and
Prevention, 2016a].
1.2 Pathogenesis of cerebral malaria
Infection with Plasmodium spp. can result in different clinical outcomes depending on the
parasite strain and several host factors like genetics or immunization status. In general,
clinical manifestations are divided into mild / uncomplicated and severe / complicated
malaria. Mild symptoms are the typical fever rhythms accompanied by phases of chill,
heat and sweating, headache and nausea. Complicated forms of malaria include severe
anemia, acute respiratory distress syndrome, multi organ failure and cerebral malaria.
Out of these, cerebral malaria is the most deadly form, which is caused almost solely by
infection with P. falciparum. Cerebral malaria develops in 1% of P. falciparum infection
and manifests with severe neurological symptoms like impaired consciousness, convulsion
and coma and leads to death within 48h after first symptoms occur, if not treated imme-
diately. However, even if treated at the onset of neuro-specific symptoms, only 80-90% of
the patients survive, some of them with life-long neurological limitations [de Souza et al.,
2010]. Interestingly, the disease outcome does not only depend on the parasite strain
but also host factors, as infection with the same parasite can cause a variety of disease
outcomes in humans. Today, many genetic factors are known to influence the disease
outcome, but still a huge knowledge gap remains regarding the question why some people
develop cerebral malaria or other severe outcomes and others do not. An answer to this
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question would help to establish diagnostic predictions on the disease outcome and there-
fore prevent fatal progression [Centers for Disease Control and Prevention, 2015].
Despite promising research, the mechanisms that lead to cerebral malaria in some P.
falciparum infections, is still a point of discussion. First observations in deceased patient
revealed a massive sequestration of infected erythrocytes in brain microvessels. These
findings led to the so-called ”sequestration theory” that suggests mechanical blockade
of brain microvasculature leading to a critical shortage of oxygen supply in the brain
and subsequent neurological deficits, causing death in the end. The ”cytokine theory”
is another common approach to explain development of cerebral malaria as a result of
an overreacting host immune response toward the parasite. Both theories have strong
arguments on their side and in the end, a combination of both approaches is very likely
[Hunt et al., 2006]. Due to ethical concerns, in-depth research is also relying animal
models, which allow more detailed analysis of all organs at different time points after
infection. Therefore, we will discuss the need and validity of mouse models before further
introduction to the sequestration and cytokine theory, with a focus on immune mechanisms
that might be involved in CM development.
1.2.1 Mouse models for malaria
Despite intensive research for several decades, the mechanisms that underlie the develop-
ment of CM are still unknown. Studies in humans are limited to non- or minimally invasive
procedures (e.g. analysis of blood or urine) or postmortem samples due to obvious ethical
reasons. Brain tissue from fatal cases of cerebral malaria has provided valuable insights
to the development of the disease in past and present studies, but these analyses also
have their limitations. Adequate controls from non-fatal cases of Plasmodium infection
or uninfected patients are difficult to access and analyses of postmortem tissue can reveal
misleading information due to physiological changes after death of the patient. These
issues limit the parameters that can be investigated in human CM, which emphasizes the
need for convenient research models [de Souza et al., 2010].
In the last decades, several animal models have been established for research of Plas-
modium infections. Next to non-human primate models and rat models, the murine models
are by far the most extensively investigated [Craig et al., 2012]. A good number of rodent
Plasmodium species are available for laboratory research and can be used to mimic differ-
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ent aspects of malaria development. Both, parasite and mouse strain influence the disease
outcome, which covers experimental forms of self-limiting, non-lethal models, models for
severe anemia, severe respiratory distress or cerebral malaria [Langhorne et al., 2002]. Ex-
perimental infections are mostly performed by intraperitoneal (i.p.) or intravenous (i.v.)
injection of parasitized red blood cells (pRBCs = infected RBCs (iRBC)), but can also be
performed by injection of sporozoites, extracted from salivary gland of infected Anopheles
mosquitoes or naturally by bites of infective mosquitoes.
Experimental cerebral malaria (ECM) is the most common and accepted experimen-
tal model for CM. Here, C57Bl/6 or CBA mice are infected (i.p. or i.v.) with RBCs
that are parasitized with P. berghei ANKA (PbA). This model mimics many features of
human CM like rapid and fatal disease development after first neuro-specific symptoms,
i.e. convulsion or coma, occur [de Souza et al., 2010]. Both, human and murine CM,
are accompanied by sequestration of blood vessels in the brain and cerebral inflamma-
tion. Besides numerous similarities, there are also distinct differences. While in human
CM the adherence of infected erythrocytes in the cerebral vasculature is a common fea-
ture, iRBC accumulation is less prominent in the mouse model. However, when comparing
ECM-inducing infection and non-ECM-infections, iRBC accumulation is only seen in mice
developing ECM [Baptista et al., 2010]. As a matter of limited samples and appropriate
controls, it is unclear whether parasite accumulation in human brains is necessary for CM
development [Clark and Cowden, 2003]. Another difference is the characteristic of the
cerebral inflammation. The rodent models of CM strongly support the relevance of an
intense inflammatory response in ECM, along with leukocyte sequestration in the brain
and an opening of the blood-brain barrier. In contrast, leukocyte adherence is less com-
mon in human postmortem brain tissues, but hemorrhages and BBB destruction in the
brain and signs of endothelial activation are also indicating cerebral inflammation [White
et al., 2010]. To overcome differences in human and murine Plasmodium infection, current
research is conducted to generate humanized mouse models [Vaughan et al., 2013].
In summary, mouse models provide a unique and useful way to investigate mechanisms
underlying CM development. We are able to gain valuable insights in the disease devel-
opment of ECM, that would not be possible in human studies. However, one always has
to be careful about how results from murine studies translate to the human disease.
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1.2.2 Sequestration theory in cerebral malaria
Finding sequestered iRBCs in cerebral blood vessels of patients that had died from cere-
bral malaria led to one of the first theories to explain the pathogenesis of the disease
[MacPherson et al., 1985]. Survival of the Plasmodium parasite in its intermediate host
is dependent on its ability to prevent recognition and removal of infected red blood cells
(iRBCs). Therefore, the parasite has developed different methods to circumvent detec-
tion. Sequestration of Plasmodium-infected erythrocytes to blood vessels is one method
for the parasite to impede transport to the spleen where abnormal blood cells are usu-
ally removed from the blood stream. Other methods are binding of iRBCs to uninfected
RBCs (rosetting) or platelets (clumping), which does not only hamper the recognition in
the spleen but also hides the infected cells from peripheral immune cells which would not
attack the agglutinated healthy cells. While sequestration, rosetting and clumping help
the parasite to survive, they harm the host by microvessel occlusion in the brain but also
other organs with high blood flow-through like lungs or kidneys.
Sequestration is directly caused by the parasite that induces the formation of knobs
on the RBC surface with expression of specific erythrocyte membrane proteins (EMPs).
Specifically, P. falciparum infection leads to expression of PfEMP-1 (P. falciparum EMP)
on knobs of infected erythrocytes which mediates their binding to host tissue via receptors
and adhesion molecules like CD36 or intracellular adhesion molecule-1 (ICAM-1) [Sherman
et al., 2003].
In most CM cases, sequestration of iRBCs in brain microvessels and the severity of the
disease correlate positively [MacPherson et al., 1985]. However, later studies have chal-
lenged the picture of sequestration being the sole mediator of CM: not all fatal CM cases
showed sequestration of iRBCs in their brains [Clark et al., 2003] and the proposed recep-
tors for PfEMP (CD36 and ICAM-1) have been shown to be dispensable on endothelial
cells in development of ECM [Sherman et al., 2003, Ramos et al., 2013].
Interestingly, the immunoglobulin (Ig) superfamily member ICAM-1 was shown to be
dispensable on endothelial cells, but its expression on leukocytes was needed for ECM
development in a mouse model [Ramos et al., 2013]. However, co-localization with iRBCs
and upregulated ICAM-1 levels in brains of CM patients suggest that this interaction
could as least exaggerate the course of disease [Sherman et al., 2003].
A combination of sequestration of iRBCs and a profound pro-inflammatory immune
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response in the brain is most likely the cause of pathology with endothelial activation being
a linking factor and both events further augmenting the other [Schofield and Grau, 2005].
For example, in vitro stimulation of murine endothelial cells with the pro-inflammatory
molecules IFNγ and TNF led to an increased expression of ICAM-1 and the cerebral se-
questration of iRBCs and also other immune cells, which initiates a local immune response
[Coisne et al., 2006, Schofield and Grau, 2005].
1.2.3 Cytokine theory and immune responses in cerebral malaria
Next to sequestration of parasites and peripheral lymphocytes in brains, inflammatory
responses in the periphery and brains of CM patients have come into focus. The patho-
genesis of CM is seen as a result caused by an overwhelming immune response that is
initiated for parasite elimination but accidentally damages the brain, rather than a direct
harm by the parasite [Clark et al., 2004]. The so-called cytokine theory was initiated by
Clark et al., due to numerous parallels between malaria and septic conditions i.e. strong
similarities of cytokine patterns. They also suggested parasite-induced nitric oxide (NO)
in addition to cytokine production as the final cause of cerebral symptoms and death in
CM [Clark and Rockett, 1994]. Rising cytokine levels in the blood after infection are often
correlated with severity of the disease and clear evidence for inflammation in the brain
was found in experimental models of CM [Day et al., 1999, de Kossodo and Grau, 1993]).
Finallay, a tightly regulated balance of pro-inflammatory and cytotoxic responses and
anti-inflammatory immune regulation does likely decides whether or not (E)CM develops.
Among the pro-inflammatory cytokines, tumor necrosis factor (TNF) was one of
the first mediators associated with fatal outcome during Plasmodium falciparum infection
[Grau et al., 1987]. TNF levels in serum of human and murine studies, correlated positively
with disease severity and were suggested as a diagnostic marker for disease progression
[Sahu et al., 2013, de Kossodo and Grau, 1993, Kinra and Dutta, 2013]. In vivo depletion of
TNF in usually ECM-susceptible mouse strains protected mice from disease development
and therefore provided more evidence for the importance of TNF in ECM [Grau et al.,
1987].
Interestingly, not only the quantity of TNF is determining the outcome of cerebral
malaria, but also the reactivity of endothelial cells to TNF was shown to be a crucial factor.
Upon in vitro simulation, cultured endothelial cells from brains of ECM-susceptible mice
7
CHAPTER 1. INTRODUCTION
expressed more ICAM-1 and produced higher amounts of IL-6 compared to cells derived
from ECM-resistant mice [Lou et al., 1998]. Similar results were found in cell cultures
from patients with or without CM [Wassmer et al., 2010].
Meanwhile, recent results rather favor a role for other members of the TNF family
and their receptors such as lympotoxin-α (LT-α) and LIGHT-lymphotoxin-β receptor
than for TNF [Togbe et al., 2008, Randall et al., 2008]. Also, the activity of cytotoxic
T cells including their capacity to produce powerful effector molecules such as IFNγ and
granzyme B, moved into the focus of ECM with help of the experimental models.
1.2.3.1 Cytotoxic effector immune responses in cerebral malaria
Cytotoxic T lymphocytes (CTLs) are crucial in ECM development, where they ac-
cumulate in brains of susceptible mice and contribute to the local tissue damage. Several
studies have shown the importance of CD8+ T cells by use of RAG deficient mice or by
depletion experiments that protected mice from ECM. Protection was still achieved when
anti-CD8+ antibodies were administered shortly before the onset of neurological symp-
toms [Re´nia et al., 2006, Belnoue et al., 2002].
Upon blood stage PbA infection, cells of the innate immune system engulf parasitized
red blood cells and induce an inflammatory response due to the presence of multiple innate
triggers (e.g. toll-like receptor ligands). Since infection Plasmodium spp. is an systemic
incident, the generation of adaptive immune responses takes place in the spleen, involving
splenic macrophages that preferably pick erythrocytes in order to recycle the iron as well
as dendritic cells, which finally prime the T lymphocytes. The involved processes have
been studied extensively during the last years and added valuable knowledge to the un-
derstanding of inflammatory immune responses during malaria.
Recognition of specific peptides that are presented on major histocompatibility com-
plex (MHC) class I molecules, which are expressed by all nucleated cells, and additional
co-stimulation initiates the activation of CD8+ T cells. In Plasmodium infection, T cells
first encounter parasite antigen in the spleens of infected individuals were they are primed
by cross-presenting dendritic cells (DCs) [Lundie et al., 2008]. This small subset of
DCs, which was formerly characterized by CD8 or Clec9A expression and more recently
by expression of XCR1 (CD141 in humans), is able to take up exogenous antigen and pro-
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cess it for presentation over MHC class I (= cross-presentation) in order to prime CD8+
T cells [Bachem et al., 2012]. As Plasmodium parasites infect erythrocytes, which lack a
nucleus and consistently do not express any MHC molecules, cross-presentation of antigen
by these specialized cross-presenting DCs is the only way to generate a CD8+ T cell re-
sponse against the parasite. Detailed studies showed that indeed, cross-presentation from
these DCs is required for CTL priming [Lundie et al., 2008] and consequently, depletion
of Clec9A+ DCs protected mice from ECM [Piva et al., 2012].
Upon activation, T cells migrate toward a chemokine gradient into the brain. Ac-
cumulation of CD8+ T cells in the brain is commonly seen in mice that develop ECM,
but was also found in brains of human CM patients. However research on that matter
in human patients is difficult due to limited samples and obvious ethical concerns [Hunt,
2003].
CCL5 (RANTES) binds to chemokine receptors CCR5, but also -1 and -3, on T
cells, and is one cytokine that is likely involved in T cell attraction to the brain. It is
released by many different cell types including T cells, platelets, endothelial cells and
also astrocytes and microglia [Murphy et al., 2008] and might also enhance inflammation
by activation of brain resident cells like endothelial cells, microglia and astrocytes [Sarfo
et al., 2004].
Studies in post-mortem samples from human CM patients and experimental analysis
of mouse models correlated increased expression of CCL5 in the brain with malaria [Sarfo
et al., 2004, Sarfo et al., 2005, Miu et al., 2008]. However, while upregulation of CCL5 and
its receptors were also found in a non-ECM model, CCR5 deficient mice are not suscepti-
ble to ECM, which could further verify the importance of the CCL5 / CCR5 axis in CM
[Belnoue et al., 2003a, Sarfo et al., 2005]. Possible triggers of CCL5 release include TNF,
which can induce CCL5 secretion and is associated with cerebral malaria [Chen et al.,
2011].
The development of ECM in mice is then strongly linked to ability of these activated
T cells to produce perforin and granzyme B, as mice deficient for one of these cyto-
toxic mediators are protected from ECM [Nitcheu et al., 2003, Haque et al., 2011] and
ECM-induction by adoptive transfer of CD8+ T cells was dependent on granzyme B and
perforin from antigen-specific CD8+ T cells, but independent from CD8+ T cell-derived
IFNγ [Haque et al., 2011]. Unfortunately, these findings have not been confirmed in hu-
man studies, as limitations in analysis and low numbers of T cells in brains of deceased
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patients impede detailed studies. Interestingly, it was shown that the blood-brain barrier
(BBB) breakdown is most likely T cell mediated in a perforin-dependent manner by al-
teration of tight-junction proteins but not through apoptosis [Suidan et al., 2008].
IFNγ is a well-known cytotoxic cytokine, that was associated with (E)CM in murine
and human studies [Rudin et al., 1997, Koch et al., 2002]. However, according to more
recent findings, IFNγ is more likely an activation marker for CD8+ T cells than an effector
molecule from these cells [Haque et al., 2011].
More importantly, IFNγ production by NK cells and Th1 CD4
+ T cells was shown
to initiate CD8+ T cell migration and accumulation in the brains of PbA-infected animals,
thereby contributing to ECM [Villegas-Mendez et al., 2012, Hansen et al., 2007, Belnoue
et al., 2008]. Both, NK cells and CD4+ T cells could also serve a role as cytotoxic effector
cells in CM, however, their role in CM, is less studied and an involvement of these cells
in ECM is not yet clear [Roetynck et al., 2006, Re´nia et al., 2006, Yan˜ez et al., 1996].
After reaching the brain, T cells need a second stimulus to be exert their cytotoxic
functions, most likely by cross-presentation from endothelial brain vessel cells [Howland
et al., 2013, Howland et al., 2015].
In Plasmodium infection, macrophages and later also brain residential microglia,
are associated with initiation of an inflammatory immune response in periphery and then
in the brain and therefore with the development of CM [Pais and Chatterjee, 2005].
Macrophages were shown to accumulate in brains of CM patients and, together with mi-
croglia, to cause pathophysiological alterations including release of cytokines (e.g. TNF,
IL-1β, IL-6), activation of endothelial tissue, attraction of more immune cells to the brain
and local T cell proliferation. These processes promote the blood-brain barrier break-
down and thus the fatal outcome of Plasmodium infection [Deininger et al., 2002, Pais
and Chatterjee, 2005].
Inflammatory monocytes and neutrophils are APCs that have been less stud-
ied in the context of CM. Neutrophils were long thought to be required for development
of cerebral malaria, as depletion with GR-1 antibodies prevented ECM development in
mice [Chen et al., 2000]. Based on newer observations, that GR-1 antibodies recognize
Ly6C and Ly6G isoforms, these findings were recently challenged by our lab: we found
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that only depletion of inflammatory monocytes with CCR2-antibodies, but not specific
depletion of neutrophils prevented ECM in C57Bl/6 mice by preventing immune cell accu-
mulation and inflammation in the brain [Schumak et al., 2015]. Furthermore, the ligand of
CCR2, CCL2, also known as monocyte chemo-attractant protein 1 (MCP-1), is released
from various immune cells and also neuronal cells to attract monocytes and macrophages
[Murphy et al., 2008, Banisadr et al., 2005]. CCL2 receptor CCR2 was found on CD8a+
cell, promoting their migration to the brain of PbA-infected mice, but ECM-susceptibility
was similar in WT and CCR2 knock-out mice [Belnoue et al., 2003a], which can be ex-
plained by development of compensating mechanisms and chemokine receptor redundancy.
Finally, interleukin 6 (IL-6) is considered as a link between innate and adaptive
immunity by regulation of T and B cell differentiation [Murphy et al., 2008]. Like CCL5,
the release of pro-inflammatory IL-6 can be mediated by TNF, which supports its role in
CM development [de Kossodo and Grau, 1993]. Importantly, IL-6 is multi-functional and
can also exhibit immune regulatory functions.
1.2.3.2 Immune regulation in malaria
In addition to ECM prevention by inhibition of pro-inflammatory immune responses as
discussed above, initiation of a regulatory immune response could also be beneficial for
survival after Plasmodium infection.
IL-10 is a typical anti-inflammatory cytokine that executes immune regulatory func-
tion by shifting Th1 to Th2 responses and inhibiting the release of IFNγ and TNF, which
are both associated with pro-inflammatory responses and promotion CM after Plasmod-
ium infection. The importance of IL-10 in immune regulation after Plasmodium infection
was elegantly shown in experimental models using ECM-resistant mice depleted from IL-
10 that consequently succumbed to ECM. Furthermore, application of recombinant IL-10
protected usually ECM-susceptible mice from disease development [Kossodo et al., 1997].
Interestingly, serum levels of IL-10 are generally higher in patients with severe and cere-
bral malaria when compared to uncomplicated malaria, but these levels decrease steadily
when death approaches [Day et al., 1999].
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CD4+ Tregs are known to be a major source of IL-10 in the context of immune regu-
lation. They are characterized by secretion of IL-4, -10 and TGF-β as well as expression
of CD25 and FoxP3. Murine studies showed that ECM-resistant mouse strains present
higher amounts of Tregs and IL-10 in their spleens compared to susceptible strains [Wu
et al., 2010]. In cases of cerebral malaria, the Th1 immune response is presumably too
strong to be effectively regulated by Tregs [Finney et al., 2010]
Data on Tregs in human cases of CM are currently not available, but their presence
is associated with a higher parasite burden as a result of down-regulated anti-parasitic
immune responses after Plasmodium infection which correlates with findings in murine
studies [Finney et al., 2010].
Next to Tregs, also other cells such as macrophages and B cells (Bregs) are possible
sources of IL-10. Current studies support IL-10 production by regulatory B cells (Bregs)
as a crucial factor in immune regulation of cerebral malaria [Liu et al., 2013]. Recently,
usually susceptible C57Bl/6 mice were protected from ECM by induction of alternatively
activated macrophages (AAMs) by administration of pro-Th2 cytokine IL-33 [Besnard
et al., 2015]. These results indicate the existence of several possibilities that might inter-
fere with an inflammatory outcome of PbA-infection.
While immune regulation is beneficial in malaria to prevent CM development, a pro-
found immune response is also needed to clear the parasite from the blood. In a usually
non-lethal malaria model, where C57Bl/6 mice were infected with P. chabaudi AS, IFNγ
knock-out mice showed decreased survival which was linked to increased parasitemia and
production of Th2 cytokine IL-10 [Su and Stevenson, 2000]. However, patients with se-
vere malaria anemia showed lower serum levels of IL-10 than uncomplicated or cerebral
malaria patients, which might be explained by increased CD8+ T cell-dependent erythro-
cyte clearance in the spleen [Kurtzhals et al., 1998, Safeukui et al., 2015]. These findings
support a role as a double-edged sword for the role of immune regulation in malaria which
needs careful balancing in order to fight the parasite without harming its host.
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1.3 Treatment of Plasmodium infection
Treatment of Plasmodium infection has to start as early as possible to prevent develop-
ment of a severe course of disease. Especially in suspected cases of cerebral malaria after
P. falciparum infection, immediate start of treatment is inevitable as this disease form is
100% lethal if not treated. To this day, the gold standard of diagnosis is microscopic ex-
amination of blood samples. Additionally, rapid diagnostic tests were develop to provide
an easy tool for rural areas were access to microscopes is limited. After diagnosis, the
Word Health Organization (WHO) recommends oral artemisinin-based combination ther-
apy (ACT) in uncomplicated cases of infections with all Plasmodium spp. or chloroquine
in non-resistant infections with in P. vivax, P. ovale, P. malariae or P. knowlesi. In severe
cases artesunate (an artemisinin derivate) can be given intravenous or intramuscular till
oral treatment is tolerated [WHO, 2015]. Next to these standard treatment regimens, ap-
propriate precautions have to be taken in special risk groups like pregnant women, small
infants or HIV-positive people.
All antiplasmodial treatment recommendations are based on the need of rapid parasite
clearance. While this is indisputable important, other aspects of disease are not consid-
ered. In cases of cerebral malaria lethality is still 5-20% after first neuro-specific symptoms
like convulsion are obvious and neurological longterm effects in surviving patients are a
huge burden. Targeting and preventing the neuropathology that underlies the disease
outcome might therefore be beneficial in all cases of P. falciparum infection, especially in
cases with manifested neuropathology.
1.3.1 Doxycycline treatment in malaria
Doxycycline (DOX) was originally developed as a broad-spectrum antibiotic from the
tetracycline group, which works by binding to the ribosomal 30S unit of bacteria.
Interestingly, doxycycline has also been shown to exhibit antiplasmodial activities in
vitro and in vivo [Budimulja et al., 1997, Batty et al., 2007] by acting on the apicoplast
genes in the parasite. However, impaired gene expression only shows effects in the next
generation of daughter parasites, which leads to a rather slow action of doxycycline that is
noticeable two days after treatment start [Dahl et al., 2006]. In previous WHO recommen-
dations, doxycycline was included as second-line treatment in combination with another
fast-acting anti-plasmodium drug and was also given intravenous in severe cases [WHO,
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2010]. However, the newest guidelines maintain doxycycline only as follow-up treatment
and possible prophylaxis for travelers [WHO, 2015].
Since its discovery in the 1960s, many additional properties of doxycycline and other
antibiotics in the tetracycline group have been examined. Drugs in this group have been
shown to inhibit matrix metalloproteinases (MMPs) directly via binding Zn2+ at the pro-
teases active site [Griffin et al., 2011], to regulate tight junctions [Wang et al., 2011]
and also different anti-inflammatory effects have been found: decline of T cell activation
(maybe Ca2+-mediated), modulation of mononuclear phagocytes and reduced microglia
activation, among others [Kloppenburg et al., 1995, Enose-Akahata et al., 2012, Giuliani
and Hader, 2005]. Those additional properties of doxycycline might be beneficial in treat-
ment of cerebral malaria, as the disease outcome is linked to strong neuro-inflammation.
While the original tetracycline is discussed to work less anti-inflammatory [Castro et al.,
2011], other derivatives like minocycline or tigecycline were shown to have similar prop-
erties as doxycycline and are also active against Plasmodium parasites [Griffin et al.,
2011, Starzengruber et al., 2009, Kast, 2008].
1.4 Aims and objectives
This thesis consists of two different projects, which aim at understanding immunological
mechanisms in the development of experimental cerebral malaria and in therapeutic in-
terventions after PbA-infection in mice with Bl/6 background.
First, we analyzed the changes in immune responses of Batf3-/- mice, that genetically
lack cross-presenting dendritic cells, towards infection with Plasmodium berghei ANKA
in comparison to wild type mice. Plasmodium parasites infect red blood cells, which lack
MHC class I molecules and can therefore not directly present antigen to CD8+ T cells.
This problem is compensated by presentation of antigen by specialized dendritic cells that
can digest external antigen and process it for presentation over MHC class I molecules, a
well-described mechanism called cross-presentation.
The lack of (cross-presenting) dendritic cells (genetically or by depletion), protects Bl/6
mice from developing ECM [DeWalick et al., 2007, Piva et al., 2012, Zhao et al., 2014].
Initial experiments from our lab confirmed that in contrast to PbA-infected C57Bl/6 WT
mice that develop severe cerebral symptoms, Batf3-/- mice were completely protected from
ECM, despite similar parasitemia in both groups of mice (Fig. 1.2A-C), ruling out that
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Figure 1.2: No ECM in PbA-infected Batf3-/- mice. A: Survival of WT Bl/6 mice (filled squares, n = 10)
and Batf3-/- mice (empty squares, n = 10) after infection with 5e4 iRBC i.v. till 20 dpi. B: Rapid murine coma
and behavior scale analysis for WT and Batf3-/- mice 6 days after PbA-infection (n = 6). Naive WT mice served
as control (n = 5). C: Parasitemia in infected WT and Batf3-/- mice 6 dpi (n = 4). D + E: d+6 PbA-infected
WT and Batf3-/- mice received an i.v. injection of Evans blue. When mice were sacrificed 1h later, brains were
photographed (D) and weighed before incubation in formamide for 48h in order to extract the dye that had leaked
into the brain. Naive WT mice were used as reference. The amount of dye in mice brains was read in an ELISA
reader and quantified with defined standard (E). The amount of Evans blue is calculated per mg of brain weight.
E: OVA S8L specific lysis in PbA-infected WT and Batf3-/- mice was measured 18h after S8L-labeled target and
control cells injection. Cytotoxicity was calculated by comparing the ratio of recovered target cells to control cells
in naive mice to experimental mice (n=3-4). Differences in survival were tested for significance with log-rank test.
Significance for RMCB scale and parasitemia was tested with Man-Whitney and t-test and with ANOVA with Tukey
correction for Evans Blue analysis and in vivo kill. p values below 0.05 were considered significant. (Unpublished
data set from Schumak et al.)
the protection was due to reduced parasitemia.
Absence of ECM correlated with a stable blood-brain barrier and impaired antigen-
specificity lytic capacity of splenic T cells in PbA-infected Batf3-/- mice on 6 dpi (Fig. 1.2D-
F).
Based on these findings from our lab, here we aimed to elucidate alterations of the
immune response due to the lack of cross-presenting DCs that might be responsible for
the protection of Batf3-/- mice.
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In this thesis the following questions were addressed:
1. Which differences can be observed in brains of ECM-positive WT mice and ECM-
negative Batf3-/- mice 6 days after P. berghei infection?
2. How does the composition of splenic immune effector cells and their activity differ
in Batf3-/- and WT mice at the time point of ECM onset in WT mice?
3. Are differences in the immune response between Batf3-/- and WT mice already
visible at an early time point of infection when infected mice do not yet show any
signs of ECM?
In the second part, we studied the effects of doxycycline, an antibiotic that has been
described to have anti-plasmodial and also anti-inflammatory properties, regarding the
immune response in mice infected with PbA. In previous observations that were part
of my diploma thesis, we found that mice treated with doxycycline from 4 dpi did not
develop cerebral malaria. However, we also observed a significant drop in parasitemia on
6 dpi which made it difficult to distinguish between direct anti-inflammatory properties
and diminished inflammation as a consequence of reduced parasitemia. This thesis aimed
to optimize the previous model in regard to this problem and to analyze the immune
response in doxycycline treated mice.
1. Can we establish a model where the anti-plasmodial effect of doxycycline is negligible
in the analysis of the immune response in treated mice after PbA-infection?
2. How do brains of doxycycline-treated mice differ in regard to infiltrated immune
cells and cytokine production?
3. Are anti-inflammatory effects of doxycycline treatment detectable in spleens of doxycycline-
treated mice?
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Material and Methods
2.1 Buffers and Materials
2.1.1 Anesthesia - short term
Isofluran (Abbott (Wiesbaden, Germany)) was given for inhalation.
2.1.2 Anesthesia - long term
10µl Rompun 2% (Bayer (Leverkusen, Germany)) + 40µl Ketamin 50mg/ml (Ratiopharm
GmbH (Ulm, Germany)) was given intramuscular.
2.1.3 Cell culture medium
RPMI medium (PAA Laboratories (Pasching, Austria)) for cell culture analysis of spleno-
cyte and brain cell suspensions was supplemented with 10% FCS (PAA), 100IU/ml peni-
cillin (PAA), 100µg/ml streptomycin (PAA) and 2mM L-glutamine (PAA).
IMDM medium (PAA) for culturing bone-marrow derived dendritic cells (BMDCs)
was supplemented with 10% FCS (fetal calf serum; PAA), 100IU/ml penicillin (PAA),
100µg/ml streptomycin (PAA), 2mM L-glutamine (PAA) and 0.2% (GM-CSF).
Media were stored at 4°C.
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2.1.4 CFSE stock
5,6-carboxy-succinimidyl-fluoresceine-ester (CFSE; Invitrogen (Darmstadt, Germamy))
was dissolved in DMSO (Merck KGaA (Darmstadt, Germany)) to 5mM and stored at
-20°C.
2.1.5 FACS buffer
PBS (PAA) was supplemented with 1% FCS and stored at 4°C.
2.1.6 FarRed stock
CellTrace Far Red DDAO-SE (short FarRed; Invitrogen (Darmstadt, Germamy)) was
dissolved in DMSO to 1mM and stored in aliquots at -20°C.
2.1.7 MACS buffer
PBS (PAA) was supplemented with 1% FCS and 2mM EDTA (Ethylendiamintetraacetate
dehydrate; Roth (Karlsruhe, Germany)) and stored at 4°C.
2.1.8 Machines
autoMACS® Pro Separator Miltenyi Biotec GmbH (Bergisch Gladbach, Germany)
BD FACS Canto I BD Biosciences (Heidelberg, Germany)
BD FACS Canto II BD Biosciences (Heidelberg, Germany)
BD LSRFortessa BD Biosciences (Heidelberg, Germany)
Rotorgene RG-3000, Corbett Research Qiagen (Hilden, Germany)
Spectra Max 340pc384m, Photometer Molecular Devices (Sunnyvale, USA)
2.1.9 Analysis software
BD FACS Diva flow cytometer BD Biosciences (Heidelberg, Germany)
FlowJo TreeStar Software (Ashland, USA)
Prism 5 GraphPad Software (La Jolla, USA)
Rotor-Gene 6.1, Corbett Research Qiagen (Hilden, Germany)
SoftMax® Pro 3.0 Pro Molecular Devices (Sunnyvale, USA)
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2.2 Methods
2.2.1 Mouse handling
Female C57Bl/6 mice (further referred to as WT mice) were purchased from Janvier (Le
Genest Saint Isle, France) or Charles River (Sulzfeld, Germany). Batf3-/- mice on C57
Bl/6 background (first described by Hildner et al. (2008) ) were kindly provided by
I.R. Dunay (Institut fu¨r Medizinische Mikrobiologie und Krankenhaushygiene, University
Hospital Magdeburg, Germany).
Animals were kept in our in-house animal facility under SPF (specific pathogen free)
conditions. Food and water was provided ad libitum.
All animal procedures were licensed by local regulatory agencies (Landesamt fu¨r Natur,
Umwelt und Verbraucherschutz Nordrhein-Westfalen (LANUV NRW) §84–02.04.2012.A264
and §84-02.04.2012.A295). All people working with the mice were holding a FELSA B cer-
tificate (Federation of Laboratory Animal Science Associations, category B) or equivalent
or were supervised by an appropriate person.
2.2.1.1 Infection of mice with Plasmodium berghei ANKA
C57 Bl/6 mice were infected with Plasmodium berghei ANKA (PbA) parasites. We used
two different PbA strains: the wild type Plasmodium berghei ANKA and a transgenic
PbA variant which is modified to express the model antigen ovalbumin (OVA) (kindly
provided by Ann-Kristin Mu¨ller (Heidelberg, Germany)). Both strains were compared
and no difference in the disease outcome was observed. For simplification, ”PbA” is used
throughout the document for both strains.
Infection with infected erythrocytes from stock mice Parasite stocks were pre-
pared from blood of sporozoite infected mice and stored, mixed with glycerin, in liquid
nitrogen. In order to obtain a uniformly infectious dose in vivo, 200-250µl of the parasite
stock was injected intraperitoneally (i.p.) into stock mice. After 4-5 days, parasitemia
was determined and the blood of these mice was diluted in PBS to reach the final injection
concentration. Experimental mice were infected with either 5e4 or 1e6 (as stated in the
text) infected red blood cells (iRBCs) in 200µl PBS intravenously (i.v.)
Infection with sporozoites isolated from infected mosquitoes Stock mice were
prepared as described above. On day 5 p.i., blood of these mice was stained with
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Giemsa and checked for the presence of gametocytes. Gametocyte-positive mice were
anesthetized with Rompun / Ketanest before they were shaved and placed on a net over
adult mosquitoes. Taken up gametocytes reproduced sexually in the mosquitoes and de-
veloped into sporozoites within 17 days. After this time mosquitoes were dissected and
salivary glands were extracted and crushed in PBS.Sporozoites were counted in a Neubauer
chamber and adjusted to a concentration of 5000 sporozoites / ml. 1000 sporozoites in
200µl PBS were injected i.v. into experimental animals.
Parasitemia was determined in all ex vivo experiments on the day of analysis to confirm
successful infection. In survival experiments blood smears were analyzed from 4-8 days
post infection (dpi).
2.2.1.2 Experimental cerebral malaria score and rapid murine coma and be-
havior scale for ECM surveillance
In our experimental conditions, WT mice usually started to display first signs of disease
from 6 dpi on. Therefore, mice were monitored from 5 dpi for symptoms of disease.
For this thesis, two different scoring schemes were used due to changing regulations
in between, ordered by the local regulatory agencies for animal health. The first scoring
system is a disease score (higher scores indicate sick mice) and was adapted from Amante
et al. [Amante et al., 2007]:
0 no symptoms
1 ruffled fur, hunching, wobbly gait or swollen eyes
2 two or more symptoms from 1 but agile moving
3 at least one symptom from 1 and reduced willingness to move
4 limb paralysis, rarely moving without exogenous stimuli
5 no controlled reaction to exogenous stimuli (e.g. convulsion after
touching), virtually no voluntary movement
6 coma (no reaction to exogenous stimuli)
In addition, convulsions, heavy weight loss or other abnormal behavior was noted. In this
scoring system a score of 4 or above is considered to be neuro specific.
The other scoring system is a health score (higher scores indicate healthy mice)
named ”Rapid Murine Coma and Behavior Scale” (RMCBS) for quantitative assessment
of murine cerebral malaria developed by Carroll et al. [Carroll et al., 2010]. The scoring is
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based on 10 different parameters (gait, balance, motor performance, body position, limb
strength, touch escape, pinna reflex, toe pinch, aggression, grooming), which are evaluated
with 0 to 2 points, with the latter being the optimal score of a healthy mouse. This system
gives a score between 0 (dead / coma) to 20 (completely healthy). Naive (uninfected) mice
usually reach a score between 18 and 20 points according to this system; mice under 10
are notably ill and mice with a score below 5 are severely ill.
Due to ethical reasons and in agreement with our license for animal testing mice were
killed when they reached a point of severe illness which was defined by either reaching a
score of 5 or higher in the ECM score or a score of 5 or below in the RMCBS. Mice with
a weight loss of more than 20% were also put down.
2.2.1.3 Determination of parasitemia
Parasitemia of Plasmodium infected mice was determined by Giemsa staining of thin blood
smears. Blood for analysis was collected from the tail vain and fixed with 100% methanol
on glass slides. After drying blood smears were stained in Giemsa solution (1:20 solution
adjusted to pH 7.2; Giemsa’s azur-eosin-methylene blue, Merck KGaA (Darmstadt, Ger-
many)) for approximately 15 minutes. A minimum of 800 red blood cells was counted
and infected and uninfected red blood cells were differentiated to calculate the percent
parasitemia (= (iRBC / all red blood cells)*100).
2.2.1.4 Administration of doxycycline
Doxycycline (DOX, Merck KGaA (Darmstadt, Germany)) was solved in PBS and injected
i.v. in a volume of 200µl into the tail veins. If not stated otherwise mice received 80mg/kg
bodyweight once daily from 4-6 dpi. Mice that were analyzed on 6 dpi did not receive
treatment on that day. The standard concentration of 80mg/kg/d was chosen according
to Prall et al. [Prall et al., 2002] who compared plasma level of doxycycline in mice and
human after oral administration and found that 200mg/d doxycycline in human resembles
50-100mg/kg/d given to mice in drinking water. 200mg/d is also the standard dose in
malaria treatment [Lalloo et al., 2007].
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2.2.1.5 Administration of BrdU and proliferation analysis
Bromodeoxyuridine (BrdU; BrdU Flow Kit, BD Biosciences (Heidelberg, Germany)) is
integrated in newly synthesized DNA instead of thymidine and therefore allows detec-
tion of proliferating cells by subsequent intracellular FACS staining of BrdU in mouse
organs. To obtain optimal results we chose to administer PBS-solved BrdU to living mice
once 2 days before analysis intraperitoneal (2.4 mg/mouse) and 1.5 and 0.5 days before
analysis per oral route (1.5 mg/mouse). The given amount was based on the provided
protocol from BD Biosciences (Heidelberg, Germany). On the day of analysis, the spleen
was removed from BrdU treated mice and single cell suspensions were stained for BrdU
detection according to the manufacturers protocol. Shortly, cells were first stained for
surface antibodies to distinguish between different cell populations. Cells were fixed and
permeabilized with the help of the provided buffers. Cells were then intracellularly stained
for BrdU and acquired on a flow cytometer.
2.2.1.6 Preparation of organs and plasma for analysis
Animals were anesthetized with long term anesthesia (Rompun + Ketamin) before proce-
dures. In order to eliminate cells from blood vessels within the organs, mice were perfused
with PBS for 5 min prior to organ removal, but after blood was collected. Organs were
prepared according to their further usage.
Preparation of organs for mRNA extraction Organs used for mRNA extraction
were immediately snap frozen in liquid nitrogen and stored at -80°C until further use.
Preparation of blood for serum and FACS analysis
Serum Blood was directly drawn from the heart of anesthetized mice and collected
in uncoated tubes. The blood was left at RT till clots formed and centrifuged at 8,000 rpm
for 10 min the next day. Serum was transferred to new tubes and directly used for analysis
or stored at -20°C.
FACS analysis Blood was drawn from anesthetized mice from the orbital vain prior
to perfusion and collected in EDTA coated collection tubes. In order to analyze the im-
mune cell subsets in the blood stream, blood was enriched for lymphocytes via ficoll
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gradient (Pancoll, Pan-Biotech (Aidenbach, Germany)) before staining with FACS anti-
bodies.
Preparation of brain for cell culture and FACS analysis Brains were cut into
small pieces and incubated in 0.05% collagenase A (Sigma-Aldrich (Munich, Germany))
for 30 min at 37°C on a shaker. Following this digestion, 10ml MACS buffer was added
to the brains in collagenase and the tissue was homogenized by a fine metal sieve. A
small section of the homogenate was kept on ice for primary cell culture, the rest was
centrifuged (1500rpm, 7min). The resulting pellet was taken up in 30% percoll (Sigma-
Aldrich (Munich, Germany)) and carefully underlayered with 70% percoll. Centrifugation
with 2000rpm for 20min at room temperature without brake led to an interphase between
the two percoll concentrations. This interphase, consisting of mainly lymphocytes and
microglia, was removed and washed with MACS buffer before further proceedings.
Preparation of liver for FACS analysis Liver was carefully cropped into small pieces
and incubated in 0.05% collagenase A (Sigma-Aldrich (Munich, Germany)) for 30 min at
37°C on a shaker. Following this digestion, 10ml MACS buffer was added and the tissue
was homogenized by a fine metal sieve. The homogenate was centrifuged (1500rpm, 7min)
and the resulting pellet was taken up in 40% percoll and carefully underlayered with 80%
percoll. Centrifugation with 2000rpm for 20min at room temperature without brake led
to an interphase between the two percoll concentrations. This interphase of lymphocytes,
was removed and washed with MACS buffer before further proceedings.
Preparation of spleen for cell culture and FACS analysis After removal spleens
were perfused with 0.05% collagenase A, cut into small pieces and were then incubated in
2-3ml collagenase solution at 37°C for 20 min on a shaker. After incubation approximately
10ml MACS buffer were added and a single cell suspension was generated by pushing the
spleen pieces through a fine metal sieve. Cells were washed with MACS buffer and taken
up in RPMI medium.
2.2.2 Cell culture preparation for cytokine analysis
Cell homogenates from spleen or brain were taken in a defined volume of RPMI cell culture
medium (PAA Laboratories (Pasching, Austria)) and cell concentration was determined by
counting cells with CASY® TT Cell Counter (Scha¨rfe Systems (Reutlingen, Germany)).
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After counting cells were adjusted to 1e6 cells/ml (spleen) and 1.25e6 cells/ml (brain),
respectively. 100µl of adjusted cells were plated in 96-well-plates (U-bottom, Greiner Bio-
One GmbH (Frickenhausen, Germany)) and incubated over night at 37°C / 5%CO2. To
test antigen specific immune responses, some cells were incubated with additional 1µM
OVA S8L peptide. Supernatans from cell culture were collected the next day and either
processed directly or frozen at -20°C.
2.2.3 Cell culture preparation for generation of bone-marrow derived
dendritic cells
Bone-marrow derived dendritic cells (BMDCs) were prepared by carefully flushing leg
bones of C57Bl/6 donor mice with PBS with the help of a small syringe. Cells were then
cultured in IMDM medium supplemented with GM-CSF in a petri dish for at least 6 days
before usage at 37°C / %CO2. Cells were splitted and medium was renewed once within
this time.
Cells were removed from petri dishes by incubation with 3ml 2mM EDTA for 4 minutes.
Remaining cells were carefully removed with the help of a cell scraper. All cells were
collected together, centrifuged and taken up in IMDM before further usage.
2.2.4 Cross-presentation assay for brain microvessels
The cross-presentation assay was kindly performed by Shanshan Wu Howland in the lab
of Laurent Re´nia according to their publication [Howland et al., 2013].
In short: microvessel fragments were isolated from experimental mice by mincing,
homogenization and followed by fractioning by 15% dextran gradient centrifugation. Pel-
leted Microvessels were retained on a 40 µm cell strainer and digested with collagenase
and DNaseI for 90 min. Microvessels were plated on to a filter plate and incubated with
NFAT-lacZ reporter cells (LR-BSL8.4 cells) that were transduced with a T cell recep-
tor (TCR) recognizing the SQLLNAKYL epitope. After 6h co-culture, interaction was
analyzed by β-galactosidase staining and blue spots were imaged and counted in an Im-
munoSpot Analyser.
2.2.5 Enzyme-linked immunosorbent assay (ELISA)
Sandwich ELISA were used to determine cytokine level in cell culture supernatants and
plasma. ELISA were purchased from eBioscience (Frankfurt am Main, Germany), R&D
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Systems (Minneapolis, USA) and BD Biosciences (Heidelberg, Germany) and performed
according to the manufacturers’ protocols.
Shortly: An unlabeled capture antibody (1st antibody) was incubated over night in a
high-binding 96-well-plate. After this incubation the plate was blocked for at least two
hours and samples and a defined standard for quantification was applied subsequently
for another over night incubation. On the next day the plate a biotinylated detection
antibody (2nd antibody) was added for 2 hours, followed by an incubation for 30 min with
an enzyme-linked secondary antibody that binds to the detection antibody. In the next
step tetramethylbenzidine (TMB) was used as a substrate and is converted to a colori-
metric signal by the antibody bound enzyme. The reaction was stopped by adding H2SO4
(Merck KGaA (Darmstadt, Germany)) and the optical density (OD) was measured with
a photometer at 450nm wavelength. The protein amount was calulated with the help of
a standard curve. Appropriate washing was done between the different steps.
Used antibodies and kits
Cytokine Company Kit
CCL5 R&D DuoSet
CCL2 R&D DuoSet
granzyme B R&D DuoSet
IFNγ eBioscience Ready-Set-Go!
IL-6 eBioscience Ready-Set-Go!
IL-10 BD Biosciences (Heidelberg, Germany)
TNF R&D DuoSet
ICAM-1 R&D DuoSet
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Buffers not included in kits
buffer composition for ELISA
Coating buffer PBS all DuoSets
0.1 M Na2HPO4 (Merck) IL-10
Working solution PBS + 1% BSA (PAA) all DuoSets,
IL-10
Enzyme solution Streptavidin-POD conjugate (Roche
(Mannheim, Germany))
all DuoSets,
IL-10
Substrat 0.1M Na2HPO4*H2O (pH 5.5) + 2% TMB
solution (60mg 3,3‘,5,5‘tetramethylbenzidine
Roth (Karlsruhe, Germany) in 10ml DMSO)
+ 0.02% H2O2
all DuoSets,
IL-10
Stop solution 2M H2SO4 all ELISA
Washing buffer 0.05% Tween20 (Sigma-Aldrich) in PBS
(pH 7.2)
all ELISA
2.2.6 Evans blue assay
To determine the integrity of the blood-brain barrier (BBB) we performed an Evans blue
assay. The Evans blue dye (Sigma-Aldrich (Munich, Germany)) binds to serum albumin
and is only able to cross the BBB when it is already damaged. The BBB destruction can
be directly observed by the color of the brain and can be further quantified by extraction
of the dye with formamide (Sigma-Aldrich).
For the assay 200µl of 2% Evans blue in 0.95% NaCl (natrium chloride; AppliChem
GmbH (Darmstadt, Germany)) was injected i.v. into mice. The dye was left circulating
with the blood in the animals for one hour before they were sacrificed and their brains
removed. Brains were photographed for documentation of visual assessment, weighed and
then transferred to 2ml formamide. Brains were incubated for 48h at 37°C on a shaker.
In this time the dye that had extravasated to the brain was extracted and the amount of
dye in the formamide solution could be quantified with a definied standard by reading in
an photometer at 620nm. Results were calculated as mg / g brain.
26
2.2. METHODS
2.2.7 Flow cytometric analysis
Flow cytometry (also fluorescence-activated cell sorting (FACS))was used to define the
different cell populations in blood, brain, liver and spleen of experimental animal and the
activation status of these cells.
For surface staining fluorescent labeled antibodies were diluted in FACS buffer and
incubated with single cell suspensions from the different organs for 20 minutes on ice.
Cells were washed with MACS buffer twice after staining and filtered before acquisition
on a LSRFortessaflow cytometer (BD Biosciences (Heidelberg, Germany)).
Intracellular (IC) staining was done using the ”Foxp3 / Transcription Factor Staining
Buffer Set” from eBioscience (Frankfurt am Main, Germany) according to the described
procedure for surface staining. Subsequently, the cells were permeabilized and fixed by
incubation in fixation/permeabilization reagent (1 part fixation/permeabilization concen-
trate + 3 parts fixation/permeabilization diluent) for 30 minutes at 4°C followed by wash-
ing with permeabilization buffer and 1 hour incubation of the desired antibody diluted
in permeabilization buffer. The cells were washed again and filtered before analysis on a
LSRFortessaflow cytometer (BD Biosciences (Heidelberg, Germany)).
Anti-mouse antibodies were purchased from Biolegend (Fell, Germany), eBioscience
(Frankfurt am Main, Germany) or Invitrogen (Darmstadt, Germamy). Importantly, the
antibody for granzyme B was originally developed as anti-human granzyme B, but worked
likewise in mice (clone GB11, Invitrogen).
2.2.8 In vivo cytotoxicity assay
The specificity of CD8+ T cells can be determined with an in vivo cytotoxicity assay
(adapted from [Coles et al., 2002]). After infection of mice with an OVA-expressing
Plasmodium berghei strain, T cells are primed for endogenous parasite peptides as wells
as the OVA peptide. Spleen cells from syngenic naive mice are loaded ex vivo with
fluorescently labeled MHC class I peptides from OVA (= target cells) and subsequently
transferred into a mouse 5 days after infection. Labeling the spleen cells with a CFSE
allows detection and quantification of remaining cells in the recipient mouse the next day.
For the generation of target cells, splenocytes from donor mice were splitted into two
fraction which were either incubated with 1 µM S8L (MHC I OVA peptide) or with-
out peptide (control) for 20 min at 37°C, following an incubation with the fluorescent
dyes for 25 min at 37°C. To distinguish between loaded and unloaded cells, the pep-
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tide loaded cells were incubated with a high dose of CFSE (1 µM) while the unloaded
cells were labeled with a low dose CFSE (0.1 µM). Both subsets could be recognized
as independent populations with flow cytometry. All mice received 5e6 cells of each type
intravenously on 5 dpi. Spleens of recipient mice were extracted the next day (18h incuba-
tion) and the amount of remaining CFSE-positive cells counted with FACS. The presence
of OVA specific T cells can be calculated from the elimination of labeled target cells, as
depicted in Fig. 2.1. The specific in vivo cytotoxicity is determined by comparing the
infected (immunized) animals with uninfected (naive) ones with the following formula:
specific cytotoxicity [%] = 100 -
ratio exp group
ratio ctrl group
∗ 100
Figure 2.1: Principle of the in vivo kill.The left graphic shows the cell populations before injection, the right
one after 18h incubation. Unst = unstained and unlabeled cells from recipient mouse, Ctrl = fluorescently stained
cells (0.1 µM CFSE) not labeled with peptide as reference for unspecific killing, Pep = fluorescently stained cells
(1 µM CFSE) labeled with a MHC I peptid. After injection of the amount of peptide-labeled and unlabeled cells,
both populations shrink likewise unspecifically in uninfected mice (”Ctrl” and ”Pep” in right graph), while peptide-
labeled target cells are specifically killed in PbA-infected mice, which leads to a comparably smaller target cell
population (depicted by red triangle).
2.2.9 Magnetic-activated cell sorting (MACS)
To analyze specific cell populations, cells were separated using the autoMACS from Mil-
tenyi Biotec GmbH (Bergisch Gladbach, Germany). Cells were taken in 300µl MACS
buffer and incubated with cell population specific MACS beads (magnetic beads attached
to antibodies; Miltenyi Biotec GmbH (Bergisch Gladbach, Germany)) for 15 minutes at
4°C. Afterwards cells were washed twice and filtered before proceeding with the actual
separation step in the autoMACS. Here, cells were separated into beads-bound cells and
those that were not bound, allowing either positive or negative selection. After separation,
cells were counted and adjusted to the desired concentration.
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2.2.10 Natural killer (T) cell assay
Cytokine production by NK and NKT cells was determined in supernatant of NK and
NKT cell culture, MACS-sorted by DX5 (present on both subsets). Purified cells were
incubated with recombinant IL-2 (final concentration 1e3 units per ml; Biolegend) alone or
on previously prepared BMDCs in a final volume of 200 µl. Additional wells without IL-2
served as negative controls. Supernatant was analyzed for cytokines after 24h incubation
at 37°C / 5% CO2.
2.2.11 Phagocytosis assay
Phagocytic capacity of MACS-purified CD11b+ splenocytes and lymphocyte / microglia
enriched brain cells (percoll gradient after perfusion) was analyzed ex vivo with the help
of plasma opsonized beads.
Fluorescently labeled beads (Sigma-Aldrich) were first opsonized with plasma from
experimental mice at 37 °C for 30 min to optimize uptake by cells. Thereafter, the bead
solution was diluted 1:10 with PBS and 50 µl of the beads were added to 0.5e5 cells in a
volume of 250 µl. Beads and cells were incubated 1h at 37°C / 5% CO2 to allow uptake
of beads by phagocytosing cells. The reaction was stopped by adding 2 ml ice-cold PBS /
1% BSA and spinning of cells at 1500 rpm for 7 min, 4°C. This step was repeated twice.
The cells were then stained for surface markers to differentiate between cell subsets. Flow
cytometry analysis revealed which cells had taken up the fluorescently labeled beads.
Table 2.1: Combination of serum opsonized beads and cells
Cells*:
Plasma**:
WT Naive WT PbA Batf3-/- Naive Batf3-/- PbA
CD11b+ WT Naive X X X X
CD11b+ WT PbA X X X X
CD11b+ Batf3-/- Naive X X X X
CD11b+ Batf3-/- PbA X X X X
Brain WT Naive X
Brain WT PbA X
Brain Batf3-/- Naive X
Brain Batf3-/- PbA X
*Source of potential phagocytosing cells; single approaches for all animals per group
** Source of plasma for bead opzonation; pooled plasma from all animals in one group
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2.2.12 Quantitative real-time polymerase chain reaction (PCR)
Isolation of mRNA
Isolation of mRNA from cryo tissue was performed with a single step method with TRI-
zol® (Invitrogen) and 1-bromo-3-chloropropane (BCP; Sigma-Aldrich). TRIzol® con-
tains guanidinium thiocyanate to lyse the cells and inactivate enzymes, especially RNase.
Adding BCP leads to three phases: a lower phase containing proteins, an intermediate
phase with DNA and an upper, aqueous phase which contains the desired RNA. The RNA
was then precipitated with isopropyl alcohol (Merck) and ethanol (Merck). The precip-
itate was centrifuged and the formed pellet dried and subsequently dissolved in RNase
free water. DNA digestion (reagents from Ambion® (Invitrogen)) was performed before
reverse transcription (Qiagen OmniScript® RT Kit 200, OligoDT and RNase inhibitor
from Invitrogen). The samples were 1:10 diluted and stored in aliquots at -20°C.
qRT-PCR procedure
Analysis of mRNA expression in brain tissue of mice was done by quantitative real-time
PCR. With the help of a standard curve (1:10 dilution) from samples with known concen-
tration of DNA, the amount of copies per µl can be determined. To avoid variations of
concentration due to extraction and purification of the mRNA, a so called house-keeping
gene is measured first. A house-keeping gene is constitutively expressed and can be used
for normalization (i.e. copies gene X per copies of housekeeping gene). Our house-keeping
gene was β-actin.
Primer
Primers were purchased from Invitrogen (Darmstadt, Germamy)
β-actin forward 5’ AGA GGG AAA TCG TGC GTG AC 3’
β-actin reverse 5’ CAA TAG TGA TGA CCT GGC GGT 3’
granzyme b forward 5’ CTG CTC TGA TTA CCC ATC GTC 3’
granzyme b reverse 5’ GTG AAT GGA CAT GAA GCC AGT 3’
PbA 18S rRNA forward 5’ CTA ACA TGG CTT TGA CGG GTA 3’
PbA 18S rRNA reverse 5’ CTG CTG CCT TCC TTA GAT GTG 3’
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qRT-PCR master mix
A master mix was prepared containing the following substances in optimized concentra-
tions. The volumes are given for one reaction. To a total volume of 18 µl in each reaction
tube, 2 µl of cDNA were added. All samples were measured in triplicates.
β-actin grzmB PbA
H2O 10.8 µl 14 µl 10.4 µl
10x buffer 2.0 µl 2.0 µl 2.0 µl Qiagen
MgCl2 (25 mM) 2.4 µl 0.4 µl 1.2 µl Qiagen
dNTPs (40 mM) 0.1 µl 0.1 µl 0.1 µl Fermentas, St. Leon-
Roth, Germany
primer forward (5 µM) 1.2 µl 0.6 µl 2 µl Invitrogen
primer reverse (5 µM) 1.2 µl 0.6 µl 2 µl Invitrogen
SYBR Green (1:100) 0.2 µl 0.2 µl 0.2 µl Invitrogen
HSTaq (250 U) 0.1 µl 0.1 µl 0.1 µl Qiagen
total volume 18 µl 18 µl 18 µl
Cycling
All samples were run in a Rotor-Gene 3000 (Corbett Research, Qiagen (Hilden, Germany))
using the following protocol:
β-actin grzmB PbA
Hold 95°C / 15 min 95°C / 15 min 95°C / 15 min
45x cycle 94°C / 15 sec 94°C / 30 sec 95°C / 15 sec
58°C / 20 sec 58°C / 30 sec 53°C / 20 sec
72°C / 20 sec 72°C / 30 sec 72°C / 20 sec
Melt 59-95°C / 0.8°C steps 72-99°C / 1°C steps 52-95°C / 0.8°C steps
1st 10 sec 1st 10 sec 1st 10 sec
all other 2 sec all other 2 sec all other 2 sec
2.2.13 Transmigration assay
We designed a transmigration assay using transwell plates (polycarbonate membrane,
VWR Lab Shop (Batavia, USA)) to assess the ex vivo migration of spleen cells towards a
31
CHAPTER 2. MATERIAL AND METHODS
brain cell generated cytokine gradient. Therefore, whole brain homogenate (1,25e6 cells
/ well) was cultured in the bottom of a transwell plate together with FarRed labeled
splenocytes (1e6 cells / well, 1 µM FarRed, 20 min incubation at 37°C) in the upper
well (depicted in Fig. 2.2). The pores of the upper chamber were 5 µm to allow mainly
active migration of lymphocytes to the chemotactic attractants produced by the brain
cells in contrast to undirectional floating of cells through the pores. Cells were incubated
together for 6h at 37°C. After this incubation time the plate was placed in 4°C for 20
min to remove leukocytes sticking to the underparts of the upper chamber. The upper
chamber was removed carefully and cells in the lower well were collected. The amount
of FarRed labeled cells was calculated among the total amount of measured cells (same
number for all samples). Additional FACS surface staining after migration allowed to
distinguish between different cell subsets.
Figure 2.2: Principle of the migration assay. Brain and spleen cells were removed from experimental animals
and cultured for 6h in a transwell plate as with brain cells in the lower and fluorescently (FarRed) labeled spleen
cells in the upper chamber. After incubation cells were analyzed by flow cytometry.
2.2.14 Statistical analysis
Most statistical analysis was done using GraphPad Prism software. P-values below 0.05
were considered significant. Survival curves were analyzed with the Log-rank test. Data
up to 20 dpi were taken into calculation. ECM scores are displayed as median values
and significance was testes with Kruskal-Wallis with Bunn’s post-test (>2 groups) or
Mann Whitney test (2 groups). If not stated otherwise, all other graphs represent mean
values (±SD or SEM, as indicated). Differences between groups (>2) were evaluated
with ANOVA followed by Tukey post-test, groups with 2 animals were tested with t test.
Analysis of the PCR array was done with R version 3.1.0. using the Mann-Whitney test
(non-parametric without assumptions on the distribution of Ct values). Adjustment for
multiple testing was performed by Benjamini-Hochberg.
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Results
3.1 Batf3-/- mice were protected from experimental cere-
bral malaria after PbA-infection
Batf3-/- mice genetically lack the transcription factor Batf3 which is required in the devel-
opment of XCR1+ dendritic cells (DCs), a DC subpopulation, which is known to be the
major cell type for cross-presentation of antigen via MHC class I to CD8+ T cells. During
their blood stage phase, Plasmodium parasites infect vertebrate erythrocytes, which do
not express any MHC molecules on their own. Cross-presentation is therefore indispens-
able to prime CD8+ T cells for a fully functional Th1 immune response to the parasite.
The development of cerebral malaria is well associated with a strong Th1 response of
CD8+ T cells. In this study we were interested how ECM development is altered in
Batf3-/- mice, since the crucial cell population responsible for priming of CD8+ T cells
via cross-presentation is lacking in these mice. We confirmed the Batf3 knock-out by flow
cytometry analysis on spleen cells (Fig. S1). In initial experiments our lab could demon-
strate that PbA-infected Batf3-/- mice are completely protected from ECM, as shown by
survival and a stable blood-brain barrier in these mice (Schumak et al., (unpublished),
summarized in Fig. 1.2A-E).
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3.1.1 Batf3-/- mice did not develop ECM upon PbA-infection with ex-
tracted sporozoites
Infection of mice with infected red blood cells (iRBCs) is a common technique for using
experimental mouse models for malaria, but only focuses on the blood stage aspects of
the disease. We wanted to confirm that the disease outcome was comparable to a more
natural infection, that also includes the liver stages of the parasite’s life cycle. To address
this point, mice were infected intravenously with 1,000 sporozoites, which were extracted
from salivary glands of mosquitoes that had ingested PbA gametocytes 17 days earlier.
Mice were observed for survival, disease outcome and parasitemia. ECM development
was monitored according to the rapid murine coma and behavior scale (RMCBS, [Carroll
et al., 2010]), a fitness score composed of 10 parameters with a maximum score of 2 points
each.
Figure 3.1: Batf3-/- mice did not develop ECM after infection with PbA spopozoites. A: Survival of
WT (filled squares, n=6) and Batf3-/- mice (empty squares, n =6) after inoculation with 1,000 sporozoites from
17 dpi infected mosquitoes is shown. B and C: RMCBS and parasitemia, are shown for 7 dpi. Differences in
survival were tested for significance with log-rank test. Significance for RMCB scale and parasitemia was tested
with Man-Whitney and t-test. p values below 0.05 were considered significant.
After sporozoite infection, WT mice developed cerebral symptoms and died after 7 dpi,
while Batf3-/- mice survived the infection without any signs of disease (Fig. 3.1). In com-
parison to blood-stage infection (Fig. 1.2A, B), disease development and ECM phase was
delayed for 1-2 days in WT mice. This observation could be explained with the different
stages of parasites that were injected: sporozoites have to develop in the liver before reen-
tering the blood stream, while parasites in RBCs can directly start blood cycle divisions.
ECM onset was observed in WT mice on dpi 7 (B: RMCBS of 4-7 dpi) while PbA-infected
Batf3-/- mice were still healthy at that time point (RMCBS of 19.5 7 dpi). Similar to
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iRBC-infected Batf3-/- mice, sporozoite-infected knock-out mice did also not develop spe-
cific neurological symptoms later in infection (Fig. S2). Importantly, parasitemia did not
differ between WT and Batf3-/- mice on 7 dpi, when WT mice developed severe ECM
symptoms (3.6% vs. 3.8%; Fig. 3.1C).
Thus, Batf3-/- mice did not develop ECM after PbA-infection, neither with iRBCs
nor sporozoites. As disease development in WT mice was also comparable, we performed
blood-stage infection for all following experiments.
3.1.2 Brains of PbA-infected Batf3-/- mice did not show signs of cellular
infiltration and inflammation
It is widely accepted that cerebral malaria is a combination of sequestration of blood cells
in the microvessels within the brain and local inflammation, caused by an overreaction of
the host’s immune system [Hunt et al., 2006]. Therefore, it is inevitable to have a closer
look at the brains of PbA-infected Batf3-/- mice to analyze ongoing immune responses
and compare them to infected WT mice and naive mice.
3.1.2.1 Immune cell infiltration to the brain was reduced in PbA-infected
Batf3-/- mice
Cells of hematopoietic origin can be distinguished from other cells by their high expression
of the cell surface marker CD45. Especially in the brain this marker is extremely helpful
to differentiate between CD45hi cells, identifying as infiltrated immune cells and CD45lo
cells, which are mostly brain resident microglia and still present after percoll gradient
purification of a brain homogenate.
To get a first idea of possibly infiltrated cells in the brain of Batf3-/- mice vs. WT
mice after infection with Plasmodium berghei ANKA, we did a FACS analysis of immune
cells that were isolated from the brain 6 days after infection and compared them to naive
control animals. Therefore we anesthetized the experimental animals and perfused them
intracardially with PBS to remove the majority of the cells that were present in the
vessels due to blood circulation. Brains were taken out, cut into small pieces and digested
in collagenase for 30 min at 37°C before homogenization through a metal sieve. The
brain homogenate was then applied to a percoll gradient in order to enrich leukocytes
and remove brain parenchyma. The forming layer of mainly leukocytes and microglia was
then stained with FACS antibodies for surface markers to distinguish between different cell
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subtypes. For analysis of the cells that infiltrated the brain, we first gated purified cells
for expression of CD45 and CD11b to discriminate between leukocytes from the periphery
(CD45hi), brain-resident microglia (CD45loCD11b+) and other brain cells that were not
excluded by the gradient (CD45−CD11b−). The latter were not included in our analysis.
Figure 3.2: FACS gating scheme for brain cells. Schematic drawn to show the different population in brains
from mice that were isolated after PBS perfusion and enrichment for leukocytes via a percoll gradient. Cells are
stained for CD45 and CD11b to distinguish between resident microglia (CD45lo CD11b+) and infiltrated immune
cells (CD45hi). Cells are stained for CD3 to identify T cells (CD3+). CD3+ cells were separated into CD8+ and
CD4+ T cells. Cells negative for CD3 were analyzed for B cells (B220+), B220− cells were gated for dendritic cells
(CD11c+I-Ab+). Other cells were analyzed for the presence of CD11b and were further separated into macrophages
(Ly6C−Ly6G−), Ly6C+ monocytes (Ly6C+Ly6G−) and neutrophils (Ly6C+Ly6G+).
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Figure 3.2 illustrates the general gating scheme for brain derived cells after a percoll
gradient for leukocyte enrichment in PbA-infected WT mice. The plot shows the CD45hi
population which represents cells with hematopoietic origin, present in blood vessels in
the brain or cells that had crossed the blood-brain barrier and infiltrated the brain. These
cells were further divided into different cell types according to additional surface markers
and were analyzed for activation markers. The other population of gated cells contains
microglia (CD45loCD11b+) which were also analyzed for activation markers.
Figure 3.3: Less CD45hi cells infiltrated the brains of PbA-infected Batf3-/- mice. Brain cells were
prepared from d+6 PbA-infected mice (n=4-5) and stained for CD45 and CD11b for flow cytometry analysis. Naive
mice from both strains were used as control (n=3-4). CD45hi cells were gated as shown before in fig. 3.2. A: FACS
dot plots from representative naive WT, PbA-infected WT and Batf3-/- mice. B: The absolute amount of brain
infiltrated cells calculated by multiplying the relative amount of CD45hi cells by the total cell number counted after
the leukocytes gradient. Significance was tested by ANOVA following Tukey post test. p values below 0.05 were
considered significant.
Flow cytometric analysis of naive mice and PbA-infected mice revealed that naive mice
contained almost no cellular infiltrates or adherent cells in their brains, while PbA-infected
C57Bl/6 mice displayed a prominent CD45hi population (Fig. 3.3A). In comparison, this
population was less prominent in PbA-infected Batf3-/- mice. The difference seen in figure
3.3A, was also quantified by cell counting. With an average total amount of 6.31e5 cells,
infected WT mice showed more than 10-fold increase (p < 0.001) in leukocytes infiltration
compared to naive WT mice as well as naive PbA-infected Batf3-/- mice (”WT Naive”:
5.63e4 cells, ”WT PbA: 6.31e5 cells, ”Batf3-/- Naive”: 6.22e4 cells, ”Batf3-/- PbA”: 7.57e4
cells, p < 0.001 between ”WT PbA” vs. ”Batf3-/- PbA”; Fig. 3.3B).
We were first interested in the different cell subsets that migrated from the periphery
into the brain. It is assumed that effector cells, such as CD8+ T cells, are primed in the
spleens of infected animals but migrate to the brain where they cause substantial damage
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[Re´nia et al., 2006]. Therefore, we analyzed the CD45hi cells from 6 dpi infected WT and
Batf3-/- mice for different surface markers to get an impression of the cell subsets that
had infiltrated the brain after PbA-infection. It has to be kept in mind, that PbA-infected
Batf3-/- mice had 10-fold less cell infiltration to their brains, which led to lower total cell
numbers in general (Fig. 3.3).
First of all, we focused on T cells, as especially CD8+ T cells are well-known for their
major role in the pathogenesis of experimental cerebral malaria [Re´nia et al., 2006]. In
order to identify T cells, we gated for CD3+ cells, which were further differentiated into
CD4+ and CD8+ T cells.
Figure 3.4: Levels of CD8+ T cell infiltration were not increased in brains of PbA-infected Batf3-/-
mice at 6 dpi. Brain infiltrated leukocytes from PbA-infected mice 6 dpi (n=5) or naive mice (n=3) were first
gated for CD45high cells as shown before and than analyzed for T cell marker CD3 (A). These CD3+ cells were
further differentiated in CD4+ and CD8+ T cells (B and C). Significance was tested by ANOVA following Tukey
post test. p values below 0.05 were considered significant.
Of the few cell that were found in the brains of naive WT and Batf3-/- mice, 31%
were T cells in both strains (Fig. 3.4A). In brains of PbA-infected WT mice on 6 dpi,
the T cell proportion from all brain infiltrated cells was significantly increased (44.6%),
in contrast to brains of infected Batf3-/- mice that contained unchanged proportions of
T cells in relation to naive mice (28.5%). Among the gated CD3+ cells, PbA-infected
WT mice contained mostly CD8+ T cells (18.2% CD4+ vs. 74.6% CD8+, ratio 0.25),
whereas brains of PbA-infected Batf3-/- mice showed more CD4+ T cells among the few
cells that had infiltrated to the brain (40.5% CD4+ vs. 29.6% CD8+, ratio 1.4; Fig. 3.4B
and C). In naive mice, the frequencies of CD4+ and CD8+ cells was were similar (”WT
Naive”: 35.2% CD4+ vs. 38.7% CD8+, ratio 1,01, ”Batf3-/- Naive”: 32.5% CD4+ vs.
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41.9% CD8+, ratio 0.96). Additionally to these significant differences of T cells subset
proportions between PbA-infected WT and knock-out mice (p < 0.001 in both subsets),
the different amount of cells infiltrating the brain has to be considered. Batf3-/- mice had
significantly less leukocytes migrating to their brains (Fig. 3.3B), which means, that the
total cell number for both CD8+ but also CD4+ T cells was higher in PbA-infected WT
mice compared to infected Batf3-/- mice and naive controls (Fig. S3).
Next, we examined the other cell populations that were purified with help of a per-
coll gradient of homogenized brains from PbA-infected WT and Batf3-/- mice and their
respective naive controls. Flow cytometry staining was performed in order to divide
CD45hiCD3− cells into B cells (BCs, B220+), dendritic cells (CD11c+I-Ab+ but no B or
T cells) and CD11b+ cells that were neither TCs, BCs cells nor DCs. CD11b+ mononu-
clear cells were further differentiated into Ly6C+ monocytes (Ly6C+Ly6G−), neutrophils
(Ly6C+Ly6G+) and macrophages (Ly6C−Ly6G−).
B cell frequencies in brains of PbA-infected Bl/6 dropped significantly compared to
the frequencies in naive WT mice (1.5% vs. 14.5%; p < 0.001), but Batf3-/- mice (± PbA)
showed similar results to naive WT mice (”Batf3-/- Naive” 13.0%, ”Batf3-/- PbA”: 10.7%;
Fig. 3.5A). As brains of PbA-infected WT mice contained significantly more infiltrated
cells, the absolute numbers of B cells were similar in all groups (Fig. S3D).
The percentage of dendritic cells found in brains of the experimental animals was very
low and did not differ between all analyzed groups (”WT Naive” 1.3%, ”WT PbA”: 1.9%,
”Batf3-/- Naive” 1.5%, ”Batf3-/- PbA”: 1.6%; Fig. 3.5B), which led to an increase of total
DC numbers in PbA-infected WT mice compared to all other groups (Fig. S3E).
Analysis of CD11b+ cells isolated from brains of the described groups revealed a sig-
nificant increase of Ly6C+ monocytes in WT mice that were infected with PbA 6 days
before when compared to their naive controls (23.9% vs. 9.4%, p < 0.001; Fig. 3.5C). This
increase was not observed in PbA-infected Batf3-/- mice (8.3%; p < 0.001 to ”WT PbA”),
that did not differ from their uninfected control mice (8.8%). Due to higher total cell num-
bers in brains of PbA-infected WT mice, these differences in total monocyte numbers were
even more prominent (Fig. S3F). Neutrophils numbers were rather low in all investigated
groups and showed a high standard deviation. Naive mice from both groups, showed the
highest percentages of neutrophils in their brains (”WT Naive”: 3.8%, ”Batf3-/- Naive”:
3.2%; Fig. 3.5D). Six days after PbA-infection, the number of neutrophils dropped in WT
(0.2%; p < 0.01) and Batf3-/- mice (1.0%; not significant; Fig. 3.5D), despite higher cell
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Figure 3.5: Composition of brain-infiltrated leukocytes did not differ between d+6 PbA-infected
Batf3-/- mice and naive controls. Brain-infiltrated leukocytes from PbA-infected (6 dpi) and naive WT and
Batf3-/- mice were differentiated by flow cytometry (n=3-5). B cells were defined as CD3−B220+ (A), dendritic
cells were gated for CD11c+I-Ab+ from CD3−B220− (B) and CD11b+ cells, that were neither of the other cell
types, were subdivied into Ly6C+ monocytes (Ly6C+Ly6G−; C), neutrophils (Ly6C+Ly6G+; D) and macrophages
(Ly6C−Ly6G−; E). Differences were statistically analyzed with ANOVA and Tukey post-test; p < 0.05 was consid-
ered significant.
numbers in PbA-infected WT mice, the differences in percentages led to reduction of total
neutrophils in both infected groups (Fig. S3G). The small difference between infected mice
from both strains was not significant. Macrophage frequencies were around 10% in both
naive groups (”WT Naive” 10.6%, ”Batf3-/- Naive” 9.7%; Fig. 3.5E). In PbA-infected WT
mice this number changed only marginally to 6.1% while there was a small increase in
Batf3-/- mice after infection (11.3%). Differences within both strains were not significant,
but the PbA-infected Batf3-/- showed an elevated frequency of macrophages among their
infiltrates in their brains compared to PbA-infected WT mice (p < 0.05; Fig. 3.5E), how-
ever the total number in Batf3-/- mice was only half the amount compared to infected
WT mice (Fig. S3H).
Taken together, the analysis of the different cell types of brain-infiltrated cells on 6 dpi
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revealed a strong increase in T cells (Fig. 3.4) and Ly6C+ monocytes (Fig. 3.5C) in PbA-
infected WT mice, which were not present in infected Batf3-/- mice. Due to the relative
increase of these two cell subsets, the frequencies of B cells and neutrophils were lower in
the ”WT PbA” group. However, as the absolute number of infiltrated cells to the brains
of PbA-infected WT was significantly higher compared to that of infected Batf3-/- mice
(Fig. 3.3), the absolute cell numbers did not differ in these cell populations and differences
in T cells and monocytes were even more prominent.
3.1.2.2 Brains of PbA-infected Batf3-/- mice showed reduced inflammation
We had observed significantly reduced levels of T cells and Ly6C+ monocytes in the brains
of PbA-infected Batf3-/- mice (relative amount and absolute numbers) compared to high
numbers of these cell types that had infiltrated the brains of PbA-infected WT mice. Next,
we addressed the question whether there were functional differences between these T cell
populations and / or other signs of inflammation, as Batf3-/- mice showed no symptoms
of ECM and maintained an intact BBB upon PbA-infection.
Granzyme B is an important marker for cytotoxicity of CD8+ T cells and was reported
to play a major role in experimental cerebral malaria [Haque et al., 2011]. Therefore if
was important to test if the cellular production in brain infiltrated CD8+ T cells as well
as the actual release of granzyme B was altered in infected Batf3-/- mice (6 dpi) compared
to infected WT mice (6 dpi). Naive mice from both strains served as controls.
We analyzed the production of granzyme B on different levels using quantitative real
time PCR, FACS and ELISA (Fig. 3.6A-C).
We extracted mRNA from brains of d+6 infected mice and the transcribed cDNA was
then subjected to qPCR. Results were normalized to the house-keeping gene β-actin and
are displayed as copies granzyme B per 1e6 copies β-actin. Samples from PbA-infected
WT mice showed a strong upregulation of granzyme B (912 copies granzyme B per 1e6
copies β-actin) compared to naive controls (9.17 copies granzyme B per 1e6 copies β-actin)
and infected Batf3-/- mice (60 copies granzyme B per 1e6 copies β-actin, p < 0.05 to WT
PbA). Brain samples from naive WT and infected Batf3-/- mice did not show significant
differences in granzyme B expression (Fig. 3.6A).
After measuring expression levels, we analyzed the amount of granzyme B that was
stored specifically in CD8+ T cells from brains of d+6 infected mice. The geometric mean
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Figure 3.6: T cells from Batf3-/- mice produced less granzyme B and general inflammation in the
brain was reduced. Granzyme B production was analyzed 6 dpi in brains of PbA-infected Batf3-/- and WT
mice by qPCR (A), FACS (B) and ELISA (C), naive mice served as controls. (A) mRNA was extracted from snap
frozen brains and transcribed to cDNA. cDNA was subjected to quantitative real time PCR for granzyme B and
standardized with β-actin as house keeping gene. (B) For FACS analysis, cells were gated for CD8+ T cells and
the geometric mean fluorescence intensity (gMFI) was calculated with the low cytometry analysis program FlowJo.
(C) Granzyme B production ex vivo was determined by measuring the cytokines from unpurified brain homogenate
supernatant after 24h incubation at 37°C / 5% CO2 with ELISA. D: ICAM-1 expression was analyzed on brain
infiltrating CD8+ T cells by flow cytometry. The gMFI was calculated on cells from PbA-infected mice 6 days p.i.
and naive mice from WT and Batf3-/- strains. E: TNF was measured in brain homogenates that had been cultured
over night at 37°C / 5% CO2 and supernatants were subjected to an ELISA. Values are displayed as mean (n=3-6).
Significance was tested by ANOVA following Tukey post test. p values below 0.05 were considered significant.
fluorescence intensity (gMFI) for granzyme B from these cells was significantly upregulated
in WT mice after PbA-infection (22,507 units) compared to uninfected mice (301 units,
p < 0.001; Fig. 3.6B). In contrast to WT animals, granzyme B levels in PbA-infected
Batf3-/- mice did not increase (1,173 units, p < 0.001 to ”WT PbA”) and was comparable
to their naive controls (2869 units; Fig. 3.6B).
As granzyme B can be stored in cells and is secreted when needed, it was also impor-
tant to check the actual release from cultured brain cells. Therefore, we extracted brains
from PbA-infected mice on 6 dpi and prepared brain single cell suspensions which were
cultured ex vivo in medium for 24h at 37°C / 5% CO2. The supernatant was collected
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the next day and measured for cytokines. ELISA measurements on these supernatants re-
vealed a significant increase (about 20-fold) in granzyme B release in samples from infected
WT mice as compared to naive control animals (46.8 pg/ml vs. 2.5 pg/ml, p < 0.001) as
well as an 10-fold increase in samples from infected WT mice compared to PbA-infected
Batf3-/- mice (5.4 pg/ml, p < 0.001). Cytokine levels from brains of PbA-infected Batf3-/-
mice did not differ from that in naive Batf3-/- controls (2.33 pg/ml; Fig.3.6C).
ICAM-1 is an adhesion molecule which supports cell-cell-interactions and is upregu-
lated on activated T cells. Its importance on T cells in disease development of experimental
cerebral malaria was shown before [Ramos et al., 2013]. We analyzed the ICAM-1 expres-
sion of brain infiltrated CD8+ T cells in PbA-infected WT and Batf3-/- mice on 6 dpi as
well as their respective naive controls via flow cytometry.
We observed a significant increase in ICAM-1 expression on CD8+ T cells in brains of
PbA-infected WT mice compared to uninfected control mice (gMFI 4,547 in PbA-infected
vs. gMFI 2,679 in naive; p < 0.001; Fig. 3.6D). While CD8+ T cells in brains cells from
naive Batf3-/- mice showed a small, but not significant increase in ICAM-1 expression in
general (”Batf3-/- Naive” gMFI 3,517), PbA-infection did not result in upregulation of
this adhesion molecule (”Batf3-/- PbA” gMFI 3,481). However, the ICAM-1 expression
was significantly lower in PbA-infected Batf3-/- than and WT mice (p < 0.01).
Brains from ECM-positive mice do not only show T cell activation but a general
inflammatory milieu in the brain. In order to analyze the immune responses in the brain
of PbA-infected WT versus Batf3-/- mice in more detail, we analyzed the brain cell culture
for TNF, which can be produced by various immune cells.
We determined very low levels of TNF in supernatants from naive WT (3.0 pg/ml)
and Batf3-/- derived brain samples (4.7%; Fig. 3.6E). After PbA-infection the measured
amount of TNF from cultured brain cells increased significantly in samples from WT mice
(46.8 pg/ml; p < 0.01) but not from Batf3-/- mice (9.2 pg/ml). The comparison between
both infected groups showed significant less TNF in samples from Batf3-/- than from WT
mice (p < 0.01; Fig. 3.6E).
In summary, brains of PbA-infected Batf3-/- mice showed less cellular infiltration and
a strongly reduced activation of the few T cells that migrated to the brains of Batf3-/- mice
upon PbA-infection, thus mirroring the absent brain inflammation in these mice (brains
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of naive and PbA-infected Batf3-/- mice showed similar results).
3.1.2.3 Phagocytic capacity of microglia was impaired in Batf3-/- mice
Microglia are immune-competent resident brain cells, which can phagocyte and present
antigen and also contribute to the development of ECM [Medana et al., 1997].
We wanted to clarify whether microglia, the brain resident macrophages, from WT
and Batf3-/- mice differed in their ability to take up antigen, as this might influence the
ECM pathogenesis. Presentation of antigen to immune cells stimulates functional immune
responses in vivo; phagocytosis - the uptake of particles and cellular fragments - is the first
step in antigen processing. As the presentation of antigen might be important before the
onset of disease symptoms, we analyzed mice 3 and 6 days after infection with PbA. Naive
mice from both strains served as controls. To test phagocytosis ex vivo, we performed a
bead-phagocytosis assay. Therefore, we opsonized fluorescent labeled beads with serum
from the respective groups to enforce potential bead-uptake. These opsonized beads were
then incubated with brain cells that had been isolated with the help of a percoll gradient.
After one hour, we stopped the uptake processes by adding ice-cold PBS and identified
the percentage of microglia that had taken up the beads by flow cytometry.
Combination of serum opsonized beads and cells (see also Table 2.1)
Cells*:
Plasma**:
WT Naive WT PbA Batf3-/- Naive Batf3-/- PbA
Brain WT Naive X
Brain WT PbA X
Brain Batf3-/- Naive X
Brain Batf3-/- PbA X
*Source of potential phagocytosing cells; single approaches for all animals per group
** Source of plasma for bead opzonation; pooled plasma from all animals in one group
Microglia in all groups were able to take up beads. Interestingly, at both time points
of the analysis (3 and 6 dpi), we found differences in the phagocytic capacity of microglia
from naive mice from WT and Batf3-/- strains, as microglia from the latter took up
significantly less beads than cells from uninfected WT mice (14.2% to 10.1%; p < 0.05
and 10.3% to 4.3%; p < 0.01, respectively; Fig. 3.7). We did not observe any differences
in phagocytosis in cells from infected mice of both groups on 3 dpi (Fig. 3.7A). However,
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Figure 3.7: Microglia from brains of Batf3-/- mice were in general less capable of phagocytosis than
WT microglia. The capability of microglia to take up beads was tested 3 (A) and 6 (B) days p.i. in Batf3-/-
and WT mice (n=2-6). Naive mice from both groups served as control (n=4-5). In this phagocytosis assay brain
cells were purified for leukocytes and microglia before 1h incubation with fluorescent labeled beads. Following this
incubation time, cell were stained with FACS antibodies to distinguish between different cell subset. Microglia were
defined as CD45lowCD11b+. Values are displayed as mean. Significance was tested by ANOVA following Tukey
post test. p values below 0.05 were considered significant.
6 days post infection, the capacity for phagocytosis was increased in both strains with
PbA-infection (10.3% to 13% in WT (not significant but strong trend), 4.3% to 8.4%
(p < 0.01) in Batf3-/-; Fig. 3.7B).
These results indicate, that PbA-infection enhances phagocytosis in microglia. In-
terestingly, microglia from Batf3-/- mice are less efficient in bead-uptake in general, but
phagocytic ability was improved upon infection.
3.1.3 Immune responses in early PbA-infection were less pronounced in
spleens of PbA-infected Batf3-/- mice and led to reduced T cell
activation in the late phase of ECM development
As the term cerebral malaria implies, the brain is a critical organ in this disease. It was
shown that brain infiltrating immune cells, that cause fatal damage during ECM, are
primed in the spleen of infected individuals [Engwerda et al., 2005]. Therefore, it is also
important to analyze immune responses towards PbA blood stage infections in the spleen
as a secondary lymphoid organ, which plays a crucial role in blood-borne infections.
Different outcomes in the late phase of PbA-infection were associated with differences
in infiltrating cell subsets, which are active at the time point when cerebral symptoms are
visible. Analyzing these cells subsets not only in the brain but also in the spleen could
provide important insights of potential mechanisms that are involveld in pathology or
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immune regulations. However, the priming of immune effector cells takes probably place
at an earlier time point. On day 3 after PbA-infection, the immune system should already
have initiated a response against the Plasmodium parasites, but neither ECM symptoms
nor parasitemia is yet detectable at this early stage. Therefore, we decided to analyze
the immune status in the spleen on day 3 and 6 after PbA-infection in WT and Batf3-/-
mice. In order to illustrate differences between WT and Batf3-/- mice at both time points
during ECM development, we normalized all values to naive WT mice and displayed them
in joined graphs. Graphs with absolute numbers of individual experiments can be found
in the appendix.
Figure 3.8: Total amount of splenocytes did increase in PbA-infected Batf3-/- mice at 6 dpi. A: Spleen
length was measured and one representative picture from each group is shown. B: Spleens from experimental mice
were weighed directly after perfusion on 6 dpi (n = 3-5). C: Spleens from dpi 3 and 6 infected WT and Batf3-/-
mice (n=5-6) as well as naive control mice (n=3-4) were digested with collagenase and homogenized. The cell
concentration of in this suspension was counted and the total amount of splenocytes was calculated. Values from
different time points of analysis are presented as mean fold change (±SD (standard deviation)) to naive WT mice.
Dashed lines are shown for better visualization but time points were analyzed in different mice. Values from 6 dpi
are presented as mean ± SEM. Significance was tested with ANOVA followed by Tukey post-test, p< 0.05 was
considered significant (* = p < 0.05, ** = p < 0.01, *** = p < 0.001).
Removal of spleens from WT and Batf3-/- mice 6 dpi showed obvious splenomegaly
in both infected groups when compared to their naive controls as shown by representa-
tive pictures from one spleen per group and spleen weights as measured directly after
perfusion (Fig. 3.8A, B). Interestingly, spleens from PbA-infected Batf3-/- mice were sig-
nificantly enlarged regarding length and weight compared to all other groups (Fig. 3.8A,
”WT Naive”: 0.07g, ”WT PbA”: 0.12g, ”Batf3-/- Naive”: 0.09g, ”Batf3-/- PbA”: 0.20g,
p < 0.001; Fig. 3.8B).
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Interestingly, the physical appearance of the spleens was only partially mirrored by
the counted splenocyte number: Before differentiation of individual cell subsets, the total
amounts of splenocytes were calculated from spleens of WT and Batf3-/- mice 3 and 6
days after PbA-infection versus naive controls. Cell counts from naive mice or on d+3
infected mice did not differ significantly between both strains. However, on 6 dpi, spleno-
cyte counts from PbA-infected Batf3-/- mice were significantly increased in comparison to
WT controls (fold change to ”WT Naive” on 6 dpi: WT 0.88 vs. Batf3-/- 1.40, p < 0.05;
Fig. 3.8A). In contrast to visual observations, we did not find increased cell counts in
spleens of d+6 PbA-infected WT mice, which might be due to dead cells which were not
counted.
First of all we analyzed the cellular composition in the spleens from PbA-infected WT
and Batf3-/- mice by flow cytometry analysis. Naive mice of both strains were used as
controls. Spleens were first digested with collagenase to recover also antigen-presenting
cells, then homogenized to obtain a single cell solution and subsequently prepared for
FACS staining as described before.
Identification of immune effector cells in the spleen was performed accordingly to the
gating scheme for analysis of the infiltrated brain cells. As the number of splenocytes was
sufficient, in contrast to the limited number of cells obtained from the brain after percoll
gradient, we could perform a more detailed analysis of spleen cells. The gating strategy
after gating for live cells is shown in figure 3.9.
3.1.3.1 Spleens of PbA-infected Batf3-/- mice contained less CD8+ T cells
compared to infected WT mice at 3 and 6 dpi
After determination of the total cell number, we stained the splenocytes for FACS analysis
to identify different subsets of immune cells, as described in the gating scheme before
(Fig. 3.9). For all analyses of splenic immune cell subsets and activities in our PbA-mouse
model, we infected WT and Batf3-/- mice with PbA-infected RBCs and isolated their
spleens 3 or 6 days later. Naive mice of both strains were included in all experiments as
controls.
As the onset of ECM after PbA-infection could be correlated with infiltration of T
cells into the brain, these effector cells were of major interest in the spleen. After gating
on live cells using forward and sideward scatter on the flow cytometer, these cells were
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Figure 3.9: FACS gating scheme for spleen cells. Schematic drawn to show the gating strategy for spleen cells
that were isolated from naive and PbA-infected mice. Cells were stained for CD3 and NK1.1 to differentiate between
T cells (CD3+NK1.1−), NKT cells (CD3+NK1.1+) and NK cells (CD3−NK1.1+). CD3+ cells were separated into
CD8+ and CD4+ T cells. Cells negative for CD3 and NK1.1 were gated for CD11c+I-Ab+ (dendritic cells), which
were further differentiated into XCR1+ and XCR1− DCs. Other cells were analyzed for the expression of CD11b
and were further separated into macrophages (Ly6C−Ly6G−), Ly6C+ monocytes (Ly6C+Ly6G−) and neutrophils
(Ly6C+Ly6G+).
differentiated into CD3+NK1.1− (T cells), CD3+NK1.1+ (NKT cells), CD3−NK1.1+ (NK
cells) and CD3−NK1.1− (other subsets that need further discrimination). Then, CD4+ T
cells were separated from CD8+ T cells.
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Figure 3.10: Increased CD4+ vs. CD8+ T cell ratios in spleens of Batf3-/- mice at all tested time
points after PbA-infection. (A) T cell frequencies of d+3 or d+6 PbA-infected mice (n=5-6) and naive controls
(n=3-4) were identified by surface marker CD3. CD3+ T cells were further differentiated into CD4+ (B) and CD8+
(C) T cells (both calculated from frequency from CD3+ cells). (D) The ratio between CD4+ and CD8+ T cells
was calculated. Values from different time points of analysis are presented as mean fold change (±SD) to naive WT
mice. Dashed lines are shown for better visualization but time points were analyzed in different mice. Differences
were tested separately with ANOVA followed by the Tukey post-test; p values below 0.05 were considered significant
(* = p < 0.05, ** = p < 0.01, *** = p < 0.001).
The analysis of CD3 positive T cells did not reveal any significant differences in fre-
quencies of this cell subset between naive and d+3 PbA-infected WT, as well as naive
and d+3 infected Batf3-/- mice (fold change to ”WT Naive”: ”WT PbA” 1.01, ”Batf3-/-
Naive” 0.96, ”Batf3-/- PbA” 0.98; Fig. 3.10A). Six days after infection, T cells frequencies
were decreased in PbA-infected WT mice, but not in the Batf3-/- group (fold change to
”WT Naive”: ”WT PbA” 0.61, ”Batf3-/- PbA” 0.92; Fig. 3.10A). The higher numbers of
total splenocytes that was observed in d+6 PbA-infected Batf3-/- mice (Fig. 3.8), magni-
fied the difference in total T cell counts compared to splenic T cells from d+6 PbA-infected
WT mice (Fig. S5).
In both naive groups, the frequencies of CD4+ and CD8+ T cells were similar (CD4+ T
cells: ”Batf3-/- Naive” 1.02-fold change to ”WT Naive”, CD8+ T cells: ”Batf3-/- Naive”
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0.92-fold change to ”WT Naive”; Fig. 3.10B, C). PbA-infection in WT mice did not
influence CD4+ frequencies significantly, albeit we saw a small increase on 6 dpi (3 dpi:
0.91-fold change to ”WT Naive”, p < 0.01; 6 dpi: 1.18-fold change to ”WT Naive”, not
significant). In contrast, in Batf3-/- mice, splenic CD4+ T cell frequencies did not change
significantly at any of the analyzed time points after PbA-infection (fold change to ”WT
Naive” on 3 dpi: 1.01; on 6 dpi 1.07). The difference between WT and Batf3-/- mice was
significant on 3 dpi (less CD4+ cells in WT) but the increase in CD4+ in WT mice 6 days
after PbA-infection remained a trend (Fig. 3.10B).
Importantly, we observed an early expansion of CD8+ T cells in PbA-infected WT
mice on day 3 p.i., which slightly decreased on 6 dpi. In contrast, the analysis of spleens
from PbA-infected Batf3-/- mice revealed decreased frequencies of CD8+ T cells, which
were significantly different to CD8+ T cell frequencies in PbA-infected WT mice (fold
change to ”WT Naive” on 3 dpi: ”WT PbA” 1.23 vs. ”Batf3-/- PbA” 0.90, p < 0.001; on
6 dpi: ”WT PbA” 1.13 vs. ”Batf3-/- PbA” 0.27, p < 0.001; Fig. 3.10C).
Calculation of CD4+/CD8+ T cell ratios mirrored the strong drop of splenic CD8+ T
cells in PbA-infected Batf3-/- mice in comparison to infected WT mice, in particular at
6 dpi, while the ratios did not differ between naive mice from both strains (Fig. 3.10D).
PbA-infected WT mice presented a significantly lower CD4+/CD8+ T cell ratio compared
to Batf3-/- mice on both analyzed time points after infection (fold change to ”WT Naive”
on 3 dpi: ”WT PbA” 0.86 vs. ”Batf3-/- PbA” 1.09, p < 0.001; on 6 dpi: ”WT PbA” 1.05
vs. ”Batf3-/- PbA” 1.47, p < 0.001; Fig. 3.10D).
Taken together, these data showed an early expansion of splenic CD8+ T cell upon
PbA-infection in WT mice, but not in spleens of infected Batf3-/- mice on 3 dpi. Over
the time course of infection, the CD4+/CD8+ T cell ratio was always significantly lower
in WT animals than in Batf3-/- mice.
3.1.3.2 Cytotoxicity and activation of splenic CD8+ T cells was reduced in
PbA-infected Batf3-/- mice on dpi 6
Even more important than the size of a certain cell subset is its activation status. The
presence and ability of cytotoxic T cells to release pro-inflammatory cytokines and to
kill specifically (infected) cells that might endanger the health of the host organism is
essential for effective immune functions. However, in the case of cerebral malaria, an
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excessive activation of T cells can be detrimental in those cases when host tissue is also
affected.
Building on preliminary data from our lab on T cell activity on 6 dpi, which revealed
an impaired ability of CTLs from Batf3-/- mice to lyse antigen-specific target cells (Schu-
mak et al., unpublished data: Fig. 1.2F), we analyzed spleens from PbA-infected WT
and Batf3-/- mice on both 3 and 6 dpi more detailed for their immune effector activity
in comparison to their naive controls. The cytotoxicity of splenocytes from our experi-
mental groups was determined by measurement of cytokines release (granzyme B, IFNγ)
of cultured spleen cells. Cytokines were analyzed by ELISA in supernatants of spleen
cells which were obtained from d+6 PbA-infected mice and cultured for 24h. IFNγ was
measured also in serum of all experimental groups. Furthermore, splenic CD8+ T cells
from all groups were examined by flow cytometry for their expression profile of surface
marker ICAM-1, an adhesion molecule that is associated with T cell activation. In all
experiments naive mice served as controls.
Splenocyte single cell suspensions from naive animals of WT and Batf3-/- mice showed
similar granzyme B release, which increased in both groups after PbA-infection (Fig. 3.11A).
Three days after PbA-infection, splenocytes from WT mice released more granzyme B
compared to Batf3-/- mice as shown by significant differences in fold change to naive WT
mice for both groups (fold change to ”WT Naive” on 3 dpi: ”WT PbA” 2.11 vs. ”Batf3-/-
PbA” 1.10, p < 0.01). In the late phase of infection, granzyme B release from both strains
was strongly increased, but again, splenocytes from WT mice produced significantly more
granzyme B than those from Batf3-/- mice and this difference was even bigger compared
to 3 dpi (fold change to ”WT Naive” on 6 dpi: ”WT PbA” 33.32 vs. ”Batf3-/- PbA”
11.82, p < 0.01; Fig. 3.11A).
We measured increased IFNγ levels in supernatants of spleen cells from d+3 PbA-
infected WT mice to uninfected WT and found similarly elevated levels of IFNγ in spleno-
cyte cultures from d+3 PbA-infected Batf3-/- mice (fold change to ”WT Naive” on 3 dpi:
”WT PbA” 3.84 vs. ”Batf3-/- PbA” 3.05, not significant; Fig. 3.11B). Similar to granzyme
B release, the IFNγ production from cultured splenocytes increased strongly on 6 dpi in
both infected groups. However, splenocytes from PbA-infected WT mice produced sig-
nificantly more cytokines that those from Batf3-/- mice (fold change to ”WT Naive” on
6 dpi: ”WT PbA” 32.46 vs. ”Batf3-/- PbA” 21.37, p < 0.001; Fig. 3.11B).
In agreement with the cytokine production from spleen cell culture, more IFNγ was
detected in serum from d+3 PbA-infected WT mice than in plasma from naive WT
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Figure 3.11: Cytotoxicity was reduced in spleens of Batf3-/- mice. PbA-infected WT and Batf3-/- mice
were analyzed on 3 and 6 dpi together with naive control mice (n=3-5). A and B: Granzyme B (GrzmB) and
IFNγ were measured by ELISA in supernatant of 24h splenocyte culture. C: IFNγ was determined by ELISA in
serum of all experimental animals. D: Presence of surface marker ICAM-1 on CD8+ T cells was analyzed by flow
cytometry. Values from different time points of analysis are presented as mean fold change (±SD) to naive WT
mice. Dashed lines are shown for better visualization but time points were analyzed in different mice. Differences
were tested separately with ANOVA followed by the Tukey post-test; p values below 0.05 were considered significant
(* = p < 0.05, ** = p < 0.01, *** = p < 0.001).
mice. Serum levels of IFNγ from Batf3-/- mice were slightly increased on 3 dpi but were
significantly lower compared to infected WT controls (fold change to ”WT Naive” on
3 dpi: ”WT PbA” 18.96 vs. ”Batf3-/- PbA” 2.56, p < 0.001; Fig. 3.11C). Interestingly,
IFNγ in the serum of d+6 PbA-infected mice was at similar high levels in both WT and
Batf3-/- mice (fold change to ”WT Naive” on 6 dpi: ”WT PbA” 22.13 vs. ”Batf3-/- PbA”
25.87, not significant; Fig. 3.11C).
The analysis for surface marker ICAM-1 on CD8+ T cells revealed a small, but signif-
icant reduction in expression of this adhesion molecule in Batf3-/- mice compared to WT
controls 3 days after infection (fold change to ”WT Naive” on 3 dpi: ”WT PbA” 1.17 vs.
”Batf3-/- PbA” 1.01, not significant; Fig. 3.11D). Six days after PbA-infection, ICAM-1
expression was increased in both infected groups when compared to naive controls, but
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CD8+ T cells from Batf3-/- mice expressed significantly less ICAM-1 when compared to
the WT infection controls (fold change to ”WT Naive” on 6 dpi: ”WT PbA” 2.30 vs.
”Batf3-/- PbA” 1.83, p < 0.001; Fig. 3.11D).
In summary, peripheral production of inflammation-associated cytokines and ICAM-1
expression on CD8+ T cells was elevated in WT mice but not in Batf3-/- mice in early
and late phases of PbA-infection.
In addition to the previously shown results we analyzed CD8+ T cells in more detail
on 6 dpi. Analysis of T cell activation markers was performed via flow cytometry anal-
ysis on CD8+ T cells for intracellular cytokine production (granzyme B and IFNγ) and
extracellular expression of CD11c, which is an accepted marker of T cell activation.
Figure 3.12: Impaired cytotoxicity in spleens of PbA-infected Batf3-/- mice on 6 dpi. WT and Batf3-/-
mice were analyzed 6 days after PbA-infection and compared with naive control mice of both strains. CD8+ T cells
were gated in flow cytometry analysis as described before. We further analyzed this population for different intra-
and extracellular activation markers: granzyme B (A: dot plot from spleen cells, B: gMFI), IFNγ (C: gMFI) and
CD11c intermediate population (D: frequency). All data are presented as mean (±SEM (standard error of mean))
and were analyzed for significance with ANOVA and Tukey correction. p values smaller than 0.05 were considered
significant.
53
CHAPTER 3. RESULTS
On day 6 after PbA-infection, we measured high levels of granzyme B in splenic CD8+
T cells from WT and Batf3-/- mice which was seen in FACS dot plot as frequencies
(Fig. 3.12) and measured as geometric mean fluorescence intensity (”WT PbA”: gMFI
9093, ”Batf3-/- PbA”: gMFI 5862), compared to baseline levels in both naive groups
(”WT Naive”: gMFI 16; ”Batf3-/- Naive”: gMFI 18; p < 0.001 compared to PbA-infected
mice). However, the increase in granzyme B expression in Batf3-/- mice was significantly
lower than in infected WT mice (p < 0.05; 3.12B). We also determined increased produc-
tion of intracellular IFNγ in splenic CD8+ T cells from PbA-infected WT mice compared
to weak baseline levels in naive mice (”WT PbA”: gMFI 303, ”WT Naive”: gMFI 127,
p < 0.001; Fig. 3.12C). Interestingly, T cells from Batf3-/- mice showed an enhanced IFNγ
level already in the naive status (gMFI 199, p < 0.05 to ”WT Naive”) that was further
increased after PbA-infection (gMFI 374, p < 0.001 to ”Batf3-/- Naive”) and was signifi-
cantly (p < 0.05) higher than the gMFI of IFNγ in PbA-infected WT mice.
CD11c is expressed on regulatory and effector CD8+ T cells, but in different intensi-
ties: high CD11c expression is found on regulatory cells , intermediate expression is a sign
for effector cells [Vinay and Kim, 2009]. Therefore the analysis of the mean intensity is
not possible for this marker, but the frequency of CD8+ T cells expressing intermediate
CD11c could be determined. Similar to the other results, we found more CD11cInt CD8+
T cells in spleens of mice that had been infected with PbA before compared to naive
mice (”WT Naive”: 7.1%, ”WT PbA”: 67.4%, ”Batf3-/- Naive”: 6.9%, ”Batf3-/- PbA”:
52.6%; 3.12D). We could not see any difference between naive mice of both strains regard-
ing their frequencies of CD11cInt cells of CD8+ T cells, but in spleens of PbA-infected
Batf3-/- mice significantly less T cells expressed CD11cInt compared to T cells from in
WT mice (p < 0.01).
Taken together, these results show that the pro-inflammatory environment in the
spleen and especially the activation of cytotoxic T cells was markedly impaired in PbA-
infected Batf3-/- mice. However, we could not differentiate between different cell types in
the spleen cell culture. It is likely that also other cells, such as CD4+ T Cells, natural
killer cells (NK cells) and natural killer T cells (NKT cells) have contributed to cytokine
levels and also to immune responses in PbA-infected mice. However, activation markers
in CD4+ cells were similar to those seen in CD8+ T cells (Fig. S7).
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3.1.3.3 NK cells were more activated in the spleens of PbA-infected Batf3-/-
mice on dpi 6
In addition to T cells, also natural killer (NK) and natural killer T (NKT) cells can con-
tribute to a pro-inflammatory immune responses and fighting an infection by production
of IFNγ and granzyme B [Hansen et al., 2007]. In Plasmodium infection, NK cells are
mainly described to be involved in the first line defense as part of the innate immune sys-
tem [Roetynck et al., 2006]. Even though, NK cells are probably not the main cytotoxic
effector cells in cerebral malaria, a change of cell numbers or NK / NKT cell activation
might contribute to the high levels of IFNγ and granzyme B in whole spleen cell cultures.
To address the role of NK cells in our PbA-mouse model, spleens from d+3 and
d+6 PbA-infected WT and Batf3-/- mice were processed for FACS staining as described
before and surface markers CD3 and NK1.1 were used to differentiate between NK cells
(CD3−NK1.1+) and NKT cells (CD3+NK1.1+). Additionally we purified NK and NKT
cells via MACS separation using magnetic antibodies coupled to DX5, which is present on
NK and NKT cells. These enriched cells were cultured with IL-2 for stimulation and WT
BMDCs, BMDCs derived from Batf3-/- mice or without any BMDCs. The generated cell
culture supernatant was collected after 24h and analyzed by ELISA for granzyme B and
IFNγ.
Figure 3.13: NK and NKT cells were elevated in spleens of Batf3-/- mice after PbA-infection, compared
to infected WT mice. Spleens of d+3 and d+6 PbA-infected WT and Batf3-/- mice (n=5-6) as well as naive
controls (n=3-4) were processed for FACS analysis and stained with surface markers CD3 and NK1.1 to identify
NK cells (CD3−NK1.1+; A) and NKT cells (CD3+NK1.1+; B). Values from different time points of analysis are
presented as mean fold change (±SD) to naive WT mice. Dashed lines are shown for better visualization but time
points were analyzed in different mice. Differences were tested separately with ANOVA followed by the Tukey
post-test; p values below 0.05 were considered significant (* = p < 0.05, ** = p < 0.01, *** = p < 0.001).
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We observed no differences in the percentage of splenic NK cells on day 3 after PbA-
infection, but a strong decrease in this cell population on 6 dpi in WT and Batf3-/- mice
(fold change to ”WT Naive” on 3 dpi: ”WT PbA” 1.03 vs. ”Batf3-/- PbA” 1.13, not
significant; on 6 dpi: ”WT PbA” 0.27 vs. ”Batf3-/- PbA” 0.60, p < 0.001; Fig. 3.13A).
Interestingly, spleens of Batf3-/- mice at 6 dpi contained more NK cells compared to WT
controls at the same day.
In contrast to NK cells, NKT cell frequencies did not drop during the course of infec-
tion. Spleens of PbA-infected WT mice contained similar frequencies of NKT cells on 3
and 6 dpi (fold change to ”WT Naive” on 3 dpi: ”WT PbA” 0.86, on 6 dpi: ”WT PbA”
1.11; Fig. 3.13B). Uninfected Batf3-/- mice contained similar frequencies of NK cells in
their spleens, but this cell population increased upon PbA-infection and led to significantly
(p < 0.001) more splenic NKT cells in Batf3-/- mice at 3 and 6 dpi (fold change to ”WT
Naive” in ”Batf3-/- Naive”: 1.07, on 3 dpi: 1.26, on 6 dpi: 1.56; Fig. 3.13B).
Taken together, PbA-infected Batf3-/- mice contained more NK and NKT cells in their
spleens compared to their WT infection-controls.
Figure 3.14: NK and NKT cells from spleens of Batf3-/- mice produced significantly more granzyme B
after PbA-infection than infected WT mice. NK and NKT cells from all experimental groups (n=3-5; 3 and
6 dpi for PbA-infected mice) were sorted via MACS sorting after labeling with magnetic beads coupled to DX-5
antibody. Sorted cells were incubated with IL-2 and BMDCs from naive WT donor mice that were cultured with
GM-CSF for a week prior to the experiment. Supernatant was collected the next day and subjected to sandwich-
ELISAs for granzyme B (A) and IFNγ (B). Values from different time points of analysis are presented as mean fold
change (±SD) to naive WT mice. Dashed lines are shown for better visualization but time points were analyzed
in different mice. Differences were tested separately with ANOVA followed by the Tukey post-test; p values below
0.05 were considered significant (* = p < 0.05, ** = p < 0.01, *** = p < 0.001).
Production of granzyme B and IFNγ from DX-5 sorted NK and NKT cells was sim-
ilarly low in both naive groups and increased around 2-fold in both infected groups at
3 dpi (granzyme B fold change to ”WT Naive” on 3 dpi: ”WT PbA” 1.97 vs. ”Batf3-/-
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PbA” 1.64, not significant; IFNγ on 3 dpi: ”WT PbA” 2.58 vs. ”Batf3-/- PbA” 1.77,
not significant; Fig. 3.14A, B). Cells purified from spleens of d+6 PbA-infected mice of
both strains produced more than 10-fold more granzyme B and IFNγ than naive controls
(granzyme B fold change to ”WT Naive” on 6 dpi: ”WT PbA” 9.91 vs. ”Batf3-/- PbA”
20.72,p < 0.001; IFNγ on 3 dpi: ”WT PbA” 14.17 vs. ”Batf3-/- PbA” 11.08, not signifi-
cant; Fig. 3.14A, B). Importantly, NK and NKT cells from d+6 PbA-infected Batf3-/- mice
produced significantly more granzyme B than cells from infected WT mice (p < 0.001).
Additionally to culturing the DX55 sorted cells with BMDCs from naive WT mice,
we performed another two approaches. Here, splenic DX5-sorted NK/T cells were either
incubated with BMDCs from naive Batf3-/- mice or without any BMDCs. Culturing with
BMDCs from Batf3-/- mice did not show any difference in levels of cytokine production for
IFNγ and granzyme B. When cells were incubated without BMDCs, they were still able
to produce cytokines, but at a reduced level (10-fold less). Interestingly, the differences
between the experimental groups remained the same.
Additionally, we examined the NK/T cells of d+6 PbA-infected WT and Batf3-/-
mice by flow cytometry for signs of activation such as changes in intracellular cytokine
production and surface markers. We analyzed the expression of intracellular granzyme B
and IFNγ and extracellular surface markers which are associated with inflammation such
as ICAM-1 and CD107a.
While the analysis of NKT cells did not reveal any differences between all PbA-infected
WT and Batf3-/- mice (exception CD107a, Fig. S10), we observed significant differences in
NK cells from PbA-infected WT and Batf3-/- mice (Fig. 3.15). The analysis of granzyme B
in splenic NK cells revealed a strong increase in cytokine production after PbA-infection.
While naive mice from both strains had almost no detectable granzyme B (gMFI WT:
357, gMFI Batf3-/-: 284), granzyme B expression was increased in PbA-infected WT mice
(p < 0.05 to ”WT Naive”) and in infected Batf3-/- mice (p < 0.01 to ”Batf3-/- Naive”,
Fig. 3.15A). The higher level of granzyme B in infected Batf3-/- mice was not significantly
different compared to the values of the ”WT PbA” groups, possibly also due to the high
standard deviation in the latter group.
In these splenic NK cells, IFNγ levels were very low in general, however, we detected a
significant (p < 0.05) reduction of IFNγ expression in NK cells from PbA-infected Batf3-/-
mice compared to infected WT controls (gMFIs of ”WT Naive”: 240, ”WT PbA”: 226,
”Batf3-/- Naive”: 219, ”Batf3-/- PbA”: 179; Fig. 3.15B).
57
CHAPTER 3. RESULTS
Figure 3.15: NK cells from spleens of d+6 PbA-infected Batf3-/- mice displayed enhanced activity
in both, cytotoxic and regulatory markers. NK cells from spleens of PbA-infected and naive mice of WT
and Batf3-/- strains (n=3-5) were defined as described before. Cells were then analyzed via flow cytometry for
intracellular cytokines granzyme B (A) and IFNγ (B) and surface markers ICAM-1 (C) and CD107a (D). Results
are shown as mean (±SEM) and were tested for statistical significance with ANOVA and Tukey post test. p values
below 0.05 were considered significant.
Six days after PbA-infection, the surface expression of ICAM-1 on splenic NK cells
were significantly changed in WT mice (naive: gMFI 3297, gMFI infected: 4687, p < 0.01;
Fig. 3.15C). Uninfected Batf3-/- mice had similar ICAM-1 expression as their WT counter-
parts (gMFI 2769), but NK cells from PbA-infected Batf3-/- mice expressed significantly
(p < 0.001) more ICAM-1 on their surface (gMFI 6759) compared to their naive controls
but also to PbA-infected WT mice (p < 0.001; Fig. 3.15C).
CD107a is an activation marker that is used to identify degranulating cells and was
only expressed at very low levels in NK cells from WT mice and naive Batf3-/- mice (”WT
Naive”: gMFI 11, ”WT PbA”: gMFI 10, ”Batf3-/- Naive”: gMFI 12). Interestingly, in
PbA-infected Batf3-/- mice, the surface expression of CD107a on splenic NK cells was
significantly increased (gMFI 35, p < 0.001; Fig. 3.15D). Analysis of splenic NKT cells
revealed similar results for expression of CD107a (Fig. S10D). However, this expression
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level was still very low in general.
All together, PbA-infected Batf3-/- mice had more NK and NKT cells in their spleens
and these cells were found to produce more cytokines and express more pro-inflammatory
markers than cells from PbA-infected WT mice.
3.1.3.4 CD4+ dendritic cells from Batf3-/- mice expressed more CD40 on
their surface after PbA-infection
Dendritic cells represent a link between innate and adaptive immunity by presenting anti-
gen to effector cells. As Batf3-/- mice genetically lack cross-presenting dendritic cells
(defined as XCR1+), which are important in generation of the cytotoxic CD8+ T cell
response, we were interested if XCR1− dendritic cells would be more activated to com-
pensate for this lack.
To address this question, we sacrificed PbA-infected WT and Batf3-/- mice 3 and 6
days p.i. as well as naive mice from both strains and prepared their spleens for flow
cytometry analysis as described before. After excluding CD3+, NK1.1+ and B220+ cells
from analysis, dendritic cells were defined as CD11c+I-Ab+. Dendritic cells were further
divided into XCR1+ and CD4+ subsets, with the first being cross-presenting DCs (which
are lacking in Batf3-/- mice) and the latter being conventional DCs.
Figure 3.16: Dendritic cell numbers decreased in spleens of PbA-infected WT and Batf3-/- mice. Spleens
of d+3 and d+6 PbA-infected WT and Batf3-/- mice and their respective naive controls were processed for FACS
staining (n=3-6). A: Dendritic cells were defined as CD11c+I-Ab+ from CD3−NK1.1−B220− cells. Dendritic cells
were further subdivided into XCR1+ DCs (B) and CD4+ DCs (C). Values from different time points of analysis
are presented as mean fold change (±SD) to naive WT mice. Dashed lines are shown for better visualization but
time points were analyzed in different mice. Differences were tested separately with ANOVA followed by the Tukey
post-test; p values below 0.05 were considered significant (* = p < 0.05, ** = p < 0.01, *** = p < 0.001).
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The results of dendritic cell staining indicated that uninfected Batf3-/- mice contained
significantly more DCs in their spleens compared to WT mice (fold change to ”WT Naive”
1.39, p < 0.001; Fig. 3.16A). Compared to their respective naive controls, PbA-infected
mice of both experimental groups contained reduced DC frequencies in spleens from 3 dpi
on, which further declined on 6 dpi. The higher frequency of dendritic cells in Batf3-/-
mice compared to WT controls seen in naive mice remained visible on 3 dpi, but was no
longer seen 6 days after infection (fold change to ”WT Naive” on 3 dpi: ”WT PbA” 0.71
vs. ”Batf3-/- PbA” 1.06, p < 0.001; on 6 dpi: ”WT PbA” 0.48 vs. ”Batf3-/- PbA” 0.54,
not significant; Fig. 3.16A).
As expected, we confirmed the genetic deficiency of cross-presenting DCs, as in Batf3-/-
mice almost no XCR1+ DCs were found (fold change to ”WT Naive”: naive 0.09, on 3 dpi
0.07, on 6 dpi 0.07; Fig.3.16B) and the vast majority of DCs were CD4+ (fold change to
”WT Naive”: naive 1.14, on 3 dpi 1.15, on 6 dpi 1.13; Fig.3.16C). Interestingly, in spleens
of WT mice frequencies of cross-presenting DCs, identified by XCR1, decreased 3 day
after PbA-infection and further declined in the course of infection till 6 dpi (fold change
to ”WT Naive”: on 3 dpi 0.86, on 6 dpi 0.24; Fig.3.16B). Accordingly, the number of
CD4+ (XCR1−) dendritic cells increased in WT mice till 6 days after PbA-infection (fold
change to ”WT Naive”: on 3 dpi 1.01, on 6 dpi 1.13; Fig.3.16B). Differences in DC subsets
between both strains were found to be significant in naive mice and on 3 dpi (p < 0.001),
but no longer on 6 dpi were almost no XCR1+ DCs were found in PbA-infected WT mice.
Additionally to the regulations in cell frequencies, we were also interested in the ac-
tivation status of the dendritic cells. The lack of XCR1+ DCs in Batf3-/- mice could
lead to a regulation of the remaining DCs in order to compensate for the missing subset.
Therefore, CD4+ DCs were stained for CD40, CD80 or CD86 and CCR7, which enhance
the interactions of dendritic cells with T cells but also B cells and regulate their functions.
Surface expression of CD40 on CD4+ dendritic cells found in the spleens of d+6 PbA-
infected WT mice was slightly increased on 3 dpi in both, WT and Batf3-/- mice, compared
to CD40 levels in naive WT mice (fold change to ”WT Naive” on 3 dpi: ”WT PbA” 1.41
vs. ”Batf3-/- PbA” 1.54, not significant; Fig. 3.17A). However, splenic DCs of naive and
d+3 PbA-infected Batf3-/- mice did not differ from those of WT control mice in their
CD40 expression. After 6 days of PbA-infection, the surface expression of CD40 on CD4+
dendritic cells increased in both groups, but significantly more so in Batf3-/- mice (fold
change to ”WT Naive” on 6 dpi: ”WT PbA” 2.35 vs. ”Batf3-/- PbA” 3.76, p < 0.001;
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Figure 3.17: CD40 was increased on splenic DCs in d+6 PbA-infected Batf3-/- mice. CD4+ dendritic
cells that were identified from spleens of d+3 and d+6 PbA-infected Batf3-/- and WT mice and their respective
uninfected controls (Fig. 3.16), were analyzed for expression of surface marker CD40 (A), CD80/CD86 (B) and
CCR7 (C, 6 dpi only) by flow cytometry (n=3-6). Values from different time points of analysis are presented as
mean fold change (±SD) to naive WT mice. Dashed lines are shown for better visualization but time points were
analyzed in different mice. Values from 6 dpi are presented as mean ± SEM. Differences were tested separately
with ANOVA followed by the Tukey post-test; p values below 0.05 were considered significant (* = p < 0.05, ** =
p < 0.01, *** = p < 0.001).
Fig. 3.17A).
Unlike for CD40, we could not detect an increase of CD80 expression on non-cross-
presenting DCs in spleens of PbA-infected Batf3-/- mice compared to the WT infection
control, but rather a small down-regulation on 3 dpi, which was resolved by 6 dpi (fold
change to ”WT Naive” on 3 dpi: ”WT PbA” 2.16 vs. ”Batf3-/- PbA” 1.58, p < 0.01; on
6 dpi: ”WT PbA” 1.80 vs. ”Batf3-/- PbA” 1.47, not significant; Fig. 3.17B).
The expression of CCR7, a receptor that is involved in Treg regulation by DCs, was
significantly increased in both infected groups on 6 dpi (p < 0.001) with no differences be-
tween WT and Batf3-/- mice (”WT Naive”: gMFI 212, ”WT PbA”: gMFI 481, ”Batf3-/-
Naive”: gMFI 246, ”Batf3-/- PbA” gMFI 451, ; Fig. 3.17C).
In summary, frequencies of dendritic cells were higher in uninfected Batf3-/- mice and
in early infection but did not differ between d+6 PbA-infected Batf3-/- and WT mice.
Six days after PbA-infection, splenic CD4+ DCs from knock-out animals had a stronger
upregulation of CD40 on their surface, but this observation was not consistent throughout
all experiments.
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3.1.3.5 Antigen-presenting cells in Batf3-/- mice showed a reduced pro-inflam-
matory milieu on 3 dpi, compared to WT controls
Not only dendritic cells but also other antigen-presenting and phagocytic cells like neu-
trophils, Ly6C+ monocytes and macrophages help to fight an infection as part of the innate
immune response but also for initiation and support for the adaptive immune response.
First, we were interested if frequencies of neutrophils, Ly6C+ monocytes or macrophages
would change differently in Batf3-/- and WT mice upon PbA-infection. Therefore spleens
were harvested from those mice 6 days after PbA-infection and analyzed for these cell
types by flow cytometry. Spleens of infected and naive mice of both strains were prepared
as usual. After exclusion of T cells, NK cells, NKT cells, B cells and dendritic cells, the re-
maining cells were gated for CD11b before differentiation into Ly6C+Ly6G+ (neutrophils),
Ly6C+Ly6G− (Ly6C+ monocytes) or Ly6C−Ly6G− (macrophages) subsets.
The flow cytometric analysis did not reveal any differences in CD11b+ frequency in
d+3 PbA-infected WT mice compared to their naive controls, but a significant increase
of these cells in d+3 PbA-infected Batf3-/- mice compared to their WT infection controls
(fold change to ”WT Naive” on 3 dpi: ”WT PbA” 1.03 vs. ”Batf3-/- PbA” 1.43, p < 0.01;
Fig. 3.18A). Six days after infection, the frequencies of CD11b+ cells in spleens of PbA-
infected mice dropped in both groups and the difference seen on 3 dpi was no longer
significant (fold change to ”WT Naive” on 6 dpi: ”WT PbA” 0.31 vs. ”Batf3-/- PbA”
0.54, not significant; Fig. 3.18A).
CD11b+ cells were then gated for Ly6C and Ly6G to distinguish between neutrophils
(Fig. 3.18B), Ly6C+ monocytes (fig, 3.18C) and other macrophages (Fig. 3.18D). When
analyzing neutrophils we did observe a small decrease of neutrophil frequencies on 3 dpi,
followed by a strong increase in frequencies on 6 dpi in both PbA-infected groups. Differ-
ences between WT and Batf3-/- mice were very small and only 3 dpi revealed significant
differences (p < 0.05, as spleens of Batf3-/- mice contained slightly more neutrophils among
CD11b+ cells (fold change to ”WT Naive” on 3 dpi: ”WT PbA” 0.63 vs. ”Batf3-/- PbA”
0.75, not significant; on 6 dpi: ”WT PbA” 1.90 vs. ”Batf3-/- PbA” 1.89, not significant;
Fig. 3.18B).
While there was also no difference between naive WT and Batf3-/- mice in the percent-
age of Ly6C+ monocytes (fold change to ”WT Naive” 0.99), the analysis of d+3 infected
mice revealed a significant increase of Ly6C+ monocytes in spleens of WT mice but not
in Batf3-/- mice (fold change to ”WT Naive” on 3 dpi: ”WT PbA” 1.43 vs. ”Batf3-/-
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Figure 3.18: Inflammatory monocytes were not increased in spleens of Batf3-/- but in WT mice on
dpi 3. Spleens of PbA-infected (3 and 6 dpi) and naive WT and Batf3-/- mice (n=3-6) were analyzed for CD11b+
cells by FACS (A), after exclusion of other cell subsets and further differentiated into neutrophils (Ly6C+Ly6G+,
B), Ly6C+ monocytes (Ly6C+Ly6G−, C) or macrophages (Ly6C−Ly6G−, D). Values from different time points of
analysis are presented as mean fold change (±SD) to naive WT mice. Dashed lines are shown for better visualization
but time points were analyzed in different mice. Differences were tested separately with ANOVA followed by the
Tukey post-test; p values below 0.05 were considered significant (* = p < 0.05, ** = p < 0.01, *** = p < 0.001).
PbA” 1.02, p < 0.001; Fig. 3.18C). Accordingly, the amount of other macrophages was
significantly reduced in PbA-infected WT mice on 3 dpi when compared to synchronistic
infected Batf3-/- mice (fold change to ”WT Naive” on 3 dpi: ”WT PbA” 0.80 vs. ”Batf3-/-
PbA” 1.05, p < 0.01; Fig. 3.18D).
Interestingly, we observed a reduction in Ly6C+ monocytes and other macrophage
populations in d+6 PbA-infected WT and Batf3-/- mice, but no differences between both
strains in the late phase of infection (fold change to ”WT Naive” in Ly6C+ monocytes:
”WT PbA” 0.74 vs. ”Batf3-/- PbA” 0.78, not significant; in other macrophages: ”WT
PbA” 0.49 vs. ”Batf3-/- PbA” 0.41, not significant; Fig. 3.18C, D).
Overall we saw a shift to more Ly6C+ monocytes in splenic CD11b+ cells in WT mice
but not in Batf3-/- mice on 3 dpi. Analyses on 6 dpi did not reveal any differences in
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CD11b+ cells and defined subsets.
Additionally to surface markers on dendritic cells, we checked for cytokines like TNF
and CCL2 that are produced by antigen-presenting cells, in supernatants of cultured
splenocytes, that were isolated from d+3 PbA-infected WT and Batf3-/- mice or their
respective controls and incubated for 24h.
Figure 3.19: TNF production in the spleen was increased 3 days after PbA-infection, but CCL2 levels
remained unchanged. Cytokine production for TNF (A) and CCL2 (B) was measured in spleen cells harvested 3
days after PbA-infection and uninfected animals (WT and Batf3-/-; n=4-6). Cells supernatant was collected after
24h and subjected to an ELISA assay. Results are shown as mean (±SEM). Statistical differences with p < 0.05
calculated with ANOVA + Tukey were considered significant.
TNF was similar in supernatants of naive mice from both strains (WT: 38.3 pg/ml,
Batf3-/-: 27.8 pg/ml) and increased upon PbA-infection (3 dpi) (WT: 68.0 pg/ml, Batf3-/-:
41.8 pg/ml; Fig. 3.19A). Importantly, splenocyte cultures of PbA-infected WT mice pro-
duced significantly more TNF than PbA-infected Batf3-/- mice and also naive WT controls
(p < 0.05). CCL2 production of splenocytes did not differ between all analyzed groups
(76-110 pg/ml; Fig. 3.19B)
In summary, we observed a significantly reduced TNF production from splenocytes
of PbA-infected Batf3-/- mice when compared to infected WT mice, but CCL2 levels re-
mained unchanged in all groups.
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3.1.3.6 Phagocytic capacity of CD11b+ cells from PbA-infected Batf3-/- mice
was reduced on 6 dpi compared to WT mice
Antigen-presentation is indispensable for initiation of the adaptive immune response. Anti-
gen uptake (phagocytosis) is an important first step to its later presentation by MHC
class II molecules, which leads to activation of CD4+ T cells. As Batf3-/- mice lack cross-
presenting dendritic cells we were interested to see if other classical antigen-presenting
cells would differ in their ability to take up antigen. To answer this question we set up a
phagocytosis assay were spleen cells from uninfected and PbA-infected mice (6 dpi, WT
and Batf3-/-) were first MACS-sorted for CD11b. Sorted cells were then incubated with
opsonized, fluorescent labeled beads for one hour to give cells time to take up the beads.
For opsonation beads were incubated with pooled plasma from naive and infected mice of
both strains.
Combination of serum opsonized beads and cells (see also Table 2.1)
Cells*:
Plasma**:
WT Naive WT PbA Batf3-/- Naive Batf3-/- PbA
CD11b+ WT Naive X X X X
CD11b+ WT PbA X X X X
CD11b+ Batf3-/- Naive X X X X
CD11b+ Batf3-/- PbA X X X X
*Source of potential phagocytosing cells; single approaches for all animals per group
** Source of plasma for bead opsonation; pooled plasma from all animals in one group
We first compared the phagocytic activity in CD11b+ cells after PbA-infection sepa-
rately for Ly6C+ monocytes (Ly6C+Ly6G−), neutrophils (Ly6C+Ly6G+) and macrophages
(Ly6C−Ly6G−) on 3 dpi. Overall around 10% of CD11b+ cells were able to phagocyte
the beads opsonized with serum from the corresponding groups (”matched approach”,
Fig. 3.20). However, we could neither observe any difference between the two different
mouse strains nor between d+3 PbA-infected mice and their uninfected controls. Incu-
bating cells from uninfected mice with beads opsonized with serum from infected mice
and vice versa did not alter these findings.
When we analyzed the phagocytic capacity 6 days after PbA-infection, the frequency
of phagocytic splenic monocytes was significantly increased in WT mice as compared to
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Figure 3.20: Phagocytosis of APCs in the spleen was impaired in Batf3-/- mice on 6 dpi but not
changed in early PbA-infection (3 dpi). Phagocytic activity was tested with a bead-uptake-assay 3 and 6
days after PbA-infection in WT (n=2-5) and Batf3-/- mice (n=5-6) and their respective naive controls (n=4-5).
For enhancement of bead uptake, beads were opsonized with plasma from the corresponding groups. Graphs show
the percentage of different CD11b+ cell subsets that were able to take up beads during one hour incubation. Cell
subsets were differentiated via FACS staining into Ly6C+ monocytes (CD11b+Ly6C+Ly6G−; A: 3 dpi, D 6 dpi),
neutrophils (CD11b+Ly6C+Ly6G+; B: 3 dpi, E 6 dpi) and macrophages (CD11b+Ly6C−Ly6G−; C: 3 dpi, F 6 dpi).
Data is shown as mean (±SEM), statistical significance was tested with ANOVA followed by Tukey post test. p
values less than 0.05 were considered significant.
samples from naive WT controls (”WT Naive”: 12.1%, ”WT PbA”: 19.2%, ”p < 0.05;
3.20D). This was also observed in samples from Batf3-/- mice when we compared naive
and PbA-infected mice (7.7% in naive to 13.9% in infected animals, p < 0.05). Similar to
analysis on 3 dpi, phagocytosis in naive Batf3-/- mice did not differ significantly to WT
mice).
Similarly, in splenic neutrophils from WT and Batf3-/- mice the capacity to phago-
cyte beads increased significantly in both strains upon in PbA-infection (”WT Naive”:
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20.5%, ”WT PbA”: 51%, ”Batf3-/- Naive”: 14.2%, ”Batf3-/- PbA”: 32.6%, p < 0.001;
Fig. 3.20E). Importantly, while the phagocytic capacity increased in both strains after
PbA-infection, splenic neutrophils from Batf3-/- mice took up significantly less beads than
neutrophils from WT mice (p < 0.01). Again, no significant difference between naive mice
from both strains were observed.
Analysis of macrophages showed that only few cells of this subtype were able to phago-
cyte the beads in this experiment (1.5-5.2%); 3.20F. However, a trend to more phagocy-
tosis in infected animals of both strains remained (WT 3.8 vs. 4.6%, Batf3-/- 1.9% vs.
3.1%). In this experiment cells isolated from naive Batf3-/- mice showed a small decrease
in phagocytic activity when compared to naive WT animals (p < 0.05).
Additionally to the described ”matched” setup (beads were opsonized with plasma
from one group and then incubated with CD11b+ cells from the same group), we also
performed ”mixed approaches” (incubation of beads that were opsonized with plasma
from naive WT and PbA-infected mice and then incubated with CD11b+ cells from all
groups; see Chapter 2.2.9). First, we observed that more cells from naive mice of both
strains ingested beads which were opsonized with plasma from PbA-infected WT mice
(compared to uptake of bead opsonized with naive plasma). On the other hand, less WT
PbA-CD11b+ cells were able to phagocyte beads that were incubated with naive plasma
compared to opsonation with PbA-plasma.
In summary, phagocytic activity was not changed in any CD11b+ cell subset in early
PbA-infection (3 dpi) in neither WT nor Batf3-/- mice and no differences between both
strains were seen. Six days after infection, we observed an increase in phagocytic activity
in both mouse strains after PbA-infection, but this increase was less in Batf3-/- mice.
Interestingly, our ”mixed approach” showed that the plasma that was used to opsonize
the beads was also influencing the number of beads that were taken up by CD11b+ cells.
3.1.3.7 Immune regulatory mechanisms in PbA-infected Batf3-/- mice were
elevated on 6 dpi
Pro-inflammatory immune responses need regulatory mechanisms to prevent damage to
healthy cells by undesired side effects of the immune response. As cerebral malaria is
partly caused by an overwhelming immune response to the parasite, the role of regulatory
immune mechanisms in Plasmodium infections have to be considered. The analyses of
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PbA-infected Batf3-/- mice revealed complete protection from ECM in these mice and an
impaired cytotoxic activity in CD8+ T cells. We were now interested whether the protec-
tion from ECM in Batf3-/- mice was caused not only by attenuated cytotoxicity in T cells
but also by active regulatory mechanism. As regulatory functions are described to take
also place early in infection [Mitchell et al., 2005], we compared spleens of PbA-infected
WT and Batf3-/- mice on 3 and 6 dpi with naive animals serving as controls.
First, we analyzed the capability of splenocytes to produce the regulatory cytokine IL-
10 in whole spleen cell cultures from all experimental groups on 3 and 6 dpi. Therefore,
single cell suspensions were generated from harvested spleens and cultured for 24h.
Figure 3.21: IL-10 and IL-6 production from splenic CD11b+ cells was increased in PbA-infected
Batf3-/- mice. WT and Batf3-/- mice were infected with PbA (n=3-5) and spleens were analyzed 3 and 6 days
later. Naive mice (n=3) served as controls. IL-10 was measured in supernatant of 24h incubated splenocyte culture
with whole spleen cell suspension (A) or cells sorted for CD4 (B) or CD11b (C). IL-6- was measured in supernatants
of whole splenocytes cultures (D) and cultured CD11b MACS-sorted cells (E) that were obtained from d+6 PbA-
infected and naive mice. Results from 6 dpi are presented as mean (±SEM). Values from different time points of
analysis are presented as mean fold change (±SD) to naive WT mice. Dashed lines are shown for better visualization
but time points were analyzed in different mice. All differences were tested separately with ANOVA followed by the
Tukey post-test; p values below 0.05 were considered significant (* = p < 0.05, ** = p < 0.01, *** = p < 0.001).
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The ELISA of samples from whole splenocyte cultures did not show any significant
difference in all experimental groups without PbA-infection and on 3 dpi, however we
observed increased IL-10 production at 6 dpi in both groups with more IL-10 in super-
natants of splenocyte culture from Batf3-/- mice (fold change to ”WT Naive” on 3 dpi:
”WT PbA” 0.91 vs. ”Batf3-/- PbA” 0.87, not significant; on 6 dpi: ”WT PbA” 1.59 vs.
”Batf3-/- PbA” 1.93, p < 0.05; Fig. 3.21A). Repetition experiments showed similar trends,
but not all reached significance with this number of experimental animals per group.
We observed increased IL-10 levels in splenocyte cultures from Batf3-/- mice on 6 dpi
and therefore, asked which cell type could be the source of the measured IL-10, as it can
be produced by different immune cells with regulatory functions like CD4+ T cells, M2
Macrophages, CD11b+ dendritic cells but also by B cells. We analyzed IL-10 in super-
natant of MACS-purified CD4+ (mainly T cells) and CD11b+ (macrophages, dendritic
cells) cells which were cultured separately to gain insight in the source of IL-10 produc-
tion. As also IL-6 can be produced by M2 macrophages, we measured this interleukin in
CD11b+ cell culture.
IL-10 production from in CD4+ sorted spleen cells was rather low in general (around
6-fold less compared to total spleen cell culture) and PbA-infection further reduced IL-10
production in both strains (”WT Naive”: 0.05 ng/ml, ”WT PbA”: 0.03 ng/ml, ”Batf3-/-
Naive”: 0.07 ng/ml, ”Batf3-/- PbA”: 0.03 ng/ml; Fig. 3.21B). The difference between
naive and infected Batf3-/- mice was big enough to reach statistical significance (p < 0.01)
which was not the case in the WT groups. Interestingly, CD11b+ cells from naive mice
of both groups but also PbA-infected WT mice produced only low levels of IL-10 while
production of this cytokine was markedly increased in PbA-infected Batf3-/- mice (”WT
Naive”: 0.12ng/ml, ”WT PbA”: 0.20 ng/ml, ”Batf3-/- Naive”: 0.15 ng/ml, ”Batf3-/-
PbA”: 0.78 ng/ml, p < 0.001; Fig. 3.21C).
IL-6 levels in supernatants of whole spleen cell cultures and in MACS-sorted CD11b+
splenocytes cultures were generally higher in Batf3-/- mice compared to WT mice, in-
dependent of the infection status, but interestingly, IL-6 production did not change sig-
nificantly in either group upon PbA-infection. (whole splenocyte culture: ”WT Naive”:
0.08 ng/ml, ”WT PbA”: 0.08 ng/ml, ”Batf3-/- Naive”: 0.15 ng/ml, ”Batf3-/- PbA”: 0.18
ng/ml, p < 0.05; CD11b+ cell culture: ”WT Naive”: 0.05 ng/ml, ”WT PbA”: 0.05 ng/ml,
”Batf3-/- Naive”: 0.12 ng/ml, ”Batf3-/- PbA”: 0.13 ng/ml, p < 0.05; Fig. 3.21D,E).
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In summary, we observed higher levels of IL-10 in spleen cell culture supernatant from
d+6 PbA-infected Batf3-/- mice, especially in cultures containing CD11b+ cells, which
also produced more IL-6.
After detection of increased IL-10 production in Batf3-/- mice, we investigated possibly
regulatory cell types, which could be the source of IL-10, in more detail. CD4+ T cells
did not produced more IL-10 in cell culture, but a change in cell number could alter the
regulatory milieu in Batf3-/- mice after PbA-infection. In the previous experiments we
discovered an expanded CD4+ T cell population in PbA-infected Batf3-/- mice 3 and 6 days
p.i. (increased CD4+ vs. CD8+ T cell ratio, 3.10B). Therefore we first analyzed CD4+ and
CD8+ T cells for common markers of regulatory T cells (Treg), FoxP3 (intracellular) and
CD25, but also for the programmed death protein 1 (PD-1) which has immune regulatory
functions and is found on the surface of T cells. PD-1 has been shown to be involved in
T cell exhaustion in a mouse model of chronic malaria [Horne-Debets et al., 2013].
Analyses of Tregs (FoxP3
+CD25+) in spleens of experimental animals revealed signif-
icantly higher Treg frequencies in naive Batf3
-/- mice compared to naive WT mice (fold
change 1.30, p < 0.001, Fig. 3.22A). However, after a small increase on 3 dpi, the Treg fre-
quencies in PbA-infected Batf3-/- dropped again to similar levels on 6 dpi as in naive mice,
while in WT mice the Treg frequencies increased steadily throughout infection. These dif-
ferent progresses in Treg populations led to more Tregs in Batf3
-/- mice on 3 dpi, but less
on 6 dpi (fold change to ”WT Naive” on 3 dpi: ”WT PbA” 1.35 vs. ”Batf3-/- PbA” 1.54,
p < 0.01; on 6 dpi: ”WT PbA” 1.65 vs. ”Batf3-/- PbA” 1.25, p < 0.05; Fig. 3.22A).
Interestingly, the increase in CD4+ vs CD8+ T cell ratio in PbA-infected Batf3-/- mice
did not have an impact on Treg populations. A calculation of frequencies of all T cells
revealed that naive Batf3-/- mice contained more FoxP3+CD25+ cells in their spleens
compared to uninfected WT mice (WT: 5.8%, Batf3-/- 3: 7.9%, p < 0.05). The Treg
percentages increased in WT mice 6 days after infection (9.6%, p < 0.001) but did not
change in PbA-infected Batf3-/- mice (7.3%; Fig. 3.22B). Comparing the frequencies of
regulatory T cells in the ”WT PbA”-group and the ”Batf3-/- PbA”-group, revealed a sig-
nificant (p < 0.01) decrease of FoxP3+CD25+ cells in the knock-out animals. However,
when calculating against the total spleen cell number, which was higher in PbA-infected
Batf3-/- mice, these differences were reversed. The total number of Tregs in spleens of
Batf3-/- mice was significantly higher than in their WT infection controls (p < 0.001) and
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Figure 3.22: The total amount of Tregs was increased in spleens of PbA-infected Batf3
-/- mice on
6 dpi. WT and Batf3-/- mice were infected with PbA (n=3-6) and spleens were analyzed at 3 and 6 dpi. Naive
mice (n=3-4) were used as controls. A: T cells were identified via FACS as described before and CD4+ cells were
analyzed via flow cytometry for CD25 and FoxP3 double positive cells (Tregs). Fractions were calculated to present
the percentage of Tregs from all T cells. B and C: Tregs at dpi are shown separately in frequency and total cell
count. D and E: PD-1 expression was analyzed on CD4+ and CD8+ T cells by calculation of the geometrical
mean fluorescence intensity. Results from 6 dpi are presented as mean (±SEM). Values from different time points of
analysis are presented as mean fold change (±SD) to naive WT mice. Dashed lines are shown for better visualization
but time points were analyzed in different mice. All differences were tested separately with ANOVA followed by the
Tukey post-test; p values below 0.05 were considered significant (* = p < 0.05, ** = p < 0.01, *** = p < 0.001).
naive Batf3-/- mice (p < 0.05). Naive mice from both groups did not differ in their total
amount of Tregs in their spleens and the relative increase seen in FoxP3
+CD25+ cells
among CD4+ T cells from PbA-infected WT mice compared to their naive controls was
no longer observed in the total cell amount (”WT Naive”: 1.3e6 cells, ”WT PbA”: 1.1e6
cells, ”Batf3-/- Naive”: 1.4e6 cells, ”Batf3-/- PbA”: 2.0e6 cells; Fig. 3.22C).
PD-1 expression was low on both CD4+ and CD8+ T cells in WT mice, independent of
their infection status (”WT Naive”: gMFI on CD4+ 74, gMFI on CD8+ 49, ”WT PbA”:
gMFI on CD4+ 75, gMFI on CD8+ 57; Fig. 3.22D, E). Naive Batf3-/- showed similar
expression patterns, but PbA-infection led to a significant (p < 0.05) increase of PD-1
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on T cells in Batf3-/- mice (”Batf3-/- Naive”: gMFI on CD4+ 120, gMFI on CD8+ 63,
”Batf3-/- PbA”: gMFI on CD4+ 246, gMFI on CD8+ 223; Fig. 3.22D, E). However, the
increased PD-1 expression on cells from infected Batf3-/- mice was less prominent in other
experiments. Further experiments are required to draw final conclusions.
Splenic NK cells, which can also contribute to regulatory mechanisms, showed similar
increased expression of PD-1 in d+6 PbA-infected Batf3-/- mice, comparable to the results
from T cell analysis and additional increased CTLA-4 expression (Fig. S16). Both surface
markers have been shown to down-regulate IFNγ production in NK cells [Stojanovic et al.,
2014, Alvarez et al., 2010].
We did not observe an expansion of Treg frequencies but a higher number of total
Tregs in Batf3
-/- mice on 6 dpi and higher PD-1 levels in CD4+ and CD8+ T cells from
d+6 infected Batf3-/- mice.
Alternatively activated macrophages (AAM) are another type of regulatory immune
cells, which could play a role in the development of cerebral malaria [Besnard et al., 2015].
As we observed increased levels of IL-10 and IL-6 in supernatants of cultured CD11b+
cells, we analyzed spleens of PbA-infected WT and Batf3-/- for the presence of AAM.
Therefore, splenocytes were prepared for analysis as described before and AAMs were
identified from CD11b+ cells as F4/80hiRelmαhiLy6CloLy6Gint.
Flow cytometry analysis of CD11b+ cells for alternatively activated macrophages
showed different cell populations that were differentiated into AAMs (F4/80hiRelmαhi
Ly6CloLy6Gint; dark green), neutrophils (F4/80negRelmαnegLy6CintLy6Ghi; light green)
and monocytes (F4/80intRelmαnegLy6ChiLy6Gneg; light blue). An overlay of these popu-
lation is shown in Fig. 3.23A. On average, 6.8% of CD11b+ splenocytes were identified as
AAMs in uninfected WT and Batf3-/- mice. Six days after PbA-infection, the frequencies
of AAMs among CD11b+ cells decreased in spleens of both strains (”WT PbA”: 1.0%,
”Batf3-/- PbA”: 2.1%, p < 0.001 to naive controls; Fig. 3.23B). Despite the decrease
of AAMs after infection, spleens of PbA-infected Batf3-/- mice contained a significantly
(p < 0.001) higher frequency of AAMs in their spleens when compared to WT infection-
controls. This difference was even more prominent in total cell counts, as splenocytes
counts (Fig. 3.8C) and CD11b+ cells (Fig. 3.18A) were higher in d+6-infected Batf3-/-
mice: spleens from both naive groups contained more AAMs than their infected counter-
parts, but PbA-infected Batf3-/- mice showed almost 5-fold more AAMs than infected WT
controls (”WT Naive”: 3,406e5 cells, ”WT PbA”: 6,359e4 cells, ”Batf3-/- Naive”: 4,971e5
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Figure 3.23: Splenic CD11b+ cells from d+6 PbA-infected Batf3-/- mice contained higher frequen-
cies of alternatively activated macrophages. WT and Batf3-/- mice were infected with PbA and spleens
were analyzed 6 days later with spleens from naive mice serving as controls (all n = 3-5). A: Representative
dot plot of CD11b+ cells (red in dot plot, prepared and identified as before) from naive WT mice compared to
PbA-infected WT and Batf3-/- mice. Ly6C, Ly6G, F4/80 and Relmα were used to distinguish between AAMs
(F4/80hiRelmαhiLy6CloLy6Gint; dark green), neutrophils (F4/80negRelmαnegLy6CintLy6Ghi; light green) and
monocytes (F4/80intRelmαnegLy6ChiLy6Gneg ; light blue). Relative amount of AAMs among CD11b+ splenocytes
(B) and total AAM count (C) are shown for all experimental groups. Results are presented as mean (±SEM). After
confirmation of overall statistical significance with ANOVA paired with Tukey post test, differences between two
groups were tested additionally with an unpaired t-test; p < 0.05 was considered significant.
cells, ”Batf3-/- PbA”: 2,992e5, ”WT PbA” vs. ”Batf3-/- PbA”p < 0.001; Fig. 3.23C).
In summary, these results showed that spleens of Batf3-/- mice show a more immune
regulatory phenotype when compared to WT mice after PbA-infection. We observed
higher levels of regulatory cytokine IL-10 and elevated total amounts of Tregs and alter-
natively activated macrophages in spleens of PbA-infected Batf3-/- mice. Additionally,
the expression of regulatory PD-1 was increased in Batf3-/- mice after PbA-infection on
T cells and NK cells.
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3.2 ECM development after doxycycline administration from
4 dpi
An artemisinin-based combination therapy (ACT) is the standard treatment in human
malaria in order to achieve rapid parasite elimination [WHO, 2015]. The tetracycline
derivate doxycycline, that was initially developed as a broad-spectrum antibiotic, is avail-
able as follow-up treatment and prophylaxis but no longer in the treatment guidelines as
first line treatment [WHO, 2015], because of its slow anti-plasmodial effect. Nevertheless,
we found this drug to be interesting because of its described additional anti-inflammatory
properties [Krakauer and Buckley, 2003, Griffin et al., 2011], which prompted us to inves-
tigate a possible use of doxycycline not only as an anti-parasitic drug but in the control
of the Plasmodium infection induced inflammatory processes in the brain that are associ-
ated with cerebral malaria. This first chapter will summarize our preliminary data that
provided the background for further studies.
We made use of the standard murine CM model with experimental P. berghei ANKA
infection of C57Bl/6 mice that are susceptible to experimental cerebral malaria (ECM,
[Li et al., 2001]). In initial experiments we compared different routes of doxycycline
administration in PbA-infected mice in order to find a treatment regimen that would
prevent ECM in C57Bl/6 mice. Therefore, Bl/6 mice were infected with a standard
dose of 5e4 iRBCs and subjected to different treatment regimens. Two groups received
different doses (80 mg/kg/d or 250 mg/kg/d) of the drug orally (p.o.) and one group was
injected intravenously (i.v.) with 80 mg/kg/d doxycycline. We determined the doses due
to pharmacokinetic studies conducted by Prall et al. [Prall et al., 2002]. In this study, they
compared plasma levels of doxycycline in mice and human after oral administration and
found that 200 mg/d doxycycline in human, which is also the standard dose in malaria
treatment [Lalloo et al., 2007], resembled a dose of 50-100 mg/kg/d given to mice in
drinking water. We treated all groups once daily with their respective dose from 4 to
7 dpi. Untreated PbA-infected mice served as control. All mice were monitored for
survival, disease score and parasitemia from 4 dpi on until the end of the experiment.
While untreated control mice developed ECM, as expected, between 6 and 8 dpi, we
observed that all PbA-infected mice that received 80 mg/kg/d doxycycline i.v. were pro-
tected from ECM. In contrast, only 20-30% of the mice receiving oral doxycycline were
protected from developing ECM (Fig. 3.24A). Thus, among the different approaches, only
i.v. injection of 80 mg/kg/day doxycycline from 4 dpi was effective in ECM prevention
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Figure 3.24: Intravenous doxycycline prevented ECM when given from 4 dpi. A: Survival was analyzed
in mice that were infected with a dose of 5e4 PbA-infected RBCs. Groups of 10 mice each received doxycycline in
oral form at 80 mg/kg/d (filled square) or 250 mg/kg/d (X) or an i.v. dose of 80 mg/kg/d (empty circle). One
group was left untreated as infection control (filled diamond). B: Parasitemia was counted from blood smears of
untreated PbA-infected mice and mice treated i.v. with doxycycline at 6 dpi, shortly before death of the untreated
control group. Differences in survival were tested for significance with log-rank test. Statistical significance between
the two groups for parasitemia were analyzed by t-test. p values below 0.05 were considered significant.
in PbA-infected Bl/6 mice, which was therefore used for the following experiments. Fur-
thermore, we found that treatment for 3 days (4-6 dpi) was sufficient to prevent ECM.
Importantly, peripheral parasitemia was strongly reduced on 6 dpi in DOX treated
mice when compared to untreated infection controls (Fig. 3.24B).
In order to analyze the anti-inflammatory effects of doxycycline treatment after Plas-
modium infection, we characterized disease hallmarks like BBB disruption and immuno-
logical features of doxycycline-treated PbA-infected mice versus control-infected mice and
and naive controls. Both infected groups were inoculated i.v. with 5e4 iRBC and the
treatment group received i.v. injections of 80 mg/kg/d doxycycline from 4 dpi on. Mice
were sacrificed 6 days post infection and perfused with PBS before isolation of spleens and
brains for various analyses.
Doxycycline-treated mice showed a stable blood-brain barrier, as seen in an Evans blue
Assay (13.4 µg Evans blue / g brain in ”PbA 5e4 + DOX”: versus 80.8 µg Evans blue / g
brain in untreated PbA-mice, p < 0.05, Fig. 3.25A) and reduced infiltration of peripheral
immune cells into the brain (1.62e5 cells / brain in ”PbA 5e4 + DOX”: versus 4.64e5 cells /
brain in ”PbA 5e4”, p < 0.001, Fig. 3.25B). Next we isolated mRNA from brain tissue from
PbA-infected mice ±DOX treatment on 6 dpi to analyze differences in gene expression
in a PCR array. Brain tissue of DOX-treated mice revealed a significant reduction of
cell adhesion molecules L- and P-selectin and cytokines CCL2, CCL5 and CXCL2 as
75
CHAPTER 3. RESULTS
Figure 3.25: Doxycycline treatment from 4 dpi led to a stable BBB and reduced cytotoxicity in PbA-
infected mice. Mice were infected with 5e4 iRBC and either treated with doxycycline (80 mg/kg/d i.v. from 4 dpi,
”PbA 5e4 + DOX”, n=3-6) or left untreated (”PbA 5e4”, n=3-6). Naive mice served as controls (”Naive”, n=3-6).
All analyses were performed 6 days p.i. when untreated mice showed symptoms of neuro-specific symptoms. A:
Mice were injected with 2% Evans blue dye i.v. and sacrificed after one hour. Brains were removed and EB was
extracted by incubation in formamide for 2 days. Results are displayed as mean of Evans blue per gram brain. B:
Lymphocytes were enriched with a percoll gradient after perfusion of d+6 infected mice. Total number of purified
cells was counted. C: RNA was extracted from mice brains on 6 dpi, transcribed to cDNA and subjected to an
PCR array. The dot plot graph shows differences in expression level of genes between PbA-infected mice versus
PbA-infected mice that were treated with doxycycline. Values for log2 fold change and -log10 p-value are plotted
against each other. The upper right corner represents genes that were considerably changed in their expression
(fold change >2) and their p-value considered significant (p < 0.05). D: Antigen-specific cytotoxicity was tested in
an in vivo kill using peptide loaded target cells that were injected to mice on 5 dpi and the analyzed 18h later. E:
Total number of spleen cells. Statistical analysis in A, B, D and E was performed with ANOVA, followed by Tukey
post-test. Statistical analysis of the PCR-array (C) was done with the Mann-Whitney test and Benjamini-Hochberg
correction. p values below 0.05 were considered significant.
76
3.2. ECM DEVELOPMENT AFTER DOXYCYCLINE ADMINISTRATION FROM 4 DPI
well as IL-6, which are all associated with inflammatory processes, when compared to
untreated PbA-infected mice (Fig. 3.25C). In addition to theses results, that point to
reduced inflammation in brains of doxycycline treated mice, we measured reduced parasite-
specific cytotoxicity in spleens of DOX-treated mice compared to control-infected mice
(30.5% lytic activity in ”PbA 5e4+ DOX”: versus 4.74 % lytic activity in ”PbA 5e4”,
p < 0.01, Fig. 3.25D). Interestingly, we could observe an increase in total spleen cell
numbers in DOX-treated mice compared to untreated infection controls and naive mice
(”PbA 5e4 + DOX”: 1.67e8 cells / spleen vs. ”PbA 5e4”: 1.37e8 cells and ”Naive”:
1.34e8 cells, p < 0.05; Fig. 3.25E). Naive and untreated PbA-infected mice did not differ
significantly, but showed a small increase in infected mice in some experiments; however,
the total splenocyte number was always higher in DOX-treated mice compared to all other
groups.
The results that are summarized above (Fig. 3.24 and 3.25) were acquired during my
diploma thesis. These data raised the question whether anti-inflammatory effects might
have contributed to the protection from ECM, in addition to the well-described anti-
parasitic effect of doxycycline. While parasite elimination is doubtless helpful in treatment
of Plasmodium infection, it makes it difficult to distinguish between anti-inflammatory
effects and decreases in inflammation due to reduced parasite load. The following ex-
periments aims to overcome this problem and to study the anti-inflammatory features of
doxycycline.
3.2.1 Increased splenocyte numbers in doxycycline treated mice was
neither caused by altered migration patterns nor by increased pro-
liferation
The observed low cell numbers in brains of doxycycline-treated, PbA-infected mice (Fig. 3.25B)
and the concurrent increase in total spleen cell numbers (Fig. 3.25E) made us question
whether doxycycline treatment resulted in a hampered ability of splenocytes from the
treated group to migrate to the brains of infected animals. To address this question, we
designed a migration assay were brain cells from d+6 PbA-infected mice were cultured
in the bottom of a transwell plate together with FarRed labeled splenocytes in the upper
well (see Fig. 2.2) The pores of the upper chamber were small enough to allow mainly
active migration in contrast to cells falling through the pores. We expected the brain cells
to produce cytokines which should attract cells from the upper chamber, which could give
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us a hint about the in vivo situation. As cells have already reached the brain in untreated
PbA-infected mice on 6 dpi, we decided to perform our experiment one day earlier, when
migration occurs.
Figure 3.26: Migration of spleen cells towards in vitro cultured brain cells was not altered in samples
from doxycycline-treated mice. Mice were intravenously injected with 80 mg/kg doxycycline daily from 4 dpi
on. Brains and spleens were removed from these animals on 5 dpi and cultured for 6h in a transwell plate as with
brain cells in the lower and fluorescently (FarRed) labeled spleen cells in the upper chamber, as depicted in Fig. 2.2.
After this incubation period, cells in the lower chamber were analyzed for the presence of spleen cells (A, shown
as total cells from 3e4 analyzed cells) and those spleen cells were further differentiated for CD4 and CD8, which
were analyzed for their geometric mean fluorescent intensity of the FarRed labeling (B, C). Statical analysis was
performed with ANOVA, followed by Tukey post-test. p values below 0.05 were considered significant.
Analysis of the lower chamber of our transwell plate after 6 hours showed a back-
ground of 9.98e3 FarRed labeled cell in the 3e4 cells analyzed per well (Fig. 3.26A).
After PbA-infection, the number of splenocytes among the analyzed cells increased sig-
nificantly in untreated mice (p < 0.05), but not in doxycycline-treated animals (”PbA
5e4”: 1.28e4 cells, ”PbA 5e4+ DOX”: 1.19e4 cells). However, the difference between
doxycycline-treated and untreated mice after PbA-infection was only small and not signif-
icant. Additionally, we stained the cells from the lower well for CD4 and CD8 (mainly T
cells of the respective subset) to be able to analyze especially the behavior of T cells in this
assay. While there were no differences between CD4+, CD8+ and double negative cells
in their migration pattern, we came across another interesting finding: CD4+ and CD8+
cells from PbA-infected mice had a lower mean fluorescence intensity of the FarRed label
than cells from naive animals (gMFI FarRed on CD4+ cells: ”Naive”: 4378, ”PbA 5e4”:
1859, ”PbA 5e4 + DOX”: 1834, p < 0.01; gMFI FarRed on CD8+ cells: ”Naive”: 4129,
”PbA 5e4”: 2087, ”PbA 5e4 + DOX”: 1809, p < 0.01; Fig. 3.26B, C). These observations
could be a sing of proliferation of these cells on PbA-infected mice. Again, we could not
find a difference between PbA-infected mice with or without DOX treatment.
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All together, we concluded, that doxycycline did not alter the migration pattern in
this assay. However, improvement of the assay might provide more insights to this subject.
We further asked ourselves whether different proliferation activity of spleen cells in
doxycycline treated PbA-infected mice could explain the higher splenocyte cell count in
this group. BrdU is a synthetic nucleoside that is inserted in newly synthesized DNA
instead of thymidine and can therefore be detected in proliferating cells. To analyze
proliferation in our model, mice were given oral BrdU 2 days before splenocytes were
isolated and stained for living cells with 7AAD followed by intracellular staining of BrdU.
We analyzed the mice on 5 dpi and 6 dpi to get a picture shortly after treatment start
and just before ECM onset in untreated controls.
Figure 3.27: Splenocytes from doxycycline-treated mice had a similar proliferation rate as untreated
mice on 5 dpi. Mice from all groups received BrdU 2, 1.5 and 0.5 days before analysis on 5 or 6 dpi. Animals
in the ”PbA + DOX” group were intravenously injected with 80 mg/kg doxycycline daily from 4 dpi on. Spleens
were removed from all animal on 5 and 6 dpi (n = 4 / day / group). A: The total splenocyte count was determined
with the help of a cell counter. B: Living cells were identified by flow cytometry analysis of 7AAD followed by
intracellular BrdU staining as an indicator for proliferating cells. Mean results are presented as bars with SD.
Statical analysis was performed with ANOVA, followed by Tukey post-test. p values below 0.05 were considered
significant.
The total amount of spleen cells, counted from a single cell suspension with a cell
counter, was already increased in both PbA-infected groups on 5 dpi when compared to
naive mice (fold change to ”Naive” on 5 dpi ”PbA”: 1.71, ”PbA + DOX”: 1.61) and
remained at similar levels at 6 dpi (fold change to ”Naive” on 6 dpi ”PbA”: 1.50, ”PbA
+ DOX”: 1.71; Fig. 3.27A). While differences in this experiment were not significant
between both infected groups (±DOX) on 6 dpi, the trend of higher splenocyte counts in
”PbA + DOX” mice remained. Interestingly, untreated mice showed a small decrease in
cell numbers from 5 to 6 dpi, but the splenocyte count increased slightly in doxycycline
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treated mice in the same time frame.
We detected an increase in proliferation in the spleens from d+5 PbA-infected mice
(±DOX), as shown by higher frequencies of BrdU positive cells among living spleen cells,
but no differences between both infected groups (fold change to ”Naive” on 5 dpi ”PbA”:
1.88, ”PbA + DOX”: 1.81; Fig. 3.27B). Interestingly, proliferation was similar in all
groups on 6 dpi (fold change to ”Naive” on 6 dpi ”PbA”: 1.03, ”PbA + DOX”: 1.07;
Fig. 3.27B).
These results showed, that the higher splenocyte counts from PbA-infected mice af-
ter doxycycline treatment compared to untreated controls was not caused by increased
proliferation in the treated animals.
3.2.2 Higher infective dose in doxycycline treated animals allowed the
comparison between treated and untreated animals with similar
parasite loads
We next addressed the question whether mice with an increased parasite infectious load
would still be protected from ECM and whether this approach could help to distinguish
between DOX-induced anti-inflammatory effects and reduced inflammation due to anti-
parasitic properties. Therefore, we infected the groups of mice that would receive doxycy-
cline treatment with a higher initial dose of parasites in order to achieve the same blood
parasitemia that is observed in untreated mice on 6 dpi, when they show first symptoms
of ECM. We decided to infect mice intravenously with 1e6 iRBCs in comparison to the
infectious standard dose of 5e4 iRBC that was used before and from each infection group,
half of the infected animals were left untreated and the other half received the dose of
doxycycline that was established before (80 mg/kg/d, 4-6 dpi). The groups were named
”PbA 5e4 ±DOX” and ”PbA 1e6 ±DOX”.
Consistently with previous findings, the control group ”PbA 5e4 + DOX” survived
PbA-infection past the time point of 20 dpi without any signs of ECM while untreated
mice (”PbA 5e4) developed severe neurological symptoms between 6-8 dpi and died from
ECM (Fig. 3.28A+B). The group of mice that had been infected with an elevated dose of
PbA iRBCs (”PbA 1e6”) also developed ECM and showed a similar survival (80% died
before 10 dpi, Fig. 3.28A) and ECM score (Fig. 3.28B) as compared to 5e4 infected mice.
Doxycycline treatment of mice infected with 1e6 iRBC resulted in a similar protection
from ECM and survival as we had observed before in doxycycline treatment of mice
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Figure 3.28: ECM was prevented in mice infected with high parasite load and treated with doxycycline.
Mice were infected with 5e4 or 1e6 iRBC i.v. and either treated with 80 mg/kg/d doxycycline (4-6 dpi) or not
(all groups n = 10). All groups were analyzed for survival (A), ECM score (B, displayed as median). C: Mean
parasitemia is shown from 5 to 7 dpi. Small numbers above the bars indicate how many mice were still alive and
considered for analysis. At 5 dpi all mice were alive and analyzed for parasitemia. Differences in survival were
tested for significance with log-rank test. Significance for parasitemia was tested with ANOVA followed by Tukey
post test. p values below 0.05 were considered significant.
infected with the standard dose of 5e4 iRBCs. Both doxycycline-treated group survived
past 20 dpi (Fig. 3.28A) with only unspecific symptoms of illness around the critical phase
(6-8 dpi), which were completely reversible (Fig. 3.28B).
Doxycycline targets the apicoplast genome in Plasmodium parasites which leads to
impaired apicoplast function in daughter merozoites and a noticeable drop in parasitemia
2 days after treatment start [Dahl et al., 2006]. Therefore, one day after treatment start
(5 dpi), the parasitemia was not changed significantly between doxycycline treated mice
and the control-infected animals but higher in 1e6 iRBC infected animals (”PbA 1e6”:
9.0%, ”PbA 1e6 + DOX”: 6.4%) when compared to their respective groups that were
inoculated with 5e4 iRBCs (”PbA 5e4”: 3.5%, ”PbA 5e4 + DOX”: 3.4%, Fig. 3.28C). In
untreated groups, parasitemia increased throughout the analyzed time frame (”PbA 5e4”
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3.4 to 16.5%, ”PbA 1e6” 9.0 to 13.3%), while parasitemia declined in doxycycline treated
mice (”PbA 5e4 + DOX” 3.5 to 1.6%, ”PbA 1e6 + DOX” 6.4 to 3.3%). Importantly, when
we compared untreated 5e4 iRBC infected mice to the ”PbA 1e6 + DOX” group, we did
not find any differences in parasitemia on day 6 post infection (”PbA 5e4” 6.0%, ”PbA
1e6 + DOX” 5.5%), but significant differences in survival of both groups (Fig. 3.28A).
These results show, that we could establish a model to compare untreated mice with
doxycycline treated mice at 6 dpi with a similar parasitemia. In the following experiments
we compared these two groups with the same parasitemia (”PbA 5e4” and ”PbA 1e6 +
DOX”) with naive control mice in order to investigate the anti-inflammatory effects of
doxycycline in the mouse model of cerebral malaria.
3.2.3 Blood-brain barrier remained stable after doxycycline treatment
despite high parasitemia
The first step in characterizing the anti-inflammatory effects of doxycycline in ECM was
the analysis of the blood-brain barrier. As described before, the opening of the BBB is
a hallmark in ECM and can be easily tested with an Evans blue assay. Therefore, we
infected one group of mice with 5e4 iRBCs (”PbA 5e4”) and one group with 1e6 iRBCs,
which was treated with doxycycline (”PbA 1e6 + DOX”). Both groups were subjected
to the Evans blue assay and compared to naive mice on 6 dpi. In addition, we were also
interested in the progression of the BBB stability in ”PbA 1e6 + DOX” mice. Therefore
some mice of this group were analyzed on 7, 8 and 9 dpi. As untreated mice succumb to
ECM after 6 dpi, ”PbA 1e6 + DOX” mice were only compared to naive mice.
The blood-brain barrier in mice that were infected with 5e4 iRBC but not treated
with doxycycline was clearly destroyed, indicated by the blue color of the brain, which
was in sharp contrast to almost unstained brains of naive and doxycycline treated mice
(Fig. 3.29A). These findings were also quantified by formamide extraction of the ex-
travasated dye. Brain samples from untreated PbA-infected mice contained significantly
more Evans blue dye when compared to naive mice (7.5 fold change to naive mice;
Fig. 3.29B) and doxycycline treated mice (2.3 fold change to naive, p < 0.01 to ”PbA
5e4”).
On all days the difference between naive mice and ”PbA 1e6 + DOX” mice was not
significant, but we could detect a slightly higher EB leakage in brains of PbA-infected,
doxycycline treated mice on 6 dpi, which clearly reduced in the following days (Fig. 3.29D
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Figure 3.29: Stable Blood-brain barrier in 1e6 iRBC infected mice after doxycycline treatment. An
Evans blue assay was performed with mice that were either infected with 1e6 iRBCs and treated with doxycycline
(n=5 / day) or infected with 5e4 iRBC and left untreated (n=5). Naive mice served as controls (n=3 / day). On
6 dpi all groups were compared to each other, the following days only ”PbA 1e6 + DOX” mice and naive controls
were analyzed. A: Photographs of one exemplary brain from each group on 6 dpi. B: Dot plot for Evans blue dye
that was extracted from brains after EB injection on 6 dpi. Data is presented as mg EB per g brain. C: Amount
of Evans blue that was extracted from brains of the described groups. All values were normalized to the naive mice
from the respective day. Bars represent means. Significance for results from Evans blue assay was calculated with
ANOVA following Tukey post test. p values less than 0.05 were considered significant.
presents fold changes of ”PbA 1e6 + DOX” to naive: 6 dpi: 2.3, 7 dpi: 0.9, 8 dpi: 1.7,
9 dpi: 0.9)
In summary we observed a stable blood-brain barrier ”PbA 1e6 + DOX” mice whereas
untreated mice that were infected with 5e4 iRBCs displayed a severely ruptured BBB
despite a similar parasitemia.
3.2.4 Immune cell infiltration and activation was reduced in brains of
doxycycline treated mice
The opening of the blood-brain barrier is often attended by an infiltration of immune cells
from the periphery into the brain. Especially in cerebral malaria the infiltration of immune
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cells that were primed in the periphery (mainly spleen) is of great interest and probably
the main factor driving the disease [Engwerda et al., 2005]. Therefore, we isolated immune
cells that were present in the brains of mice that were either infected with 5e4 PbA-iRBCs
and left untreated or were injected with 1e6 PbA-iRBCs and treated daily with 80 mg/kg
doxycycline from 4 dpi on. Naive mice served as controls. The cells were harvested from
PBS-perfused animals and purified via a percoll-gradient to enrich leukocytes. These cells
were then stained for different extra- and intracellular markers and analyzed with a flow
cytometer.
Figure 3.30: The total number of brain infiltrated cells was reduced after doxycycline treatment.
Brains of d+6 5e4 iRBC infected (n=4) and d+6 1e6 iRBC infected doxycycline treated mice (n=4) were analyzed
for cellular infiltrates by counting cells after leukocyte enrichment and identification of infiltrated cells by CD45
in flow cytometry. Naive mice (n=4) served as control. A: Total number of cells purified from brains of the
respective groups, counted with a cell counter. B / C: Percentage and total amount of CD45hi cells from these cells.
Results were tested for significance with ANOVA, followed by Tukey post-test. p values below 0.05 were considered
significant.
The total amount of cells from homogenized brains of PBS-perfused mice was counted
after a percoll gradient. Mice infected with 5e4 PbA-infected erythrocytes contained sig-
nificantly more cells in their purified brain fractions than samples from naive mice (”PbA
5e4”: 1.04e6 cells/brain vs. ”Naive”: 4.75e5 cells/brain, p < 0.05; Fig. 3.30A). Mice that
were infected with the higher amount of iRBCs (1e6) and treated with doxycycline did
not show an increase in total cell numbers (4.55e5 cells/brain; p < 0.05 to ”PbA 5e4”, not
significant different to ”Naive”).
These purified cells were further analyzed for the hematopoietic cell surface marker
CD45 via flow cytometry to differentiate between infiltrated immune cells (CD45hi), mi-
croglia (CD45lo) and other cerebral cells or cell debris that were not culled out in the gra-
dient. In both groups of infected mice (±DOX) the frequencies of CD45hi cells were signifi-
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cantly increased (”PbA 5e4”: 41.9%, ”PbA 1e6 + DOX”: 48.2%) when compared to naive
mice (12.4%, p < 0.001 against both PbA groups, Fig. 3.30B). However, while frequencies
of CD45hi cells did not differ between doxycycline treated mice (”PbA 1e6 + DOX”) and
untreated mice (”PbA 5e4”), the total amount of infiltrating CD45hi cells per brain was
significantly reduced in doxycycline treated animals (p < 0.05, Fig. 3.30C). With an av-
erage of 2.25e5 CD45hi cells per brain in doxycycline treated mice (”PbA 1e6 + DOX”)
this group contained more cellular infiltrates than naive mice (6.36e4 cells/brain), but this
difference was not significant. We found significantly more CD45hi cells in brains of PbA-
infected, untreated mice than in those from naive mice (”PbA 5e4”: 6.36e4 cells/brain
vs. ”Naive”: 4.31e5 cells/brain, p < 0.05) and almost twice as many cells as doxycycline
treated mice.
Taken together, mice that were infected with 1e6 iRBC and treated with doxycycline
contained less cellular infiltrates in their brains compared to untreated mice with a lower
infectious dose.
3.2.4.1 Brain infiltrated T cell were less activated but did not differ in fre-
quencies after doxycycline treatment
As mentioned before, the host immune response - especially driven by T cells - is important
in the development of cerebral malaria. Therefore, we analyzed the infiltrated cells from
PbA-infected mice with or without doxycycline treatment regarding their phenotype and
activation status in more detail. For this purpose we isolated brains from the three different
groups of mice (”Naive”, ”PbA 5e4”, ”PbA 1e6 + DOX”). The organs were prepared as
described before and analyzed with flow cytometry. We gated the cells according to their
CD45 expression and from CD45hi cells we separated into different cell subtypes, such as
CD3+ T cells, CD11c+ dendritic cells and CD11b+ mononuclear cells. CD3+ T cells from
CD45hi cells were further differentiated into CD4+ and CD8+ T cells.
On 6 dpi, brains of PbA-infected mice showed a significant increase of CD3+ T cells
compared to naive mice (”PbA 5e4”: 58.6% vs. ”Naive”: 17.9%; p < 0.001), which was
interestingly also observed in doxycycline treated mice (68.4%, p < 0.001; Fig. 3.31A).
The difference between both infected group was not significant.
Further analysis of T cell subsets showed that almost no CD4+ were present in the
brains of the experimental animals (”Naive” 3.3%, ”PbA 5e4” 1.6%, ”PbA 1e6 + DOX”
1.4%; Fig. 3.31B) and CD8+ T cells were the majority of infiltrated T cells in all groups
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Figure 3.31: T cells in the brains of PbA-infected mice showed no alteration in their frequencies after
doxycycline treatment. T cells were identified from CD45hi cells of naive, d+6 ”PbA 5e4” and ”PbA 1e6 +
DOX” mice (all n=4) by CD3 and further differentiated into CD4+ and CD8+ T cells. A: Percentage of CD3+
cells from all CD45hi cells. B / C: Percentages of CD4+ and CD8+ T cells from CD3+. Statistical significance was
tested with ANOVA and Tukey; p < 0.05 was considered significant.
of mice. Importantly, the analysis of CD8 between the different groups revealed a sig-
nificant increase in CD8+ T cell frequencies after PbA-infection (p < 0.001), irrespective
of doxycycline treatment (”Naive” 32.0%, ”PbA 5e4” 71.6%, ”PbA 1e6 + DOX” 75.6%;
Fig. 3.31C).
Since we calculated similar T cell frequencies in PbA-infected mice with or without
doxycycline treatment, we addressed the question whether these T cells displayed different
activation profiles which could result in the protection of doxycycline treated mice from the
development of cerebral malaria. Therefore, these cell populations were evaluated for the
expression of molecules that are well-known to play a role in cerebral malaria development:
granzyme B (Grzm B, an intracellular cytotoxic serine protease) and ICAM-1 (CD54, a
surface adhesion molecule). The expression of these activation markers on T cells was
evaluated via the average geometric fluorescent mean intensity (gMFI).
Granzyme B was almost absent on CD8+ T cells analyzed from brains of naive mice
but was significantly increased in the untreated ”PbA 5e4” group and the doxycycline
treated group (”Naive”: gMFI 1449 vs. ”PbA 5e4”: gMFI 24,372 vs. ”PbA 1e6 + DOX”:
gMFI 17,766; p < 0.001; Fig. 3.32A). Importantly, we observed a statistically significant
reduction of granzyme B expression in CD8+ T cells from brains of doxycycline treated
animals (p < 0.05). The analysis of adhesion molecule ICAM-1 on the surface of T cells
showed significant differences between PbA-infected mice depending on their treatment
regimen (p < 0.01; Fig. 3.32B). While T cells from untreated PbA-infected mice showed
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Figure 3.32: CD8+ T cells found in the brains of PbA-infected mice were less activated after doxy-
cycline treatment. CD8+ T cells from brains of doxycycline treated (PbA 1e6), untreated (PbA 5e4) and naive
animals (n=4) were analyzed for different activation markers by flow cytometry. A: intracellular granzyme B stain-
ing, B: surface staining for ICAM-1. Statistics were performed with ANOVA and Tukey post-test with p < 0.05
considered significant.
an enhanced expression of ICAM-1 compared to naive control animals (”PbA 5e4”: 800
vs. ”Naive”: gMFI 603; p < 0.01), this up-regulation was not observed in samples from
doxycycline treated PbA-infected mice (gMFI 608).
Taken together, the frequencies of brain infiltrating T cells were comparable between
doxycycline treated and untreated mice 6 days after PbA-infection. However, total CD8+
T cell numbers were reduced after treatment and these cells showed decreased activity in
doxycycline treated animals that were protected from ECM in comparison to untreated
PbA-infected controls which were suffering from ECM. We found a similar activity profile
in CD4+ T cells (Fig. S17).
3.2.4.2 Antigen presenting cell frequencies were not altered in brains of doxy-
cycline treated mice, but they expressed less activation markers
Antigen-presenting cells are required to prime and activate T cells and therefore contribute
to ECM development. Next to infiltration of APCs from the periphery, like dendritic cells
or mononuclear cells, also microglia and endothelial cells play a role in ECM development
[Medana et al., 1997, Howland et al., 2015].
In order to characterize antigen-presenting cells from our experimental groups of inter-
est, we prepared brain infiltrates from naive mice (”Naive”), mice infected with 5e4 iRBCs
6 days before analysis (”PbA 5e4”) and animals infected with 1e6 iRBCs and treated with
doxycycline from 4 dpi (”PbA 1e6 + DOX”). Infiltrates were gated for CD45hi as de-
scribed before. From CD3− cells we gated for CD11c+I-Ab+ cells which are defined as
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dendritic cells (DCs). These DCs were also checked for changes in activation markers such
as ICAM-1.
Figure 3.33: Dendritic cells in the brain expressed less ICAM-1 after doxycycline treatment in PbA-
infection. Dendritic cells among brain infiltrated cells from the respective groups (Naive, PbA 5e4, PbA 1e6 +
DOX; n=4) were identified by flow cytometry analysis for surface markers CD11c and I-Ab (A, percent of total
CD45hi cells). Activation of these cells was investigated by changes in surface expression of ICAM-1 (B, gMFI).
Results were statistically analyzed by ANOVA followed by Tukey post test; p < 0.05 was considered significant.
We found markedly decreased dendritic cell frequencies in brains of mice after PbA-
infection (±DOX treatment; Fig. 3.33A). From 8.7% in naive mice, the frequency of
DCs dropped significantly (p < 0.01) on 6 dpi to 2.9% in ”PbA 5e4” mice and 1.4%
in PbA-infected mice of the DOX-group (”1e6 + DOX”). The small difference between
both PbA-infected groups (±DOX treatment) was not significant. It is of note that even
though the percentage of dendritic cells was higher in naive mice, they have a low cell
count regarding the total number of infiltrated cells and therefore the total amount of
DCs was smaller than in PbA-infected mice without doxycycline treatment. Accordingly,
dendritic cells numbers in brain samples from untreated mice will be higher than in ”PbA
1e6 + DOX” mice due to the difference in total infiltrated cells.
Next, we evaluated the expression of adhesion molecule ICAM-1 on brain infiltrated
DCs from the different groups. We found increased levels of ICAM-1 on DCs from both
PbA infected groups compared to cells from naive animals (”PbA 5e4” gMFI 2,350, ”PbA
1e6 + DOX” 4,436”, Naive”: gMFI 854, p < 0.01; Fig. 3.33B). Interestingly, dendritic
cells expressed less ICAM-1 on their surfaces in mice that were infected with 1e6 iRBCs
and treated with doxycycline compared to mice that were infected with 5e4 iRBCs but
were left untreated (p < 0.001).
CD11b+ cells comprise several groups of antigen-presenting cells including macrophages,
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monocytes, neutrophils but also a dendritic cell subset. For flow cytometry analysis, we
first excluded microglia, T cells and CD11c+ cells that were analyzed separately. After
defining the group of antigen-presenting CD11b+ cells, they were analyzed for different
markers of activation.
Figure 3.34: CD11b+ cells in the brain were less activated in PbA-infected mice after doxycycline
treatment. CD45hi cells that were derived from brains of PbA-infected (5e4 iRBC or 1e6 iRBC + DOX) and
naive mice (all n=4) were gated for CD11b expression and the presence of activation markers. A: Percentage of
CD11b+ cells from CD45hi cells. B-C: gMFI of I-Ab and ICAM-1 from flow cytometry analysis. Significance was
tested with ANOVA and Tukey post-test; p < 0.05 was considered significant.
The frequency of CD11b+ cells in the brain was reduced after PbA-infection in both
infected groups which had significantly less CD11b+ cells (”PbA 5e4” 32.7%, ”PbA 1e6 +
DOX” 24.3%; Fig. 3.34A) than uninfected animals (”Naive” 52.2%, p < 0.01). The small
decrease of CD11b+ cells in brains of doxycycline treated mice compared to the untreated
group was not significant but we observed differences in expression of activation markers.
Expression of I-Ab increased from a gMFI of 240 in naive mice to gMFI 663 in untreated
5e4 iRBC infected mice (p < 0.001; Fig.3.34B). Brain CD11b+ cells from DOX-treated
mice showed significantly reduced expression of I-Ab compared to untreated mice (”PbA
1e6 + DOX”: gMFI 430, p < 0.05) but the gMFI was still a bit higher compared to naive
controls (p < 0.05). ICAM-1 expression on brain infiltrated CD11b+ cells, did not differ
between PbA-infected animals with or without doxycycline treatment (”PbA 5e4” gMFI
1,453, ”PbA 1e6 + DOX” gMFI 1,408; Fig.3.34C). However, as seen for the other markers,
CD11b+ cells in brains from naive mice had significantly less ICAM-1 expression on their
surface compared to both infected groups (gMFI 283, p < 0.001).
Similar to the results from dendritic cells we could not observe a difference in the
frequencies of CD11b+ cells, but cells from doxycycline treated mice were generally less
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activated as shown by MHC class II expression.
Taken together, we frequencies of CD11c+ and CD11b+ cells in brains of PbA-infected
mice did not change after doxycycline treatment. However, their activation was slightly
reduced.
3.2.4.3 Microglia showed reduced expression of MHC class II molecules in
doxycycline-treated PbA-infected mice
Besides infiltrating immune cells that were primed and activated in the periphery, mi-
croglia, brain resident APCs, could also contribute to the development of cerebral malaria.
As microglia are present in brains of healthy and diseased mice, we were especially in-
terested in changes in activation of these cells in PbA-infected ±DOX-treated mice. The
percoll gradient that we used to enrich leukocytes does includes microglia. Therefore,
we used this approach to harvest microglia before staining them for surface markers to
distinguish them from other immune cells and to check their activation.
Figure 3.35: Microglia expressed less I-Ab in PbA-infected mice after doxycycline treatment. Microglia
were defined as CD45loCD11b+ cells that were derived from brains of PbA-infected (5e4 iRBC or 1e6 iRBC + DOX)
and naive mice (all n=4) these microglia were then analyzed for changes in expression of activation markers. A:
Percentage of microglia (CD45loCD11b+) from total cells after gradient. B-C: gMFI of I-Ab and ICAM-1 from flow
cytometry analysis. Significance was tested with ANOVA and Tukey post-test; p < 0.05 was considered significant.
The frequencies of microglia did not differ significantly between both experimental
groups and naive control mice (”Naive”: 51.9%, ”PbA 5e4”: 36.7%, ”PbA 1e6 + DOX”:
40.2%; Fig. 3.35A). We further checked these cells for I-Ab and ICAM-1 expression, which
could be both upregulated upon activation. I-Ab expression on microglia was significantly
upregulated in PbA-infected mice (”PbA 5e4” gMFI 603, ”PbA 1e6 + DOX” gMFI 430)
compared to naive controls (gMFI 194, p < 0.001; Fig.3.35B). While an increase in I-Ab
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was seen in both groups of mice with and without doxycycline treatment, the upregulation
was significantly (p < 0.01) reduced in the treated mice. Expression of adhesion molecule
ICAM-1 was also significantly increased on microglia from both infected groups (”PbA
5e4” gMFI 695, ”PbA 1e6 + DOX” gMFI 712) in comparison to naive mice (gMFI 375,
p < 0.01; Fig.3.35C), but we could not observe any differences with or without doxycycline
treatment.
In general we could see a reduced I-Ab expression in microglia after doxycycline,
comparable to our findings in brain infiltrated APCs.
3.2.4.4 Cytokine production was reduced in brains of mice treated with doxy-
cycline
Not only expression of activation markers but also local cytokine production from resi-
dent and infiltrated brain cells could explain differences in disease development between
PbA-infected mice with or without doxycycline treatment. As cytokines could be either
produced by infiltrated immune cells or by brain resident cells, and we were interested in
characterizing the local cytokine milieu in the brains, we decided to culture whole brain
homogenate samples from d+6 infected animals that were either inoculated with 5e4 iR-
BCs and left untreated (”PbA 5e4”) or received 1e6 iRBCs and were treated from 4 dpi
with doxycycline (”PbA 1e6 + DOX”). Brains from naive mice were included as controls
for not inflamed brains. Supernatants from over night-incubated brain cell cultures were
analyzed by ELISA for the presence of the acute-phase protein TNF and chemokine CCL5
that are both associated with the development of cerebral malaria.
TNF production by brain tissue from PbA-infected, untreated mice was significantly
increased compared to samples from naive control mice (”PbA 5e4”: 19.5 pg/ml, ”Naive”:
0.8 pg/ml, p < 0.05; Fig. 3.36A). We also measured increased levels of TNF in samples
from doxycycline-treated mice (6.3 pg/ml), however, differences to both other groups were
not significant, probably due to the small number of mice and an outlier in the ”PbA 5e4”
group. We gained similar results for CCL5: brain cells extracted from ”PbA 5e4” mice
produced significantly more CCL5 compared to naive controls (”Naive” 6.3 pg/ml, ”PbA
5e4” 103.5 pg/ml, p < 0.05; Fig. 3.36B). With an average of 66.7 pg/ml CCL5 in brain cell
supernatant, doxycycline treated mice produced more of this chemokine than naive mice
but less compared to untreated mice. However, these differences did not reach statistical
significance.
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Figure 3.36: TNF and CCL5 release were slightly downregulated in brains of ”PbA 1e6 + DOX” mice
compared to untreated ”PbA 5e4” mice. Cytokine release was measured in brain homogenates (before percoll
gradient) of 5e4 iRBC-infected mice compared to 1e6 iRBC-infected mice that were treated with doxycycline and
also to naive mice (n=4). Brain cell homogenates were cultured in RPMI medium and after over night incubation,
supernatants were subjected to an ELISA for TNF (A) and CCL5 (B). Statistical significance (p < 0.05) was tested
with ANOVA followed by Tukey post-test.
In summary we saw a small trend to less cytokine production in brains of doxycycline
treated mice compared to their uninfected counterparts.
3.2.4.5 Cross-presentation by brain microvessels was not altered after doxy-
cycline treatment
It has been shown recently, that cross-presentation of parasite-specific antigen to CD8+
T cells by activated endothelial cells in brain microvessels is a hallmark of experimental
cerebral malaria [Howland et al., 2013, Howland et al., 2015]. To test whether doxycycline
treatment of PbA-infected mice would alter the cross-presentation in these cerebral ves-
sels, our collaborators S. Howland and L. Re´nia analyzed our experimental groups with
their established brain microvessel cross-presentation assay [Howland et al., 2013]. In this
assay microvessel fragments were isolated from all mice and incubated with NFAT-lacZ
reporter cells that were transduced with a T cell receptor (TCR) recognizing the SQLL-
NAKYL epitope and interaction was analyzed by β-galactosidase staining after over-night
culture. The presence of PbA antigen in the brains of PbA-infected mice with or without
doxycycline treatment was determined by qRT-PCR measurement of PbA 18srRNA in
cDNA that was transcribed from brains of all experimental groups.
Analysis of cross-presentation for the SQLLNAKYL epitope revealed a background
of 5 blue spots in samples from naive animals and a significant increase in blue spots
per brain in both PbA-infected groups (±DOX, p < 0.05). The small decrease in cross-
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Figure 3.37: Brain microvessels of doxycycline treated PbA-infected mice were able to cross-present
antigen. A: Brain microvessels were isolated from 5e4 iRBC PbA-infected Bl/6 mice and 1e6 iRBC PbA-infected
mice that received doxycycline treatment from 4 dpi (both n=5). Naive mice were included as controls (n=3).
Isolated cells were incubated over night with TCR-transduced NFAT-lacZ reporter cells and cross-presentation was
measured after beta-galactosidase staining as blue spot per brain. B: Parasite load in brains of all experimental
groups was determined by qRT-PCR. Results were tested for significance with ANOVA and Tukey’s post-test.
P-values below 0.05 were considered significant.
presentation in doxycycline-treated mice was not significantly different to ECM-positive
mice that were left untreated (”PbA 5e4”: 384 blue spots per brain, ”PbA 1e6 + DOX”:
249 blue spots per brain; Fig. 3.37A).
We were able to detected an increased parasite load in brains of PbA-infected mice on
6 dpi. However, no significant differences were found in mice with or without doxycycline
treatment (”PbA 5e4”: 1.27e4 copies of 18srRNA, ”PbA 1e6 + DOX”: 1.14e4 copies of
18srRNA, Fig. 3.37B).
Taken together, cross-presentation in cerebral microvessels from PbA-infected mice
was not affected by doxycycline treatment and the parasite load (= antigen levels) was
also comparable in both groups.
3.2.5 Cytotoxicity in the spleen was reduced after doxycycline treat-
ment
The results from the described brain analyses suggested that doxycycline treatment in-
terferes with the generation or amplification of the harmful immune response in the brain
in our model of experimental cerebral malaria. As the immune reaction in the brain is
initiated in the spleen (described before), we were interested in the question whether the
observed effects were local impacts in the brain or if the peripheral immune response was
also affected.
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Therefore, we analyzed spleens of mice that were either infected with 5e4 PbA-infected
iRBCs (”PbA 5e4”) or with 1e6 iRBCs and treated daily with doxycycline from 4 dpi on
(”PbA 1e6 + DOX”). Both infected groups were sacrificed 6 days p.i. when untreated mice
showed first neuro-specific disease symptoms. Naive mice of the same strain (”Naive”)
were included as uninfected controls.
Figure 3.38: Total number of spleen cells did not differ between doxycycline treated and untreated
mice. Mice were infected with PbA (5e4 or 1e6 iRBC, as indicated, n=4) and sacrificed six days later. One group
was treated with doxycycline from 4 dpi (”1e6 iRBC + DOX”). Naive mice were included as controls (n=4). Spleens
were removed after PBS-perfusion, weighed (A) and digested in collagenase before the total cell count per spleen
was measured with a cell counter (B). Statistical significance was tested with ANOVA, followed by Tukey post-test;
p < 0.05 was considered significant.
After perfusion and removal of organs we first weighed the spleens of all experimental
groups to examine splenomegaly in PbA-infected mice with or without doxycycline treat-
ment. We found that PbA-infection led to heavier spleens in both infected groups but no
difference between treated and untreated mice (”Naive”: 0.08g, ”PbA 5e4”: 0.14g, ”PbA
1e6 + DOX”: 0.14g cells, p < 0.01 to ”Naive”; Fig. 3.38A).
Afterwards we generated single cell suspensions, counted the cells with a cell counter
and calculated the total number of cells per spleen. The total splenocyte numbers did not
differ between all experimental groups (”Naive”: 1.36e8 cells, ”PbA 5e4”: 1.53e8 cells,
”PbA 1e6 + DOX”: 1.33e8 cells; Fig. 3.38B).
3.2.5.1 T cell numbers did not differ in spleens of doxycycline treated mice,
but their cytotoxicity was significantly reduced
In experimental cerebral malaria cytotoxic CD8+ T cells are thought to contribute most
to the ECM disease development. Therefore, we investigated T cell populations and
their activity in the spleens of our experimental groups (”Naive”, ”PbA 5e4”, ”PbA 1e6
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+ DOX”) 6 days after PbA-infection. We analyzed T cell populations (CD3+, divided
into CD4+ and CD8+) and different activation markers via flow cytometry and measured
cytokine production in supernatants of over night-incubated spleen cells. Additionally, we
performed an in vivo cytotoxicity assay to evaluate the lytic activity of antigen-specific
cytotoxic T cells.
Figure 3.39: T cell numbers in the spleen did not differ after doxycycline treatment of PbA-infected
mice. Spleens of naive, 5e4 iRBC-infected and 1e6 iRBC-infected mice that were treated with doxycycline were
harvested on 6 dpi and prepared for FACS staining (n=4). Cells were stained for CD3 (A) and further differentiated
into CD4+ T cells (B) and CD8+ T cells (C); shown as frequency from CD3+ cells. Graphs show mean percentages
of the indicated marker. Results were tested for significance with ANOVA and Tukey post-test; p < 0.05 was
considered significant.
The frequency of CD3+ cells in the spleen did not differ significantly between d+6 PbA-
infected mice without treatment (”PbA 5e4”: 25.3%) and doxycycline treated animals
(”PbA 1e6 + DOX”: 27.2%; Fig. 3.39A). Both infected groups had comparable T cell
numbers in their spleens in regard to the naive control group (28.4%). The analysis of
CD4+ and CD8+ T cell subpopulations did also not reveal any significant differences
between all experimental groups. Naive mice had a CD4+ T cells proportion of 58.3%
compared to 55.9% in ”PbA 5e4” mice and 55.2% in the ”PbA 1e6 + DOX” group
(Fig. 3.39B). Accordingly, the percentages of CD8+ cells among the T cell population
were also similar in all experimental groups (”Naive”: 37.3%, ”PbA 5e4”; 39.5%, ”PbA
1e6 + DOX”: 41.0%; Fig. 3.39C).
As we did not observe any differences in T cell frequencies we were wondering if T cells
from doxycycline treated mice (”1e6 PbA + DOX) showed any changes regarding their
activity as compared to untreated, PbA-infected mice (”PbA 5e4”). Therefore, we first
evaluated the expression of activation markers with the help of flow cytometry on 6 dpi
in spleen samples from infected mice ±DOX treatment.
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Figure 3.40: Activation markers were decreased in splenic CD8+ T cells from doxycycline treated,
PbA-infected mice. CD8+ T cells from spleens of 5e4 iRBC-infected, 1e6 iRBC-infected, doxycycline treated mice
and naive controls (n=4) were analyzed for different activation markers. The geometric mean fluorescence intensity
of granzyme B (A), CD107a (B) and ICAM-1 (C) was determined by flow cytometry. Statistical differences were
evaluated with ANOVA and Tukey post-test. p values below 0.05 were considered to be significant.
Granzyme B is an effector molecule released from cytotoxic T cells upon activation.
Splenic CD8+ T cells from PbA-infected mice (±DOX) showed a vast increase in intra-
cellular granzyme B compared to samples from naive controls, which were almost neg-
ative (”PbA 5e4”: gMFI 2,722, ”PbA 1e6 + DOX”: gMFI 1,217, ”Naive”; gMFI 58,
p < 0.001; Fig. 3.40A). Importantly, splenic CD8+ T cells from doxycycline treated, 1e6
iRBC-infected mice had significantly less granzyme B stored compared to untreated, 5e4
iRBC-infected mice (p < 0.001).
Analysis of CD107a, a marker for degranulation, supported the decreased cytotoxicity
in T cells from DOX-treated mice: infection of Bl/6 mice with PbA induced a significant
increase in the surface expression of CD107a on CD8+ T cells compared to a weak expres-
sion in T cells from naive mice to mean gMFI of 144 in ”PbA 5e4”-mice and gMFI 95 in
doxycycline treated mice (”PbA 5e4”: gMFI 144, ”PbA 1e6 + DOX”: gMFI 95, ”Naive”;
gMFI 60, p < 0.001; Fig. 3.40B), whereas splenic T cells from doxycycline-treated mice
showed less CD107a expression than cells from untreated PbA-infected animals (”PbA
1e6 + DOX”: gMFI 95, p < 0.001; Fig. 3.40B).
CD8+ T cells from PbA-infected mice expressed more ICAM-1 than the T cells from
naive controls, however, similar to granzyme B and CD107a, CD8+ T cells from doxycycline-
treated mice expressed less ICAM-1 compared to untreated ”PbA 5e4” mice (”Naive”:
gMFI 392, p < 0.001; ”PbA 5e4”: gMFI 818 vs. ”PbA 1e6 + DOX”: gMFI 679, p < 0.05;
Fig. 3.40C).
Similar results were seen in flow cytometry analysis of CD4+ T cells.
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In addition, we evaluated the cytotoxic activity and general cytokine production of
splenocytes from PbA-infected mice with and without doxycycline treatment. Therefore,
we analyzed the supernatants from splenocyte ex vivo cultures for the presence of pro-
and anti-inflammatory mediators via ELISA.
Figure 3.41: Cytotoxicity was reduced in spleens and serum of PbA-infected mice after doxycycline
treatment. Cytotoxicity in PbA-infected mice with (”PbA 1e6 + DOX”) or without (”PbA 5e4”) doxycycline
treatment and naive controls (n=4) was investigated by ELISA in serum and spleen and an in vivo kill. Serum (A)
and cell culture supernatant (B) from over night incubated spleen cells were analyzed for IFNγ by ELISA. Splenocyte
cell culture supernatant was additionally analyzed by ELISA for granzyme B (C) and IL-10 (D). Antigen-specific
cytotoxicity was measured with an in vivo kill (E). Statistical significance was calculated with ANOVA followed by
Tukey post-test; p < 0.05 was considered significant.
Production of IFNγ, a cytotoxic mediator, was not detectable in naive controls but
strongly increased in serum of untreated PbA-infected mice (”PbA 5e4”: 0.31 ng/ml;
Fig. 3.41A). Doxycycline treated mice that had been infected with 1e6 iRBCs, contained
significantly lower IFNγ level in their blood compared to untreated mice that had received
5e4 iRBCs ((”PbA 1e6 + DOX”: 0.03 ng/ml, p < 0.05)).
Similarly to serum levels, spleen cell supernatant from naive mice contained almost no
IFNγ and we detected a significant increase in the ”PbA 5e4” group (”Naive”: 0.01 ng/ml,
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”PbA 5e4”: 0.38 ng/ml, p < 0.001; Fig. 3.41B). Splenocyte cultures from doxycycline-
treated mice contained 4-fold less IFNγ than samples from PbA-infected control mice
(”PbA 1e6 + DOX”: 0.1 ng/ml, p < 0.001).
Cultured spleen cells from both infected groups, harvested on 6 dpi, produced signifi-
cantly more granzyme B than uninfected control mice (0.15 ng/ml, p < 0.001; Fig. 3.41C).
Doxycycline treatment after PbA-infection (1e6 iRBC) led to small but significant reduc-
tion of granzyme B production in the splenocyte cultures compared to samples from
untreated PbA-infected control mice (”PbA 1e6 + DOX”: 0.91 ng/ml, ”PbA 5e4”: 1.08
ng/ml, p < 0.01; Fig. 3.41C).
We found significantly increased production of IL-10 in supernatant from cultured
splenocytes 6 days after PbA-infection (p < 0.01), but no difference between doxycycline
treated and untreated mice was observed (”Naive”: 0.20 ng/ml, ”PbA 5e4”: 0.41 ng/ml,
”PbA 1e6 + DOX”: 0.40 ng/ml; Fig. 3.41D).
Next, we performed an in vivo CTL assay. Here, infected mice and controls received
peptide-pulsed, CFSE-labeled target cells from syngenic donors i.v. in order to determine
the cytotoxicity of antigen-specific T cells in the recipient animals on 6 dpi.
We measured a reduced antigen-specific CTL response in the spleens of DOX-treated
mice on 6 dpi (Fig. 3.41E). The minor unspecific loss of labeled target cells in naive mice
was defined as background, as those mice could not have any target-specific active T
cells. Compared to the uninfected mice, PbA-infected mice generated a significant lytic
activity (”PbA 5e4”: 68.8%, p < 0.001), whereas doxycycline treatment dampened this
response markedly: we measured a 3.5-fold reduction of lytic activity in spleens from
doxycycline-treated mice (”PbA 1e6 + DOX”: 19.3%, p < 0.001).
These results are in agreement with the attenuated expression of activation markers
we had observed in splenic T cells from DOX-treated mice as well as impaired production
of inflammatory mediators in serum and from spleen cell cultures (Fig. 3.40, 3.41A-C).
In summary, doxycycline treatment in PbA-infected mice did not change the T cell
numbers and frequencies, but splenic CD8+ T cells showed impaired activity and levels of
pro-inflammatory cytokines were reduced.
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3.2.5.2 Antigen presenting cells were less activated in doxycycline treated
mice
The analysis of T cells in doxycycline treated mice that were infected with PbA 6 days
prior to analysis showed a marked impairment of activation in this cell type. Extending
our investigation to antigen-presenting cells should help to answer the question whether
doxycycline had a direct effect on T cell activity or if our findings could be a consequence
of hampered APC function.
Analysis of splenic APCs was performed on spleen cells that were harvested from d+6
PbA-infected mice with doxycycline treatment (”PbA 1e6 + DOX”) or without treatment
(”PbA 5e4”) and naive control animals. Spleens were processed as describe before and
stained for flow cytometry analysis. CD3 was used to exclude T cells before other cells
were split into dendritic cells (CD11c+I-Ab+) and CD11b+ cells (from cells that were
not DCs) that include macrophages, monocytes and neutrophils. All cell subsets were
further analyzed for signs of activation by expression of ICAM-1, MHC I upregulation
and expression level of I-Ab in CD11b+ cells.
Figure 3.42: Activation markers on splenic dendritic cells were reduced in doxycycline treated, PbA-
infected mice. Spleen cells were isolated from naive mice and PbA-infected animals with or without doxycycline
treatment (n=4) and analyzed by flow cytometry. Dendritic cells were defined as CD3−CD11c+I-Ab+ (A, percent-
age of total cells) and further analyzed for changes in surface markers ICAM-1 (B, gMFI) and MHCI molecules (C,
gMFI). Results were tested for significance between two groups with an unpaired t-test and between three groups
with ANOVA and Tukey post-test; p < 0.05 was considered significant.
Dendritic cells frequencies (CD11c+I-Ab+) in spleens of PbA-infected, doxycycline
treated mice (”PbA 1e6 + DOX”: 1.87% of total spleen cells) did not differ significantly
from untreated, infected (”PbA 5e4”: 1.87%) and uninfected mice (”Naive”: 1.98%;
Fig. 3.42A). However, the analysis of ICAM-1 and MHC I molecules on the surface of
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DCs revealed a diminished activation in doxycycline treated mice. ICAM-1 expression on
DCs was significantly increased in untreated, PbA-infected mice (gMFI 4066) compared
to uninfected controls (gMFI 1709, p < 0.001). A smaller increase of ICAM-1 expression
was found on splenic DCs from doxycycline treated mice (gMFI 2938), which was signif-
icantly less than in untreated animals, but higher compared to naive controls (p < 0.05;
Fig. 3.42B). MHC I expression revealed a similar picture (Fig. 3.42C): we observed an
significant upregulation of MHC I in PbA-infected mice (”PbA 5e4” gMFI: 50,962) com-
pared to naive controls (”Naive” gMFI 16,263, p < 0.001). This increase was also seen in
doxycycline treated mice (”PbA 1e6 + DOX” gMFI: 40,110, p < 0.001 against ”Naive”)
but significantly reduced compared to the untreated group (p < 0.001).
CD11b+ cells from all experimental groups were gated from the CD3− cells that were
not DCs and also analyzed for activation markers.
Figure 3.43: Less Ly6C+ monocytes in spleens of doxycycline treated mice but similar activation
in CD11b+ cells in general, compared to untreated mice. Spleens of PbA-infected mice (with or without
doxycycline treatment, n=4) and naive controls (n=4) were analyzed at 6 dpi for changes in CD11b+ cell frequencies
(CD3−, no dendritic cells) by flow cytometry (A), and were further differentiated into Ly6C+ monocytes (B,
Ly6C+Ly6G−) and neutrophils (C, Ly6CintLy6G+). Furthermore, the gMFI of I-Ab (D), ICAM-1 (E) and MHC I
(F) was determined in this cell population. Statistical analysis were done with ANOVA followed by Tukey post-test
with p < 0.05 considered to be significant.
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Spleens of doxycycline treated mice (”PbA 1e6 + DOX”) showed a small, but insignif-
icant increase in CD11b+ cells (5.7%) compared to untreated PbA-infected mice (”PbA
5e4”: 3.9%) and naive controls (4.1%; Fig. 3.43A). Further differentiation of CD11b+ cells
revealed an increase in Ly6C+ monocytes in both PbA-infected groups with significantly
more Ly6C+ monocytes among the CD11b+ splenocytes in untreated 5e4 iRBC-infected
mice compared to doxycycline treated, 1e6 iRBC-infected animals (”Naive”: 20.9%, ”PbA
5e4”: 56.3%, ”PbA 1e6 + DOX”: 40.7%, p < 0.001; 3.43B). Analysis of neutrophils among
splenic CD11b+ cells showed no differences in our experimental groups (”Naive”: 2.1%,
”PbA 5e4”: 3.2%, ”PbA 1e6 + DOX”: 2.7%; 3.43C).
I-Ab expression on CD11b+ cells significantly increased (p < 0.001) from a gMFI
of 743 in naive mice to gMFI 2,269 in untreated, PbA-infected mice and even more to
a gMFI value of 2,791 after doxycycline treatment (Fig. 3.43D). Despite being a small
trend, the difference between doxycycline treated and untreated mice was not significant.
A similar pattern was observed in ICAM-1 expression on CD11b+ cells: it significantly
(p < 0.01) increased from gMFI 790 in naive mice to 1,299 in the ”PbA 5e4” group and
to 1,175 in the doxycycline treated group. No significant differences were found between
PbA-infected mice, regardless of doxycycline treatment (Fig. 3.43E). MHCI expression
was the only analyzed surface marker that differed between both PbA-infected groups.
Interestingly, CD11b+ cells from doxycycline treated animals expressed significantly more
MHCI than untreated mice (”PbA 1e6 + DOX” gMFI: 18,770, ”PbA 5e4” gMFI: 16,024,
p < 0.01). Again, cells from both PbA-infected groups expressed more MHCI than naive
mice (gMFI 5636, p < 0.001; Fig. 3.43F).
All together, analysis of antigen-presenting cells in spleens of d+6 infected mice showed
no differences in cell frequencies depending on doxycycline treatment. Dendritic cells
from doxycycline treated mice expressed less surface markers that are associated with cell
activation compared to untreated mice, while the analysis of CD11b+ cells revealed no
differences between both groups.
3.2.6 Reduction of doxycycline dose to sub-antimicrobial doses still im-
proved survival independent of parasite killing
Some studies showed, that the anti-inflammatory properties of antibiotics from the tetra-
cycline group were still maintained when the drugs were given in sub-antimicrobial doses,
i.e. a concentration that does not affect bacteria [Brown et al., 2004]. Based on these
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findings, we were interested whether we could find a sub-antimicrobial dose that would not
affect parasite growth but still work anti-inflammatory to overcome the difficulty of dif-
ferentiating between direct anti-inflammatory effects and the effects caused by a reduced
parasitemia.
To address this idea, C57Bl/6 mice were infected with 5e4 PbA-infected RBCs and
either left untreated (”PbA 5e4”, infection control group) or divided into one of four
groups that received different concentrations of doxycycline intravenously. Starting from
the already established 80 mg/kg/day (group ”PbA 5e4 + DOX 80”) we decided to reduce
the concentration of doxycycline to 32 mg/kg/day (”PbA 5e4 + DOX 32”), 16 mg/kg/day
(”PbA 5e4 + DOX 16”) and 8 mg/kg/day (”PbA 5e4 + DOX 8”). All treated groups
received doxycycline intravenously from day 4 post infection (p.i).
Figure 3.44: Mice treated with different doses of doxycycline showed better survival compared to
untreated mice. Mice were intravenously injected with their respective dose of doxycycline daily from 4 dpi on.
Differences in survival were tested for significance with log-rank test. p values below 0.05 were considered significant.
Analysis of survival confirmed our previous findings that treatment with our estab-
lished doxycycline dose of 80 mg/kg/d from 4-6 dpi led to a 100% protection from ECM
in PbA-infected mice, whereas almost all control-infected mice died from cerebral malaria
between 6-8 dpi (Survival 10% at 10 dpi, Fig. 3.44). First mice of the DOX-treated group
died after 14 dpi due to other complications like anemia, as the short treatment time
was not sufficient to clear all parasites from the blood. Other groups with lower doses of
doxycycline (32, 16, 8 mg/kg/d; 4-6 dpi) showed significantly better survival compared to
untreated mice (40-50% DOX-treated vs. 10% in untreated; p < 0.05), but the protection
was not as good as in the ”PbA 5e4 + DOX 80” group, as only about half of the mice
remained ECM free. However, we were also interested how the reduced doses would affect
parasitemia, especially in surviving mice of the low dose doxycycline groups.
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Figure 3.45: Doxycycline was able to protect mice from ECM without affecting parasitemia. PbA-
infected mice were intravenously injected with their respective dose of doxycycline daily from 4 dpi on. Parasitemia
was determined in Giemsa stained thin bloods smears, graphs are shown for 6 dpi (onset of disease in untreated
mice) and 10 dpi (time point after ECM phase). Red dots in A represent mice that survived till 10 dpi and are
shown in B. Statistical significance was tested with ANOVA paired with Tukey post test; p < 0.05 was considered
significant.
We evaluated the parasite load on 6 dpi, the typical time point of ECM onset and
appearance of neuro-specific symptoms in PbA-infected mice. At this time point PbA-
infected control mice had a peripheral parasitemia of 7.1% whereas ”PbA + DOX 80”
mice had a significantly reduced parasite load of 1.2% (p < 0.001; Fig. 3.45A). Groups
that were treated with 32, 16 or 8 mg/kg had similar intermediate parasite counts (4.4%,
5.0% and 5.7% respectively). When we analyzed the parasitemia on 10 dpi, which is a
time point already after the critical ECM phase, one surviving mouse of the untreated
controls had a blood parasitemia of 18.0% and mice treated with our previous established
doxycycline dose of 80 mg/kg/d had a mean parasitemia of only 0.28% (Fig. 3.45B). We
observed a wide range of parasitemia (0-45.8%) in the groups that received lower doses
of doxycycline (32mg/kg, 16mg/kg, 8mg/kg; Fig. 3.45B). We found mice with almost
not detectable parasitemia (0.0%; but still few parasites found in the whole slide) and
animals with rather high parasite load (up to 45.8%; Fig. 3.45B) in all groups with reduced
doxycycline doses (compared to the 80 mg/kg control group).
These results showed that some PbA-infected mice that had received reduced doses
of doxycycline (32mg/kg or less), were still protected from developing ECM, despite an
increasing parasitemia.
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Discussion
The mechanisms that form the basis of cerebral malaria are multi-factorial and have not
yet been understood completely. Mechanical obstruction of cerebral blood vessels and
subsequent shortage of nutrition in the brain caused by intravascular sequestration of
infected red blood cells were assumed to be major factors contributing to the disease.
However, detection of strong inflammatory responses in CM patients brought focus on
the host’s immune responses, which could be confirmed in experimental models of CM.
With the help of well-established and accepted mouse models, inflammatory cytokines
and CD8+ T cells were identified as indispensable components in the development of
ECM malaria and so far, several factors could be validated in human studies, linking CM
development to strong inflammation.
Using the PbA infection model in mice, we addressed the question, how the genetic
lack of cross-presenting DCs - a key cell population in the induction of a strong CD8+ T
cell-associated Th1 response - affects the development of ECM and the involved immune
responses and secondly, whether and how an experimental treatment with doxycycline
was able to interfere with the already primed effector immune responses and survival in
PbA-infected mice.
In the first part of this study, we analyzed PbA-infected Batf3-/- mice that are deficient
of cross-presenting DCs and that are completely protected from ECM. This protection was
associated with the complete absence of cerebral inflammation, which was in sharp contrast
to infected WT controls that suffered from ECM, characterized by severe brain inflam-
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mation. Importantly, whereas PbA-infected WT mice generated a strong inflammatory
immune-response in the periphery, we found weak, but still detectable cytotoxic immune
responses and a rather regulatory milieu in infected Batf3-/- mice. These findings included
reduced cytotoxic activity and increased presence of regulatory cells (Tregs, AAMs) and
cytokines (IL-10) in spleens of the infected knock-out mice. Thus, the genetic ablation
of cross-presenting dendritic cells, prevented the generation of excessive inflammatory re-
sponses and rather enabled the development of a balanced milieu, resulting in protection
from fatal ECM.
The second part of this thesis addressed the question whether a late therapeutic in-
tervention after PbA-infection of Bl/6 WT mice was able to interfere with the usually
fatal disease progression. We showed that doxycycline treatment successfully prevented
ECM development in infected mice when given from day four p.i., which is just before
first specific neurological symptoms usually manifest, but the infection is already estab-
lished (although not yet with neuro-pathological symptoms). Doxycycline-treated mice
contained less cellular infiltrates in their brains and showed strongly reduced activation of
T cells and also antigen-presenting cells, which added up to a complete ECM-protection
in otherwise susceptible mice. Importantly, we could show, that in addition to the well-
known anti-parasitic properties of doxycycline, the anti-inflammatory effect is strongly
contributing to ECM protection.
4.1 Cross-presenting dendritic cells were required for devel-
opment of ECM in a PbA mouse model
Batf3-/- mice, which genetically lack cross-presenting dendritic cells, were not susceptible
to cerebral malaria (100% survival), in contrast to PbA-infected WT mice (Fig. 1.2A, B),
which is in line with the observations from others in Batf3-/- mice [Zhao et al., 2014] or in
mice that were depleted from CD11chiCD8a+ or all conventional DCs early in infection
[Piva et al., 2012, DeWalick et al., 2007]. Interestingly, Zhao et al., using Batf3-/- mice,
described a lower survival rate of only around 50%, which might be explained by the
different infectious doses that were used. We routinely use 5e4 iRBCs (injected i.v.),
while Zhao et al. infected mice i.v. with 1e6 iRBCs. As injection of iRBC is done by
whole blood transfer from PbA-infected donor mice, this does not only mean that a higher
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parasite load but also more competent immune cells are injected, which could trigger a
stronger immune response leading to ECM.
Importantly, we observed that the lack of cross-presenting dendritic cells did not only
prevent ECM after blood-stage infection but also after sporozoite injection (Fig. 3.1A,
B). Sporozoites undergo a liver stage before they develop to merozoites that re-enter the
blood stream, resulting in a delay of 1-2 days for disease onset. Research models that
infect with blood-stage parasites bypass the liver phase, which might trigger different im-
mune responses against the pathogen. We are aware of this possibility, but since both
routes of infection resulted in the same outcome, we focused on the blood-stage infection.
A relevant finding was that blood parasitemia of WT and Batf3-/- mice after infection
with either iRBCs or sporozoites was comparable (Fig. 1.2C, 3.1C), which is in agreement
with the results from others that depleted cDCs and cross-presenting DCs in [Piva et al.,
2012, DeWalick et al., 2007]. This indicated that the ECM-protection of PbA-infected
Batf3-/- mice was not caused by a reduction of the parasite load but by other unknown
mechanisms and that the lack of cross-presenting dendritic cells neither impaired the
ability of the parasites to replicate nor did it interfere with the immune systems capability
to fight the parasites. However, infection of Batf3-/- mice with murine Plasmodium strains
like P. chabaudi chabaudi which are not lethal in C57Bl/6 mice and can be controlled by
the animals [Li et al., 2001], would further help to characterize the role of cross-presenting
DCs in replication control of Plasmodium parasites.
4.1.1 PbA-infected Batf3-/- mice maintained a stable blood-brain bar-
rier and lacked infiltration of effector T cells into the brain
In addition to sequestration of blood cells in the brain, the breakdown of the blood-brain
barrier is a hallmark of experimental cerebral malaria and has also been described in
human CM. However, the situation in human patients is less clear and until today there
is no evidence that cerebral malaria is strictly linked to a damaged blood-brain barrier in
humans. Interestingly, the link between CM and a destructed BBB were dependent on
age and origin of the patients [Renia et al., 2012].
C57Bl/6 mice that are infected with P. berghei ANKA usually die between 6 and
8 dpi, shortly after displaying neurological symptoms of disease like limb paralysis and
convulsions. The rapid disease progression that leads to death within hours after first
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symptoms is closely related to the destruction of the blood-brain barrier, which starts
at the olfactory bulb on 5 dpi, a few hours before ECM onset [Zhao et al., 2014]. We
observed a massive BBB disruption in PbA-infected WT mice, but not in Batf3-/- mice,
which were free of disease symptoms and completely protected from ECM (Fig. 1.2D,E).
This finding was also mirrored by the low number of cellular infiltrates found in brains
of PbA-infected Batf3-/- mice and naive mice, in contrast to samples from infected WT
mice containing significantly increased cell numbers (Fig. 3.3). Reduced cellular brain
infiltration was also described in other studies of PbA-infected mice that were depleted
of cross-presenting DCs [Piva et al., 2012]. However, recovered cells from brains of ex-
perimental animals have not necessarily passed the blood-brain barrier but could also be
attached to cerebral blood vessels strong enough to circumvent removal by perfusion of
the animals. Therefore, BBB breakdown and detection of peripheral immune cells in brain
samples by flow cytometry do not describe the same phenomenon; but it is likely, that
adhesion and activation of immune cells in the brain after Plasmodium infection strongly
contribute to the disruption of the blood-brain barrier.
In ECM, CD8+ T cells were clearly identified as primarily responsible effector lym-
phocytes by using transgenic mouse models and depleting antibodies [Belnoue et al.,
2002, Re´nia et al., 2006]. In contrast, the role of CD4+ T cells is less clear and studies on
this cell subset have shown inconsistent data regarding their importance [Belnoue et al.,
2002].
In brain samples of d+6 PbA-infected Bl/6 mice that suffered from ECM, we found
a clear increase of CD8+ T cells and Ly6C+ monocytes. In contrast, in brains of PbA-
infected Batf3-/- mice, which were ECM-free, we detected only minor amounts of periph-
eral immune cells and the cell count and cellular composition in the digested brain samples
did not differ to that from naive animals (Fig. 3.4, 3.5).
These findings suggested that in addition to a general reduced cellular infiltration in the
brains of Batf3-/- mice compared to WT mice, the frequencies and absolute cell counts
of certain effector cell subsets were only in ECM-susceptible mice significantly altered.
These changes resulted in a prevalence of cells promoting inflammation, which supports
the general idea that cerebral malaria is the result of overwhelming immune responses.
These alterations in brain infiltrated cells might also emerge from differences in the cellular
composition and activation in the spleen - where the infiltrated cell have been primed -
and will be discussed later.
108
4.1. CROSS-PRESENTING DENDRITIC CELLS WERE REQUIRED FOR DEVELOPMENT OF
ECM IN A PBA MOUSE MODEL
4.1.2 ECM-protected Batf3-/- mice showed no signs of cerebral inflam-
mation 6 days after PbA-infection
The migration of immune effector cells - especially of T lymphocytes - to the brain is nec-
essary but not sufficient for the development of experimental cerebral malaria. Further
important factors are effector molecules that are associated with strong inflammation and
ECM, such as granzyme B, IFNγ and members of the TNF family, which are well de-
scribed in PbA-infected WT mice and were also detected in our experiments. In contrast,
we found significantly less of these mediators and also impaired expression of activation
markers on infiltrated immune cells in brain samples from Batf3-/- mice, thereby confirm-
ing diminished cerebral inflammation.
4.1.2.1 Cells in brains of PbA-infected Batf3-/- mice produced less effector
molecules
Cytotoxic T cells that come to the brain have to be previously activated in the periphery
but require a certain local parasite (= antigen) threshold to be fully functional [Haque
et al., 2011]. Granzyme B is one of the important molecules that account for the activity
of cytotoxic T cells and was identified as a requirement for ECM development [Haque
et al., 2011].
For a thorough analysis of activation markers relevant in ECM, we need to differentiate
between a cell’s capability to produce cytotoxic or immune regulatory mediators versus
their actual release, in or ex vivo. In our study, brain samples of PbA-infected WT
mice contained strongly elevated amounts of granzyme B on protein level in CD8+ T
cells as measured by intracellular FACS as well in supernatant of whole brain cell culture
by ELISA and also on mRNA level via qRT-PCR. In contrast, we detected significantly
reduced granzyme B expression in brains of PbA-infected Batf3-/- mice (Fig. 3.6A-C).
These data fitted with reduced parasite loads in PbA-infected Batf3-/- mice in contrast to
high parasite infiltration in infected WT mice (preliminary data not shown).
All data clearly demonstrated reduced cytotoxicity of the few CD8+ T cells that were
found in the brains of Batf3-/- mice after PbA-infection, which might be also linked to
the lower parasite load in the brain. While the pure presence of granzyme B+ T cells in
brains was not sufficient to induce ECM [Shaw et al., 2015], the absence of this cytotoxic
cells are clearly an advantage for the infected Batf3-/- mice, as mice lacking granzyme B
have been shown to be protected from ECM [Haque et al., 2011].
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In addition to elevated levels of granzyme B, we measured significantly more TNF
production in brain samples of ECM positive WT mice, but not in samples from ECM-
negative Batf3-/- mice (Fig. 3.6E). TNF can be released by many cell types, such as
blood-borne macrophages and Ly6C+ monocytes, which were found in increased numbers
in brains of PbA-infected WT mice but not in infected Batf3-/- mice (Fig. 3.5), but also
from brain resident microglia and even astrocytes [Renno et al., 1995, Lieberman et al.,
1989]. Initially, TNF was shown to be necessary for ECM development, as depletion by
anti-TNF antibodies resulted in ECM protection in mice [Grau et al., 1987], however trials
in human CM patients could not validate its importance [John et al., 2010]. Over time
other members of the TNF family came into focus [Randall and Engwerda, 2010] and
more recent findings favor a role for LIGHT-lympotoxin-β and lympotoxin-α (LT-α), as
mice deficient for TNF are fully susceptible to ECM but those deficient for LIGHT-LTβ
receptor or LT-α do not develop ECM [Randall et al., 2008, Engwerda, 2002]. A possible
explanation for these conflicting data is the similarity of TNF and LT-α. Structural
similarity and common receptors (TNFR1 and 2), make selective antibody depletion of
TNF difficult [Engwerda, 2002]. Therefore, we can only conclude, that members of the
TNF super-family were regulated in Batf3-/- mice upon PbA-infection.
Taken together, we can conclude a diminished production of inflammatory cytokines
in parallel to reduced amounts of possible cellular sources such as T cells and monocytes
in brains of ECM-protected Batf3-/- mice were contributing to the observed phenotype,
4.1.2.2 Reduced ICAM-1 expression could prevent adhesion of cells in brains
of PbA-infected Batf3-/- mice
The local action and motility of cytotoxic T cells in the brain is a major factor in ECM
development [Shaw et al., 2015]. Adhesion molecules like ICAM-1 help the circulating
immune cells to adhere on endothelial cell in order to engage in a local immune response.
T cells from spleens and those immigrated to the brain showed significantly increased
ICAM-1 expression in PbA-infected WT but not in infected Batf3-/- mice (Fig. 3.6D,
3.11D). ICAM-1 is an adhesion molecule whose expression has been shown to be necessary
on leukocytes for ECM development [Ramos et al., 2013]. A reduced ICAM-1 expression
could be a direct effect of the lacking interaction of CD8+ T cells with cross-presenting
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DCs, as TC-DC-interactions give rise to a positive-feedback-loop with subsequent in-
duction of ICAM-1 expression [McBride and Fathman, 2002]. In the course of disease
development, the lack of an adhesion molecule could be beneficial, as T cells might be
less likely to attach to other cells like endothelial cells, platelets or infected erythrocytes
which could prevent cluster formation, microvessels occlusion and inflammation in brains
during ECM [Ramos et al., 2013, de Kossodo and Grau, 1993, Shaw et al., 2015].
4.1.2.3 Phagocytosis is reduced in microglia of PbA-infected and naive Batf3-/-
mice
Brain resident microglia are often described as the macrophages of the brain. Next to
their role as a possible source of TNF and other cytokines, they can also take up antigen
for clearance functions and present antigen to other immune cells. In both, human CM
patients as well as in murine ECM studies, activated microglia were found [Deininger
et al., 2002, Medana et al., 1997].
In a preliminary experiment, we observed that the capability to take up antigen was
increased in microglia isolated from brains of both PbA-infected groups (WT and ko)
on 6 dpi compared to their respective naive controls but not early in infection on 3 dpi
(compared to naive controls; Fig. 3.7). Interestingly, the frequencies of microglia that had
taken up the beads was lower in Batf3-/- mice compared to WT mice at all analyzed time
points.
Currently, there are no studies regarding putative roles of Batf3 in development or
activity of microglia. However, a recent paper showed that Batf3 is not necessary for the
initial development of pre-CD8a+ DCs but is needed for auto-activation of transcription
factor interferon regulatory factor 8 (IRF8 ), which is required for the maturation of this
DC subtype [Grajales-Reyes et al., 2015]. IRF8 but not Batf3 was shown to be also
involved in the development of microglia; however functional features such as phagocytosis
were not tested and could still be affected through a similar Batf3 -IRF8 -interaction as in
the DC development [Kierdorf et al., 2013]. Further investigations are required in order
to see how the lack of Batf3 might influence microglia actions.
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4.1.3 Protection from brain pathology in PbA-infected Batf3-/- mice
apparently resulted from altered immune responses in the spleen
The general lack of inflammatory processes in brains of PbA-infected Batf3-/- mice was
in strong contrast to the results from susceptible WT mice on 6 dpi (Fig. 3.6). Immune
responses to Plasmodium parasites are initiated in the spleen, where T cells are primed
upon antigen encounter [Engwerda et al., 2005]. These activated T cells then migrate
towards a chemokine gradient into the brain where clustering of infected red blood cells
leads to an activation of the local tissue and subsequent release of chemokines attracts
further immune cells.
Since all of these inflammatory processes were strongly impaired in PbA-infected
Batf3-/- mice, we hypothesized that reduced inflammation in the brain might be the re-
sult of a hampered T cell priming in the spleen of PbA-infected Batf3-/- mice that remain
ECM free.
It was shown before, that only depletion of DCs at an early time point of infection
leads to protection from ECM in otherwise susceptible mice, which favors a role of DCs
in the priming phase of PbA-infection [DeWalick et al., 2007]. Lundie et al. specifically
showed that CD8a+ DCs, that cross-present antigen to CD8+ T cells, are essential for
priming of CD8+ T cells in ECM [Lundie et al., 2008].
4.1.3.1 PbA-infected Batf3-/- mice displayed an impaired, but not fully ab-
sent CTL response
First of all, we determined strong production of cytotoxic molecules in the periphery in
PbA-infected WT mice. Most importantly, the functional ability of endogenously gen-
erated T lymphocytes to lyse cells that present parasite-derived antigens was tested and
successfully demonstrated for PbA-infected WT mice.
Parasite-specific cytotoxicity can be determined by lysis of peptide-loaded target cells
by endogenously generated T cells in an in vivo CTL assay. This assay was performed
previously in our lab with the help of transgenic PbA parasites that expressed ovalbumin;
in addition to the well-described MHC class I peptide from OVA (SIINFEKL), we ana-
lyzed also responses towards MHC class I peptides from the endogenous parasite-derived
protein MSP-1 (merozoite surface protein) that our group had identified before.
112
4.1. CROSS-PRESENTING DENDRITIC CELLS WERE REQUIRED FOR DEVELOPMENT OF
ECM IN A PBA MOUSE MODEL
Indeed, in addition to the lack of brain inflammation in PbA-infected Batf3-/- mice,
they generated only weak CTL responses in their spleens compared to infected WT mice
(Fig. 1.2F). Next to generally reduced CD8+ T cell frequencies throughout infection (3
dpi and 6 dpi; Fig. 3.10C), an analysis of their splenocyte cultures revealed less cyto-
toxic molecules, such as granzyme B and IFNγ, as well as reduced expression of markers
associated with T cell activation such as ICAM-1, on 3 and 6 dpi when compared to
PbA-infected WT mice (Fig. 3.11, 3.12).
The majority of CD8+ T cells found in spleens of PbA-infected WT mice expressed
CD11c, which is, according to Beyer et al., a marker for cytotoxic T cells [Beyer et al.,
2005] and fits to the finding by Tamura et al. that CD11c+CD8+ T cells are highly
activated in PbA-infection and contribute to the ECM pathology by production of in-
flammatory cytokines and by promoting T cell accumulation in the brain [Tamura et al.,
2011]. However, we found in PbA-infected Batf3-/- mice, significantly less T cells express-
ing CD11c, indicating less efficient activation (Fig. 3.12D). In addition, the presence of
CD11c+CD8+ T cells was also described for other ECM-resistant strains such as Balb/c
mice [Tamura et al., 2011]. Therefore, the pure presence of this cell subset is apparently
not sufficient to induce ECM, but CD11c expression itself might be an interesting marker
for T cell activity in ECM.
The reduced ability of splenic CD8+ T cells from Batf3-/- mice to produce and re-
lease granzyme B and IFNγ upon PbA-infection (Fig. 3.11, 3.12) is not only a sign of
their hampered activation, but most likely one part in the processes that lead to the ob-
served ECM protection, as both cytotoxic mediators, granzyme B and IFNγ, were shown
to be required for development of ECM with the help of knock-out mice [Haque et al.,
2011, Rudin et al., 1997]. Our results are in line with observations from Piva et al. (2012),
who reported reduced signs of T cell activation in Clec9A-DTR mice, which were depleted
of cross-presenting DCs by diphtheria toxin (DT) before PbA-infection [Piva et al., 2012].
Interestingly, they observed an increase in serum IFNγ levels at an early time point of
infection, before the onset of ECM symptoms in WT but not Clec9A-DTR mice. In con-
trast to our results, where serum IFNγ was only reduced in Batf3-/- mice on 3 dpi but not
on 6 dpi when compared to WT controls (Fig. 3.11C), Piva et al. observed lower IFNγ
also on 4 and 6 dpi [Piva et al., 2012]. Those differences could be caused by the different
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approaches to eliminate the cross-presenting DCs.
The study from Haque et al. showed that gzmB−/− mice (genetically lacking granzyme B)
contained more IFNγ positive CD4+ and CD8+ T cells in their spleens, but were fully
protected from ECM. They could also demonstrated by adoptive transfer experiments,
that IFNγ deficient OT-I cells were still able to induce ECM-like symptoms in PbA-OVA-
infected gzmB−/− mice [Haque et al., 2011]. These observations led them to the conclusion
that - in contrast to granzyme B - IFNγ is dispensable for ECM development. However,
the whole process leading to ECM is multi-factorial and can not be fully explained by the
presence or absence of these mediators.
Additionally to reduced T cell activity in PbA-infected Batf3-/- mice, we observed an
increase of inflammatory Ly6C+ monocytes in spleens of WT but not in Batf3-/- mice on
3 dpi, but this was not seen at later time points of infection (Fig. 3.18C). The produc-
tion of TNF was increased in WT mice on 3 dpi but was not changed in Batf3-/- mice
(Fig. 3.19A). These observations are in line with results from our lab that showed an
important role for inflammatory monocytes in the early phase of PbA-infection: early (0
dpi) but not late (3 + 5 dpi) depletion of CCR2+ monocytes prevented ECM in usually
susceptible Bl/6 mice [Schumak et al., 2015].
Taken together, we concluded that PbA-infected Batf3-/- mice were protected from
ECM due to an impaired CTL response.
NK cells could contribute to the cytotoxic immune response in Batf3-/- mice
after PbA-infection
Granzyme B and IFNγ are pro-inflammatory mediators that are usually produced by
cytotoxic T cells, but can also be produced by natural killer (NK) and natural killer T
(NKT) cells. Importantly, we detected elevated NK and NKT cell frequencies in spleens
of PbA-infected Batf3-/- mice at an early (3 dpi) and late (6 dpi) time point after infection
when compared to samples of infected WT mice (Fig. 3.13). Therefore, we analyzed these
cell subset for their ability to produce granzyme B and IFNγ at both time points. MACS-
purification by DX5 made it impossible to distinguish between NK and NKT cells, and
therefore both cell subsets together will be referred to as NK(T) cells.
In agreement with cytokine analysis from whole spleen cell culture (Fig. 3.11A, B),
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granzyme B and IFNγ were detected at very low levels in NK(T) culture supernatant
derived from d+3 PbA-infected mice of both strains (Fig. 3.14). NK cells belong to
the innate immune system, which would favor an early cytokine production by these
cells. However, NK cells as producers of early IFNγ were found to be more important
in the brain than in the spleens of PbA-infected mice [Villegas-Mendez et al., 2012].
Interestingly, IFNγ levels in serum from d+3 PbA-infected WT mice were almost 10-fold
higher compared to Batf3-/- mice (Fig. 3.11C).
In contrast to early infection, we detected high levels of both cytokines in NK(T) cell
cultures on 6 dpi (Fig. 3.14). Importantly, supernatants of NK(T) cell culture contained
more granzyme B expression in samples from PbA-infected Batf3-/- mice compared to
samples from infected WT mice, which was in contrast to observations from the whole
spleen cell culture where granzyme B level were higher in samples from PbA-infected WT
mice (Fig. 3.14A, 3.11A). While IFNγ production is assigned to NKT cells and also CD4+
T cells in later Plasmodium infection [Deroost et al., 2016], the production of granzyme B
has not yet been described in detail. Flow cytometry analysis on 6 dpi could further
enforce a cytotoxic role of NK cells in Batf3-/- mice, since degranulation marker CD107a
was significantly increased in PbA-infected Batf3-/- mice, but not in infected WT mice
(Fig. 3.15D).
Interestingly, despite observations that P. falciparum infected RBCs induce granzyme B
in NK cells [Bo¨ttger et al., 2012] and these cells are involved in parasite elimination
[Chen et al., 2014], the parasitemia was not affected by the higher levels of granzyme B
(Fig. 1.2C).
The finding that NK(T) cells from PbA-infected Batf3-/- mice produced more granzyme B
and were more activated than those from WT animals could indicate a mechanism by
which the immune system tries to compensate for the impaired cytotoxicity of CD8+
T cells and could at least in part explain the high cytokine levels in spleen cell culture
supernatants of ECM-negative Batf3-/- mice.
Alternative generation of cross-presenting dendritic cells could contribute to
the remaining CTL response in PbA-infected Batf3-/- mice
CTL responses and T cell activation in PbA-infected Batf3-/- mice were significantly
reduced compared to infected WT mice, but not completely absent. Additionally, even if
impaired, antigen-specific immune responses were still detectable in these mice (Fig. 3.11,
3.12, 1.2F). Therefore, priming of CD8+ T cells was not completely abolished.
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Spleens of Batf3-/- mice contained almost no XCR1+ DCs, but very few cells were still
detectable (Fig. 3.16). Next to the possibility of false positive signals or a leaky knock-out
phenotype, an explanation for the presence of XCR1+ DCs in Batf3-/- mice could be a
Batf3 -independent mechanism, as generation of cross-presenting DCs was shown in the
absence of Batf3 [Mott et al., 2015]. Other transcription factors that might compensate
the lack of Batf3 include Batf2 or interferon regulatory factor 8 (Irf8 ) [Seillet et al., 2013].
Later studies confirmed that pre-CD8a+ DCs develop in the absence of Batf3, but this
transcription factor was needed to maintain auto-activation of Irf8 which is necessary to
preserve the CD8+ phenotype of developing DCs [Grajales-Reyes et al., 2015].
One minor difficulty in interpretation of these results is the fact that all mentioned
studies defined cross-presenting DCs as CD8a+ DCs, which make only up for 80% of this
DC subset, with XCR1 being a better marker for the Batf3 -dependent cross-presenting
DCs [Bachem et al., 2012]. This small discrepancy has to be kept in mind when analyz-
ing the results, as CD8a+ DCs that emerge in the absence of Batf3 could be part of the
non-cross-presenting subset.
Antigen-cross-presentation by alternative cell subsets could activate CTL re-
sponses with the help of IL-6 trans-signaling
As the remaining XCR1+ DC population was very small in Batf3-/- mice, we addressed
the question whether other cells were able to induce CD8+ T cell responses.
Analysis of XCR1− DCs revealed significantly higher CD40 expression in PbA-infected
Batf3-/- mice 6 days post infection compared to infected WT mice (Fig. 3.17A). While
CD40 expression is associated with the cross-presentation in general, there is no evidence
that XCR1− dendritic cells acquire the ability to cross-present when expressing high lev-
els of CD40 [Yin et al., 2015]. Analysis of other APCs like macrophages, monocytes and
neutrophils did not show any striking differences between PbA-infected WT and Batf3-/-
mice in cell numbers (Fig. 3.18) but cells from Batf3-/- mice showed reduced phagocytic
capacity on 6 dpi (Fig. 3.20). Therefore, alternative cross-presentation within our current
analyses needs further explanation.
Liver sinusoidal endothelial cells (LSEC) are liver resident cells that can cross-present
exogenous antigen to T cells to induce tolerance [Limmer et al., 2000]. However, also rapid
generation of granzyme B-expressing CD8+ effector T cells after antigen cross-presentation
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by LSECs is possible and was shown to be dependent on IL-6 trans-signaling, where the
soluble form of IL-6 receptor (sIL-6R) binds IL-6 in order to activate the signaling trans-
ducing unit glycoprotein 130 (gp130) [Bo¨ttcher et al., 2014]. We did not yet characterize
LSECs in the livers of our PbA-infected Batf3-/- mice, but we found increased levels of
IL-6 production in these mice (Fig. 3.21D, E). Therefore, the framework requirements for
cross-presentation of Plasmodium antigen and subsequent activation of CD8+ effector T
cells by LSECs would be present in our model.
Red pulp macrophages and CD169+ macrophages are further cell populations that are
discussed to be able to cross-present antigen to CD8+ T cells [presentation by C. Kurts at
the European Congress of Immunology, 2015 in Vienna, Bernhard et al., 2015]. However,
while CD169+ macrophages were able to induce a CTL response in the absence DCs, the
mechanism of cross-presentation was not confirmed in this study.
In summary, the remaining CTL responses in PbA-infected Batf3-/- mice are probably
induced by other APC populations than CD8a+ DCs and should be further investigated
in future studies.
4.1.3.2 The lack of Batf3 resulted in a shift from inflammation to a more
regulatory milieu after PbA-infection
Remarkably, besides a strongly reduced cytotoxic immune response in brain and spleen of
PbA-infected Batf3-/- mice, we could also observe an increase in regulatory characteris-
tics in those mice. Batf3-/- mice contained higher total amounts of Tregs in their spleens
on 3 and 6 dpi and the regulatory programmed death-1 (PD-1) receptor was strongly
upregulated on CD4+ and CD8+ T cells in these mice when compared to PbA-infected
WT mice (Fig. 3.22). Cultured spleen cells produced more IL-10 in d+6 PbA-infected
Batf3-/- mice, especially the production of IL-10 by CD11b+ cells was markedly increased
(Fig. 3.21A,C). IL-10 producing CD11b+ cells might include regulatory B cells [O’Garra
et al., 1992], which might play a role in ECM regulation [Liu et al., 2013] or alternatively
activated macrophages, which will be discussed in more detail.
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In spleens of Batf3-/- mice, Tregs were slightly elevated but did not produce
more IL-10 than cells from WT mice
The increased CD4+ vs. CD8+ T cell ratio that we observed in PbA-infected Batf3-/-
mice on 3 and 6 dpi was a first hint that regulatory mechanisms might play a role in the
ECM-protection in these mice (Fig. 3.10D). These results were further supported by the
finding that absolute amounts of Tregs and IL-10 production were increased in spleens of
Batf3-/- mice after PbA-infection (Fig. 3.22, 3.21).
Our observation that the population of regulatory T cells was increased in ECM re-
sistant mice is supported by results from others who found that spleens of ECM-resistant
Balb/c and DBA/2 mice contain higher amounts of Tregs at all time points after PbA-
infection, which suggests a role for these cells in controlling the cerebral inflammation in
ECM [Wu et al., 2010]. Similar to our results, findings of Wu et al. were accompanied
by higher amounts of anti-inflammatory cytokines and a decrease in pro-inflammatory
mediators. However, the role of Tregs is conversely discussed in Plasmodium infection.
Depletion of Tregs by injection of an anti-CD25 antibody was found to protect mice from
ECM development, which reinforces the idea of a complex and multi-factorial role of this
cell type in Plasmodium infections [Amante et al., 2007]. A possible conflict in this study
is the use of anti-CD25 antibody for depletion of Tregs as CD25, the receptor for IL-2, is
also upregulated on activated cytotoxic T cells and might therefore not be specifically de-
pleting Tregs only. Additionally, these results could not be confirmed using DEREG mice
in which a bacterial artificial chromosome expresses a diphtheria toxin (DT) receptor-
enhanced GFP (eGFP) fusion protein under the control of the foxp3 gene locus which
allows specific depletion of Tregs by diphtheria toxin injection [Steeg et al., 2009]. Anal-
ysis in human patients that had been infected with Plasmodium falciparum could not
reveal any correlation between the presence of Tregs and the severity of malaria symptoms
[Torres et al., 2014]. In summary, the role of Tregs in ECM is not yet defined completely
and needs further investigation.
Could splenic CD8a− DCs induce the generation of a regulatory milieu in
PbA-infected Batf3-/- mice?
CD8a− dendritic cells are also known to regulate Treg development by interaction
118
4.1. CROSS-PRESENTING DENDRITIC CELLS WERE REQUIRED FOR DEVELOPMENT OF
ECM IN A PBA MOUSE MODEL
between CD80 / CD86 and CD28 on Tregs [Leventhal et al., 2016]. We found more DCs
in naive and d+3 PbA-infected Batf3-/- mice compared to WT mice (Fig. 3.16A). As
Batf3-/- mice are lacking CD8a+ DCs, all remaining DCs are CD8a−, which could play
a role in Treg regulation. Interestingly, cells from Batf3
-/- mice did not show an increase
in CD80 or CD86 expression, and even a small reduction compared to WT mice on 3 dpi
(Fig. 3.17B). Leventhal et. al showed that Treg regulation by DCs is dependent on CCR7,
however, while the expression of this receptor was increased after PbA-infection and could
play a role in regulation of the pro-inflammatory immune response, we could not find any
differences between WT and Batf3-/- mice 6 days post infection (Fig. 3.17C).
While dendritic cells can also be a source of IL-10, this function is mainly associated
with CD8a+ CD11b− DCs, which makes a contribution of DCs from Batf3-/- mice to IL-10
production from CD11b+ cells unlikely.
Together, these results suggest that the anti-inflammatory milieu observed in Batf3-/-
mice is not a direct consequence of altered activation of CD8a− DCs.
Alternatively activated macrophages could play a role in immune regulation
in Batf3-/- mice after PbA-infection
Tregs are an important regulatory immune cell subset and a major source of IL-10.
However, we could not detect differences in IL-10 production from CD4+ purified T cells
between all experimental groups, but we observed a strong increase in IL-10 production
from MACS-purified CD11b+ cells that were isolated from PbA-infected Batf3-/- mice
compared to almost baseline levels in infected WT mice (Fig. 3.21C).
While analyses in mice and humans did not find any proof for a relevant role of
Tregs in regulatory immune responses after Plasmodium infection, IL-10 is an important
regulator. In vivo experiments in PbA-infected mice showed that ECM could be induced
by neutralization of IL-10 in usually resistant strains and inversely, ECM-susceptible mice
could be protected from ECM by injection of recombinant IL-10 [Kossodo et al., 1997].
Alternatively activated M2 macrophages (AAMs) are of particular interest, as they
have been shown to promote Th2 immune responses which are associated with ECM pro-
tection in resistant Balb/c mice. In our experiments the frequency and total cell number
of AAMs was significantly higher in d+6 PbA-infected Batf3-/- mice when compared to
WT infection controls (Fig. 3.23). A role of AAMs in our model was further underlined
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by increased levels of IL-6 that were found in whole spleen cell cultures and cultures from
CD11b+ splenocytes from uninfected and PbA-infected Batf3-/- mice (Fig. 3.21). While
IL-6 is often described as a pro-inflammatory cytokine, it has also immune regulatory
properties. In a mouse model for obesity and insulin resistance, it was shown that IL-6
mediated the alternative activation of macrophages, which could in turn promote regula-
tion of the overwhelming pro-inflammatory response [Mauer et al., 2014]. As AAMs can
be induced by IL-6 and also produce IL-6 themselves, a connection of both is likely.
Alternatively activated macrophages have not yet been discussed in detail in Plasmod-
ium infection, however, innate lymphoid cells (ILCs) were found to participate in immune
regulation by inducing M2 macrophage polarization and are thereby be involved in ECM-
protection in an IL-33 dependent manner [Besnard et al., 2015]. The analysis of ILCs in
PbA-infected Batf3-/- mice are a topic of ongoing research in our group.
AAMs were also mentioned in the context of non-lethal P. chabaudi chabaudi infection
were a shift towards a Th2 immune response is observed [Fairweather and Cihakova, 2009].
After infection, a shift from Th1 to Th2 responses is usually comprehensible in order to
limit inflammation and the associated tissue damage, but can also give way to chronic in-
fections. AAMs have been found to play a role in typical Th2 associated parasite infections
like helminth infection [Kreider et al., 2007], but also chronic bacterial infections [Benoit
et al., 2008]. In Plasmodium infection, a shift towards a Th2 could would be favorable to
avoid an overwhelming immune response that can result in CM development.
Taken together, the immune responses to PbA in Batf3-/- mice were shifted to a more
immune regulatory milieu which could help to prevent ECM development.
4.1.4 Relevance of impaired CTL responses for PbA-infection in Batf3-/-
mice
Taken together, we hypothesize that the protection from ECM that was observed in
Batf3-/- mice upon PbA infection, resulted from an insufficient generation of a CTL re-
sponse due to the genetic ablation of cross-presenting DCs and an additional immune
regulating milieu (characterized by IL-10, AAMs and probably Tregs) that was estab-
lished in these mice (Fig. 4.1).
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Figure 4.1: Batf3-/- mice did not develop ECM as a consequence of impaired T cell priming and
subsequent reduction of inflammation in the brain. Differences in the immune response to PbA infection
between WT (upper) and Batf3-/- (lower) mice are depicted in spleen and brain. In short: PbA-infection in WT
mice leads to cross-priming of PbA antigen by XCR1+ DCs to CD8+ T cells which leads to a strong CTL response
in the spleen of those mice. Activated pro-inflammatory immune cells migrate to a cytokine gradient in brain
where they promote local inflammation which results in a breakdown of the blood-brain barrier. The lack of cross-
presenting DCs in Batf3-/- mice prevents efficient T cell priming and therefore the aftereffects, resulting in reduced
CTL responses in spleen and brain, but enhancing regulatory mechanisms.
Several disease outcomes have been shown to be dependent on cross-presenting den-
dritic cells and their ability to prime cytotoxic CD8+ T cells. Studies in Batf3-/- mice,
were the first to specifically analyze animals lacking cross-presenting dendritic cells with-
out affecting other cell populations [Hildner et al., 2008]. Using these mice, Hildner et al.
showed that cross-presenting DCs are required for a adjuvant virus-specific immune CTL
response after West Nile virus infection [Hildner et al., 2008]. Furthermore, the lack of
Batf3 was associated with impaired antigen-specific CTL responses in syngenic fibrosar-
coma transplants and Leishmania major infections, which led to a diminished clearance
function in both models [Hildner et al., 2008, Ashok et al., 2014].
Our data and also the above mentioned studies strongly indicate that the lack of Batf3
leads to a diminished CTL response with concomitant induction of immune regulation.
In some models, a strong CTL response is beneficial to clear an infection or to control
tumor growth [Hildner et al., 2008, Ashok et al., 2014]. The role of CTL responses in
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Plasmodium clearance after infection is less clear, however the involvement of cytotoxic
T cell responses in the development of CM remains unchallenged [Deroost et al., 2016],
which makes the lack of the pro-inflammatory immune response an advantage regarding
survival in our model.
Importantly, the success of vaccination with live irradiation-attenuated P. berghei
sporozoites was also dependent on T cells primed by cross-presenting dendritic cells.
Batf3-/- mice failed to generate protective IFNγ-producing CD8+ effector memory T cells
and were not able to establish a sterile and long lasting immunity against P. berghei that
is described in WT mice [Montagna et al., 2015]. This finding demonstrates, that the gen-
eration of CTLs is bivalent in malaria, as these cells are associated with immune damage
on the one hand, but are required for immune memory generation on the other hand.
The differences between CM in human patients and ECM in mice have led to pas-
sionate discussions between researchers in the malaria field ([Craig et al., 2012]. Most
researchers agreed that mouse models can be useful if certain conditions are met, like
uniformity of experimental procedures and clear discrimination between investigation of
disease development, prevention of disease and therapeutic approaches. In the end, limi-
tations of those models are still outweighed by the advantages of experimental conditions,
like defined exposure to pathogens, only specified genetic variability, inclusion of appropri-
ate control groups or the ability to analyze organs of interest before the actual symptoms
of CM are present [Craig et al., 2012]. Therefore, we have to keep in mind, that not all
findings from a mouse model translate directly to the human disease. However, results
from experimental approaches might initiate human studies to confirm the findings.
Taken together, these data confirm a key role for cross-presenting DCs in the immune
response against Plasmodium parasites and help to understand the disease mechanism.
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4.2 Doxycycline prevented ECM by exerting anti-inflam-
matory properties in susceptible Bl/6 mice
Doxycycline has previously been used in treatment of malaria because of its anti-parasitic
effects [WHO, 2010, Budimulja et al., 1997, Batty et al., 2007]. However, doxycycline has
also additional anti-inflammatory properties that could be beneficial for patients suffer-
ing from cerebral malaria, since neuro-inflammation is thought to contribute to disease
manifestations. For a long time, fast parasite elimination was the major goal of CM treat-
ment. However, recent studies explored options to directly target the inflammation in
the brain [Miranda et al., 2013, Dende et al., 2015]. Our study here, aimed to elucidate
the immune-modulating properties of doxycycline in a mouse model of CM in order to
evaluate possible treatment options that directly affect the inflammatory causes of the
disease.
Earlier findings from my diploma thesis demonstrated that intravenous injection of
80 mg/kg doxycycline starting from day four post PbA-infection successfully prevented
ECM development in susceptible C57Bl/6 WT mice and reduced CTL responses in brains
and spleens (Fig. 3.24, 3.25).
Briefly summarized, our initial studies revealed a significant reduction of brain inflam-
mation, when compared to untreated PbA-infected mice (Fig. 3.25A-D), which included
strongly reduced mRNA levels of cell adhesion molecules (L- and P-selectin) and several
cytokines (CCL2, CCL5, CXCL2 and IL-6) which are all associated with inflammatory
processes and are described to be present in brains of ECM-positive mice [Combes et al.,
2010, Miu et al., 2008, Miranda et al., 2013]. Furthermore, we detected also lower protein
levels of granzyme B in brain tissue of doxycycline treated mice. Most importantly, cyto-
toxic T cells that are associated with brain damage during ECM, exhibited significantly
less cytolytic capacity in spleens of mice after doxycycline treatment (Fig. 3.27E), despite
an enlarged spleen and increased total amounts of cells in comparison to control-infected
mice (Fig. 3.27F). This was a relevant finding, since the priming of parasite-directed CTLs
that is acquired in the spleen, was already completed before treatment start [Engwerda
et al., 2005].
Therefore, we concluded that the administration of systemic doxycycline was able to
alter the peripheral immune responses that had been already generated in the spleens
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of PbA-infected mice by modification of effector cell activities, which resulted finally
in reduced inflammation, especially in the brain and protection from ECM. However,
doxycycline-treated mice had decreased peripheral parasitemia on 6 dpi, which raised the
question whether the protective effect of doxycycline could be attributed to its immune-
modulatory properties or / and to the reduced parasite load.
To answer this question, we established a modified experimental infection, and inocu-
lated the mice with an elevated dose of iRBCs before doxycycline treatment, in order to
ensure a comparable parasite load in DOX-treated (ECM-negative) and untreated (ECM-
positive) mice. With this approach, we aimed to evaluate the immune regulatory effects of
doxycycline while reducing the impact of the anti-parasitic effects in this model. Indeed,
DOX-treatment of mice with elevated PbA parasite load was still able to prevent ECM,
which was mirrored by a stable BBB, reduced amounts of cellular infiltrates in the brain
and strongly impaired brain inflammation. Furthermore, we detected strongly impaired
functions of cytotoxic T cells in DOX-treated mice, confirming the hypothesis that doxy-
cycline – in addition to its well-described anti-parasitic properties - exerts strong immune
modulatory capacities, affecting the activity of effector T cells and attenuating inflamma-
tory immune responses, which finally protected the infected mice from fatal ECM.
4.2.1 Doxycycline treatment in mice infected with higher parasite loads
prevented ECM and protected the blood-brain barrier
An unresolved problem in the analysis of the immune responses in mice that had received
doxycycline treatment after PbA-infection, was the anti-parasitic effect of DOX. While
clearance of the parasite is desirable in actual treatment, the ability to reduce parasitemia
made differentiation between immune-modulatory and anti-plasmodial effects difficult. An
idea to overcome this obstacle was to inject mice with a higher initial dose of parasites
in order to align peripheral parasitemia in untreated mice and DOX treated mice on 6
dpi, when first neurological symptoms occur in the untreated control group. Mice infected
with 1e6 iRBCs before DOX-treatment start on 4 dpi, reached a similar parasitemia on
6 dpi when compared to untreated mice that had received the ”normal” infective dose of
5e4 iRBCs (as used before) (Fig. 3.28C). It is of notice that doxycycline treatment for
3 days was not enough to completely eliminate the parasites and parasitemia increased
in all animals later on, leading to anemia but not to later CM symptoms after 10 dpi.
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Importantly, despite a similar parasite load to untreated mice on 6 dpi, doxycycline treated
mice were still 100% protected from ECM with only minor neuro-pathological symptoms
(Fig. 3.28), similar to the results we had gained before with treatment of mice that had
been infected with the lower dose of iRBC (Fig. 3.24).
Thus, the absence of ECM despite a high parasitemia in the ”PbA 1e6 + DOX” groups
confirmed our hypothesis that the protective effect of doxycycline was not only caused by
its anti-parasitic effects. However, the later drop in parasitemia in DOX treated mice
leaves room for discussion, as we could not exclude the possibility that the parasites were
already damaged and maybe less pathogenic. An analysis with a doxycycline-resistant
PbA strain could clarify these remaining issues, but unfortunately no such strain is known
for use in the mouse model.
Consistently with the ECM-protection upon DOX-treatment, treated mice revealed a
stable the blood-brain barrier till 9 dpi, regardless of the initial infective dose of parasites,
in contrast to untreated controls which died on 6 dpi with a severely damaged BBB
(Fig. 3.29).
Studies in murine ECM model have shown that the BBB disruption in cerebral malaria
is not caused by apoptosis of endothelial cells but rather by alteration of the tight junction
proteins of cells building the BBB that are caused by CD8+ T cells in a perforin-dependent
manner [Suidan et al., 2008, Shaw et al., 2015]. These observations were used to explain
the fast recovery of the blood-brain barrier after administration of anti-malarial drugs
[Shaw et al., 2015], which we also observed in our experiments from 7 dpi (Fig. 3.29). It is
possible that doxycycline protects the blood-brain barrier through various mechanisms. In
a rat model of middle cerebral artery occlusion and reperfusion, doxycycline reduced the
BBB leakage and the cerebral infarct volume by up-regulation of tight-junction proteins
[Wang et al., 2011]. In addition, doxycycline could act in an anti-inflammatory manner
similar to minocycline, another antibiotic of the tetracycline group, which was shown to
alter T cell activation and reduce their contact with microglia [Giuliani and Hader, 2005].
125
CHAPTER 4. DISCUSSION
4.2.1.1 PbA-infected mice showed reduced cerebral inflammation after doxy-
cycline treatment: less cellular infiltrates and impaired activity of
effector T cells
BBB breakdown and migration of immune cells to the brain, especially of cytotoxic T cells,
but also macrophages, is a hall mark of experimental cerebral malaria [Nacer et al., 2014].
The stability of the BBB upon DOX-treatment was further mirrored by less infiltration
of cells with hematopoietic origin in brains of 1e6 iRBC PbA-infected mice (+DOX) com-
pared to ECM-positive control-infected mice. However, DOX-treated mice still contained
a higher number of leukocytes in their brains compared to uninfected controls (Fig. 3.30).
We found similarly increased T cell frequencies in both infected groups and subsequent
reductions in the frequencies of other cell subsets (Fig. 3.31, 3.33, 3.34). Because of the
late intervention with doxycycline at 4 dpi, we hypothesized that an effect on cell popu-
lation migration was less likely compared to alterations in cell activation.
Indeed, T cells from brains of doxycycline treated 1e6 iRBC PbA-infected mice, showed
reduced expression of activation markers such as ICAM-1 on their surface and intracellular
granzyme B (Fig. 3.32). Granzyme B is an important cytotoxic mediator in ECM. While
the pure presence of granzyme B alone is not sufficient ECM induction [Shaw et al., 2015],
its absence is clearly beneficial as gzmB−/− mice do not develop ECM [Haque et al.,
2011]. Similarly, the lack of ICAM-1 expression on T cells protected mice from ECM
[Ramos et al., 2013].
Minocycline, another tetracycline derivate, is able to reduce T cell activation due to
its Ca2+ chelating activity [Kloppenburg et al., 1995]. As doxycycline shares the chelating
ability with minocycline, a similar mechanism is reasonable.
Reduced activation of T cells in doxycycline treated mice after PbA-infection was
accompanied by diminished cytokine levels in primary brain cell cultures such as CCL5
(Fig. 3.36), which is an attractant of T cells and important player in development of CM in
mice and humans [Belnoue et al., 2003b, Hanum et al., 2003, Sarfo et al., 2004]. Migration
of T cells to the brain is a hallmark of ECM and low levels of CCL5 might hinder T cell
migration in doxycycline-treated mice. Additionally, binding of CCL5 to its receptors on
brain resident cells might activate these cells and result in subsequent BBB breakdown in
susceptible animals [Sarfo et al., 2004, Szklarczyk et al., 2007].
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Interestingly, a comparison between mice infected with the ECM-inducing parasites P.
berghei ANKA and mice infected with P. berghei NK65 parasites, that do not induce ECM
but fatal anemia, revealed that also these PbNK65-infected mice contained cellular infil-
trates in their brains, despite the absence of ECM [Shaw et al., 2015]. Interestingly, brains
of these protected mice contained activated CD8+ T cells that expressed CD11a as a sign
of previous antigen experience and similar frequencies of T cells expressing granzyme B as
in ECM-positive brains of PbA-infected mice [Shaw et al., 2015]. An important result was
that in the non-ECM mice, the CD8+ T cells remained in the perivascular space of the
brains and showed an increased motility and less cognate interaction with CD31+ brain
endothelial cells compared to T cells in brains of ECM positive mice.
However, one drawback of the Shaw study is that only frequencies of cells expressing
the different markers were shown but not analysis of the geometric mean fluorescence
intensity which could give more information about the expression level of these markers
which might vary between cells from ECM-negative and ECM-positive mice. Also func-
tional analysis, for example if granzyme B positive T cells would actually release the stored
granzyme B in vivo is missing in their analysis. All together, these observation show, that
ECM cannot simply explained by infiltration of immune cells to the brain, but also their
activity and motility profile have to be considered.
Alterations in antigen-presenting cells might contribute to reduced T cell ac-
tivation after doxycycline treatment
Doxycycline might directly affect the activity of T cells, but also other immune cells
that interact with T cells in the brain. Immigrated and resident APCs in brains of
doxycycline-treated mice after PbA-infection expressed less ICAM-1 and MHC molecules
(Fig. 3.33, 3.34, 3.35). These cells are involved in T cell priming by antigen-presentation,
but also participate in the pro-inflammatory immune responses by production of cytokines
like TNF, which was down-regulated in brain cell cultures from doxycycline treated mice,
compared to samples from untreated infection controls (Fig. 3.36A). Importantly, the par-
asite load in brains of doxycycline treated mice was similar to that in untreated mice after
PbA-infection (Fig. 3.37B), which suggests a protective mechanism by doxycycline, inde-
pendently of antigen reduction in the brain.
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An effect of doxycycline or other tetracycline-derivates on dendritic cells has not been
described yet. As DCs in general are thought to play a role in the early phase of disease
[Engwerda et al., 2005, Cockburn and Zavala, 2016], their reduced activation might be
more a consequence of generally reduced inflammation and probably not involved in the
doxycycline mediated protection in general.
CD11b+ macrophages from the periphery (CD45hi) are found in increased numbers in
brains of mice with ECM but not in non-ECM mice with hyperparasitemia. Importantly,
these cells were not only found in the blood vessels but also in the perivascular space, which
makes a possible role in ECM more likely [Nacer et al., 2014]. Additionally, microglia, that
also express CD11b, have been associated with inflammation in the context of cerebral
malaria development in humans and mice [Deininger et al., 2002, Medana et al., 1997].
Peripheral CD11b+ cells and microglia in brains from 1e6 iRBC PbA-infected mice
(+DOX) expressed less MHC class II (I-Ab) compared to cells from untreated control
mice (Fig. 3.34B, 3.35B).
These results agree with observations, that doxycycline reduced macrophage and mi-
croglia activation in general, as measured by production of TNF, IL-1β, -6 and -8 [Cazalis
et al., 2008]. Additionally, studies with minocycline specifically showed that doxycycline
is able to reduce MHC class II expression macrophages and microglia by inhibition of In-
terferon regulatory factor 1 (IRF-1 ) and protein kinase C (PKC)αβ/II [Nikodemova et al.,
2007]. Reduction of MHC class II expression on APCs suggests an impaired ability to
activate CD4+ T cells, which can also contribute to inflammatory activities in the brain
[Monso-Hinard et al., 1997]. Interestingly, IRF-1, together with its partner IRF-8 was
shown to play a role in ECM development, as mice deficient for this transcription factor
were resistant to ECM [Berghout et al., 2013]. Additionally, doxycycline was shown to
reduce microglia activation by inhibition of p38 MAPK and NF-kB signaling pathways by
[Santa-Cec´ılia et al., 2016]. While activation of microglia starts early after PbA-infection
[Medana et al., 1997], a later reduction of their pro-inflammatory status might still help to
prevent brain damage in ECM, for example by inhibiting microglia-T cell-interaction [Giu-
liani and Hader, 2005]. Further characterization of infiltrated and brain-resident APCs
by a phagocytosis assay might provide valuable information about the function of these
cells and their impairment by doxycycline treatment in our model.
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The role of antigen-presentation in CM is still under debate. Cross-presentation of
Plasmodium-derived antigen by endothelial cells is a hallmark for ECM in the mouse model
[Howland et al., 2013, Howland et al., 2015]. However, we did not measure any significant
differences in the ability of brain endothelial cells regarding cross-presentation (kindly
tested by S. Howland, L. Re´nias; Singapore) between doxycycline treated and untreated
PbA-infected mice (Fig. 3.37A). Also, a role for microparticles in antigen-presentation
is discussed, based on the finding that these can interact with T cells and trigger their
proliferation [Nacer et al., 2014, Wheway et al., 2014].
In summary, doxycycline was able to reduce brain inflammation of PbA-infected mice
that had been treated with doxycycline from 4 dpi, which then led to ECM-protection.
Doxycycline could either directly target T cells or resident or brain immigrated antigen-
presenting cells by attenuating their activity, thereby preventing fatal disease progression
of ECM.
4.2.1.2 (Antigen-specific) immune cell activation in spleens of PbA-infected
mice was reduced by doxycycline but the treatment did not affect the
composition of cell subsets
The spleen is an important organ in ECM development to prime cytotoxic T cells [Eng-
werda et al., 2005]. Intravenous application of doxycycline in PbA-infected mice from 4
dpi was likely to exert systemic effects and could modify the immune response in the spleen.
We observed a weight increase of spleens after PbA-infection which was similar in
both infected groups (± DOX), but total splenocyte numbers from single cell suspensions
which did not differ between all experimental groups (Fig. 3.38). These observations
were unexpected, as our previous results using the lower dose of parasites before DOX-
treatment (5e4 iRBC) revealed a higher cell count in the spleens of doxycycline treated
mice (Fig. 3.25F).
There are different studies on the influence of doxycycline and other tetracycline-
derivates on cell proliferation. Minocycline and doxycycline were shown to inhibit pro-
liferation of human T cells in vitro in a dose-dependent manner [Kloppenburg et al.,
1995, Chang et al., 2010]. However, these results might have been due to toxic effects
of doxycycline that were further supported by the description of pro-apoptotic effects of
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doxycycline [Chang et al., 2010]. Importantly, in vivo studies showed that splenomegaly
from Ehrlichia risticii infections were rather amplified by doxycycline treatment instead
of any suppression of proliferation [Rikihisa and Jiang, 1989]. These findings underline
our results, which suggest that the analysis of doxycycline’s effect on cell proliferation
were probably be dependent on the surrounding circumstances.
Furthermore, we had addressed the question whether the increased frequency of lym-
phocytes upon DOX-treatment in the mice infected with the lower iRBC number was
due to differences in migration capacity, but did neither observe any differences in our
transwell approach nor in an in vivo proliferation assay (Fig. 3.26, 3.27). Since there was
no significant further increase in organ size and cell count in the modified experimental
model using 1e6 iRBC before DOX-treatment, we did not follow up this hypothesis any
further.
Impaired CTL responses in PbA-infected mice after doxycycline treatment
Similar to the brain, the composition of T cells in the spleen did not differ between
doxycycline treated and untreated PbA-infected mice (Fig. 3.39). More important was
the finding that the activity of these T cells, measured by intracellular and secreted
granzyme B and IFNγ as well as by antigen-specific cytotoxicity of spleen cells from doxy-
cycline treated mice, was significantly lower compared to that of untreated mice (Fig. 3.40,
3.41), thus demonstrating an attenuated inflammatory response upon DOX-treatment.
However, we did not observe any differences in immune-regulatory IL-10 (Fig. 3.41D).
Our results showed that the reduced activation of T cells in the brains of doxycycline
treated, PbA-infected mice was not a local phenomenon but probably due to a systemic
effect of doxycycline. As some T cell activation has already taken place before start of the
treatment on 4 dpi, the CTL response was not completely abolished in the treated group
(”PbA 1e6 + DOX”) but clearly impeded.
As discussed before, doxycycline and other tetracycline-derivates are described to im-
pair T cell proliferation and activity, partly through Ca2+ chelating activity [Kloppenburg
et al., 1995]. Additionally, doxycycline might inhibit T cell activity indirectly by down-
regulation of CD40 ligand, which is needed for T cell - APC interaction [Giuliani and
Hader, 2005].
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CD11b+ cells were not affected regarding their activation but less splenic
Ly6C+ monocytes were present in doxycycline treated mice
Frequencies of dendritic cells and CD11b+ cells did not differ significantly between
control infected and DOX-treated PbA groups of mice (Fig. 3.42A, 3.43A). Most interest-
ingly, the frequency of inflammatory Ly6C+ monocytes among the CD11b+ splenocytes
was reduced in DOX-treated PbA-infected mice compared to untreated infection-controls
(Fig. 3.43B). The importance of this cell subset was shown recently since mice depleted
from inflammatory monocytes at the time point of PbA-infection were resistant to ECM
[Schumak et al., 2015], thus fitting to the generally reduced inflammation in spleens of
doxycycline treated PbA-infected mice.
Surprisingly, the activity of splenic CD11b+ cells (as defined by up-regulation of MHC
class I and II as well as ICAM-1 expression) in spleens of DOX-treated PbA-infected mice
was not reduced on 6 dpi (Fig. 3.43D-F). These results were contrary to our observa-
tions in the brain, where CD11b+ microglia but also immigrated CD11b+ cells expressed
less MHC class II (Fig. 3.34B, 3.35B). However, since the initial activation of splenic
antigen-presenting cells was probably initiated upon PbA-infection, thus before start of
the DOX-treatment, any conceivable effects of doxycycline, like regulation of MHC class
II expression [Nikodemova et al., 2007], might either take more time to be detectable or
do not visibly affect these cells.
4.2.2 Sub-antimicrobial doses of doxycycline prevented ECM without
affecting parasitemia
Administration of 80 mg/kg/d doxycycline from 4 dpi protected PbA-infected Bl/6 mice
to 100% (Fig. 3.24A). However, this dose did also significantly affect parasitemia from 6
dpi (Fig. 3.24B), which made it impossible to distinguish between direct anti-inflammatory
effect of doxycycline and reduced inflammation as a consequence of parasite reduction, as
discussed before.
Studies regarding human periodontitis and atherosclerosis had shown beneficial effects
of sub-antimicrobial doses of doxycycline on inflammatory processes [Walker et al., 2000,
Brown et al., 2004]. Based on these findings, we decided to titrate the dose of doxycycline
down to achieve a sub-antimicrobial dose that would not affect parasite replication but
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protect mice by anti-inflammatory effects. Survival studies with doxycycline doses ranging
from only 8 mg/kg/d to 80 mg/kg/d (original dose), we showed that the lower doses were
still able to protect around 50% of PbA-infected mice which received the drug daily from
4 to 6 dpi (Fig. 3.44). Even more important, we could show that single mice survived
a high parasitemia, which leaves the anti-inflammatory effects of doxycycline as the sole
cause of protection (Fig. 3.45). However, these results were not stable as we observed this
broad range of parasitemia and only around 50% protection. Another problem was that
mice with reduced parasitemia also died from cerebral malaria (with normal or reduced
parasitemia on the day of death). Due to this inconsistency, ex vivo analysis in this
approach would be difficult unless we could discover a diagnostic marker to predict which
mice would survive despite high parasitemia and which would die regardless of treatment.
Nonetheless, these results are very important, as they showed that ECM-protection
by doxycycline could be achieved with only anti-inflammatory effects.
4.2.3 Outlook - Prevention of ECM due to altered shedding of micropar-
ticle
In the last years, small particles called microparticles (MPs) came into focus in malaria
research [Wassmer et al., 2011, El-Assaad et al., 2014]. MPs are small vesicles with a
size between 0.1 and 1 µm that originate from the cell walls in a Ca2+-dependent process
called shedding. Therefore, microparticle show similar expression of surface molecules as
their parental cell and can also contain mRNA, miRNA and proteins, which they can
transfer to neighboring cells. Microparticle shedding is increased in activated cells, which
makes them a marker for cell activation, but they can also contribute to inflammation by
recruitment and activation of other immune cells [Distler et al., 2006]. The involvement
of microparticles in CM development was shown in human patients, where plasma of
P. falciparum infected CM positive children contained higher levels of endothelial MPs
compared to children with uncomplicated disease or severe anemia [Combes et al., 2004].
Murine models did not only confirm this finding but furthermore linked endothelial-derived
MPs to the development of neurological symptoms, as the transfer of MPs from activated
endothelial cells led to ECM-like symptoms in naive recipient mice [El-Assaad et al.,
2014]. Furthermore, evidence was found that endothelial MPs might interact with CD4+
and CD8+ T cells, resulting in enhanced T cell activity and proliferation [Wheway et al.,
2014]. These examples show that microparticles might be worth further investigation.
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Interestingly, TNF plasma levels correlated with the amount of circulating MPs in CM
patients [Sahu et al., 2013] and doxycycline inhibited TNF production in macrophages
and microglia [Cazalis et al., 2008, Santa-Cec´ılia et al., 2016]. As TNF was significantly
reduced in brains of our DOX-treated PbA-infected mice (Fig. 3.36A), a direct effect of
doxycycline might be possible.
A key event in MP shedding is the flopping of phosphatidylserine (PS) to the outer
leaflet of the plasma membrane, which is dependent on calcium levels in the cell [Morel
et al., 2011]. This finding hints to another possible mechanism of doxycycline: tetracycline
and its derivates are able to decrease intracellular calcium levels in plant and human cells
[Bowman et al., 2011, Szeto et al., 2011]. Hence, we hypothesize that doxycycline might
lower intracellular calcium levels in endothelial cells and thereby inhibiting shedding of
microparticles and subsequently improving the disease development. The importance of
PS flopping and microparticles in ECM was also shown in ATP-binding cassette trans-
porter A1 knock-out mice (ABCA1−/− mice). The ATP-binding cassette transporter A1
is involved in MP shedding, since it is required for the translocation of PS to the outer
leaflet of the plasma membrane. After P. berghei infection, ABCA1−/− mice were com-
pletely protected from ECM development and contained significantly reduced MPs levels
compared to susceptible WT controls [Combes et al., 2005].
Several experiments are conceivable to test the hypothesis that doxycycline might be
able to prevent microparticle shedding and therefore disease development. First of all,
quantification and identification of circulating microparticles via electron microscopy and
/ or flow cytometry should clarify whether doxycycline treated mice contain less MPs in
their blood compared to untreated mice. The direct impact of doxycycline on microparti-
cle shedding might be tested by in vitro generation of MPs with or without the presence
of doxycycline in the culture. Finally, a transfer of MPs from untreated, PbA-infected
mice into doxycycline treated mice would show whether these MPs are able to promote
ECM in doxycycline treated mice.
In summary, microparticles might play a substantial role in (E)CM development and
possible doxycycline-driven prevention of MP release might help to control CM progression
by directly ameliorating cerebral inflammation. However, further research is needed to
confirm this hypothesis.
Interestingly, we detected low TNF levels in ECM-resistant Batf3-/- mice (Fig. 3.6E);
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this could be a result of the generally reduced inflammatory milieu, and might be a hint
for successful prevention of MP shedding in this model, contributing to the protection.
4.2.4 Anti-inflammatory drugs offer promising treatment options in ECM
Although an estimated 5-20% of patients with neurological CM symptoms are still dying
after immediate treatment [de Souza et al., 2010], the current WHO treatment guidelines
for CM focus solely on parasite clearance [WHO, 2015]. As CM is associated with severe
inflammation in the patients’ brains, targeting this aspect of the disease could be beneficial
for the patients and reduce the mortality rate.
Our results indicate, that doxycycline is able to regulate the immune responses in
ECM (summarized in Fig. 4.2), resulting in improved survival chances of PbA-infected
mice, even in mice with elevated parasitemia (Fig. 3.44).
Figure 4.2: Doxycycline treatment protected PbA-infected WT mice from ECM by dampening their
inflammatory immune responses. Doxycycline treatment in PbA-infected mice prevented ECM in usually
susceptible mice. Doxycycline was discussed to reduce TNF production from antigen-presenting cells in spleen
(1a) and brain (1b) and to impair their interaction with T cells in both organs (2a, 2b). These effects (together
with other, unknown mechanisms) led to reduced CTL response in the spleen (3) and subsequently a protected
blood-brain barrier, reduced immune cell migration to the brain and a generally dampened immune response in
the brain (4). Another hypothetical target of doxycycline could be microparticle shedding (5). Source microglia:
Servier Medical Art - http://www.servier.com/Powerpoint-image-bank
These findings suggest treating parasitemia and inflammation at the same time. Doxy-
cycline is usually a well-tolerated drug that could dampen the immune response in CM
patients and improve their survival, which should be beneficial in addition to the standard
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treatment regimen.
Recently, the topic of specific treatment for cerebral inflammation in CM has also been
addressed by others using experimental mouse models. Artesunate is widely used as a fast-
acting drug in Plasmodium infection. A single dose of artesunate on 4 dpi was shown to
prevent ECM in susceptible Bl/6 mice, which contained reduced mRNA expression of dif-
ferent pro-inflammatory cytokines in their brains on 5 dpi, when first neuro-pathological
symptoms occurred [Miranda et al., 2013]. However, artesunate is a fast-acting anti-
plasmodial drug and parasitemia was significantly reduced in treated mice on the day of
analysis, when compared to untreated controls [Miranda et al., 2013]. Therefore, it could
not be ruled out that the strongly reduced parasitemia was responsible for the observed
regulation of pro-inflammatory factors in artesunate-treated mice.
In contrast, curcumin, which has been described to exert anti-inflammatory properties
[Jurenka, 2009], did not affect parasitemia but protected PbA-infected mice from ECM
when given before the onset of symptoms from 3 dpi. More importantly, treatment 12h
after onset of symptoms (but before coma) was still able to delay the death of infected
animals, which died 6-9 days later from anemia [Dende et al., 2015]. Similar to our sug-
gestions, the authors of this study proposed administration of curcumin in combination
with artether (a artemisinin derivate) for additional fast elimination of the parasite.
Taken together, our results and the cited studies above recommend an optimization
of the current standard treatment regarding CM, expanding it from solely targeting the
parasite to also addressing the pro-inflammatory immune responses in CM. In future, also
other drugs with anti-inflammatory and / or neuro-protective effects should be tested in
CM models. One promising example are Cerebralcare Granule®, which were shown to
ameliorate BBB permeability in a rat model for ischemic stroke [Huang et al., 2012].
In conclusion, we suggest to consider doxycycline for the treatment of CM patients in
combination with other fast-working anti-parasitic drugs.
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Proof of Batf3 knock-out
Figure S1: XCR1+ cross-presenting dendritic cells are missing in Batf3-/- mice. Dendritic cells from
spleens of naive WT and Batf3-/- mice were analyzed for XCR1 and CD4. As expected, the population of XCR1+
was missing in Batf3-/- mice, which confirmed the genetic knock-out of this DC subset.
Referring to Figure 1.2 and 3.1
Figure S2: Batf3-/- mice did not develop cerebral malaria. A: ECM scores (disease score, from 0 = healthy
to 6 = severely sick) of WT Bl/6 mice (filled squares, n = 10) and Batf3-/- mice (empty squares, n = 10) after
infection with 5e4 iRBC i.v. till 9 dpi. B: RMCBS scores (fitness score, from 20 = healthy to 0 = severely sick) of
WT (filled squares, n=6)and Batf3-/- mice (empty squares, n =6) after inoculated with 1,000 sporozoites from dpi
17 infected mosquitoes is shown.
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Referring to Figure 3.4 and 3.5
Figure S3: Very low levels of total cells found in brains of PbA-infected Batf3-/- mice on 6 dpi.
Brain-infiltrated CD45high lymphocytes from PbA-infected (6 dpi) and naive WT and Batf3-/- mice were differen-
tiated by flow cytometry (n=3-5) into were T cells (CD33, A), which were further differentiated in CD4+ (B) and
CD8a+ cells (C), B cells (CD3−B220+, D), dendritic cells (CD11c+I-Ab+ from CD3−B220+, E), Ly6C+ monocytes
(Ly6C+Ly6G−; F), neutrophils (Ly6C+Ly6G+; G) and macrophages (Ly6C−Ly6G−; H).
Referring to Figure 3.8
Figure S4: Total amount of splenocytes did increase in PbA-infected Batf3-/- mice at 6 dpi. C: Spleens
from dpi 3 and 6 infected WT and Batf3-/- mice (n=5-6) as well as naive control mice (n=3-4) were digested with
collagenase and homogenized. The cell concentration of in this suspension was counted and the total amount of
splenocytes was calculated. Values are presented as mean ± SEM. Significance was tested with ANOVA followed
by Tukey post-test, p< 0.05 was considered significant (* = p < 0.05, ** = p < 0.01, *** = p < 0.001).
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Referring to Figure 3.10
Figure S5: Increased CD4+ vs. CD8+ T cell ratios in Batf3-/- mice at all tested time points after
PbA-infection. (A) T cell frequencies of d+3 or d+6 PbA-infected mice (n=5-6) and naive controls (n=3-4) were
identified by surface marker CD3. Total cell counts are shown for 6 dpi. CD3+ T cells were further differentiated
into CD4+ (B) and CD8a+ (C) T cells (both calculated from frequency from CD3+ cells). (D) The ratio between
CD4+ and CD8+ T cells was calculated. Values are presented as mean ± SEM. Differences were tested with ANOVA
followed by the Tukey post-test; p values below 0.05 were considered significant (* = p < 0.05, ** = p < 0.01, ***
= p < 0.001).
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Referring to Figure 3.11
Figure S6: Cytotoxicity was reduced in Batf3-/- mice. PbA-infected WT and Batf3-/- mice were analyzed on
3 and 6 dpi together with naive control mice (n=3-5). A and B: Granzyme B (GrzmB) and IFNγ were measured by
ELISA in supernatant of 24h splenocyte culture. C: IFNγ was determined by ELISA in serum of all experimental
animals. D: Presence of surface marker ICAM-1 on CD8a+ was analyzed by flow cytometry. Values are presented
as mean ± SEM. Differences were tested with ANOVA followed by the Tukey post-test; p values below 0.05 were
considered significant (* = p < 0.05, ** = p < 0.01, *** = p < 0.001).
156
Referring to Figure 3.11 and 3.12
Figure S7: Activation of CD4+ T cells was reduced in Batf3-/- mice. PbA-infected WT and Batf3-/- mice
were analyzed on 3 and 6 dpi together with naive control mice (n=3-5). Presence of surface markers on CD4+
were analyzed by flow cytometry: ICAM-1 (A), granzyme B (B) and IFNγ (C). Values are presented as mean ±
SEM. Differences were tested with ANOVA followed by the Tukey post-test; p values below 0.05 were considered
significant (* = p < 0.05, ** = p < 0.01, *** = p < 0.001).
Referring to Figure 3.13
Figure S8: NK and NKT cells were elevated in Batf3-/- mice after PbA-infection, compared to infected
WT mice. Spleens of d+3 and d+6 PbA-infected WT and Batf3-/- mice (n=5-6) as well as naive controls
(n=3-4) were processed for FACS analysis and stained with surface markers CD3 and NK1.1 to identify NK cells
(CD3−NK1.1+; A) and NKT cells (CD3+NK1.1+; B). Values are presented as mean ± SEM. Differences were
tested with ANOVA followed by the Tukey post-test; p values below 0.05 were considered significant (* = p < 0.05,
** = p < 0.01, *** = p < 0.001).
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Referring to Figure 3.14
Figure S9: NK and NKT cells from Batf3-/- mice produced significantly more granzyme B after PbA-
infection than infected WT mice. NK and NKT cells from all experimental groups (n=3-5; 3 and 6 dpi for
PbA-infected mice) were sorted via MACS sorting after labeling with magnetically labeled beads coupled to DX-5
antibody. Sorted cells were incubated with IL-2 and BMDCs from naive WT donor mice that were cultured with
GM-CSF for a week prior to the experiment. A pooled sample of DX-5 sorted cells on BMDCs without IL-2 was
used as simulation control. Supernatant was collected the next day and subjected to sandwich-ELISAs for granzyme
B (A) and IFNγ (B). Values are presented as mean ± SEM. Differences were tested with ANOVA followed by the
Tukey post-test; p values below 0.05 were considered significant (* = p < 0.05, ** = p < 0.01, *** = p < 0.001).
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Referring to Figure 3.15
Figure S10: NKT cells from Batf3-/- mice did not produce more IFNγ or granzyme B after PbA-
infection than infected WT mice. NKT cells from spleens of PbA-infected and naive mice of WT and Batf3-/-
strains (n=3-5) were defined as described before. Cells were then analyzed via flow cytometry for intracellular
cytokines IFNgγ (A) and granzyme B (B) and surface markers ICAM-1 (C) and CD107a (D). Values are presented
as mean ± SEM. Differences were tested with ANOVA followed by the Tukey post-test; p values below 0.05 were
considered significant (* = p < 0.05, ** = p < 0.01, *** = p < 0.001).
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Referring to Figure 3.16
Figure S11: Dendritic cell numbers decreased in spleens of PbA-infected WT and Batf3-/- mice. Spleens
of d+3 and d+6 PbA-infected WT and Batf3-/- mice and their respective naive controls were processed for FACS
staining (n=3-6). A: Dendritic cells were defined as CD11c+I-Ab+ from CD3−NK1.1−B220− cells. Dendritic cells
were further subdivided into XCR1+ DCs (B) and CD4+ DCs (C). Values are presented as mean ± SEM. Differences
were tested with ANOVA followed by the Tukey post-test; p values below 0.05 were considered significant (* =
p < 0.05, ** = p < 0.01, *** = p < 0.001).
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Referring to Figure 3.17
Figure S12: CD40 was increased on splenic DCs in d+6 PbA-infected Batf3-/- mice. CD4+ dendritic
cells that were identified from spleens of d+3 and d+6 PbA-infected Batf3-/- and WT mice and their respective
uninfected controls (Fig. 3.16), were analyzed for expression of surface marker CD40 (A), CD80/CD86 (B) and
CCR7 (C, 6 dpi only) by flow cytometry (n=3-6). Values are presented as mean ± SEM. Differences were tested
with ANOVA followed by the Tukey post-test; p values below 0.05 were considered significant (* = p < 0.05, ** =
p < 0.01, *** = p < 0.001).
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Referring to Figure 3.18
Figure S13: Inflammatory monocytes were not increased in Batf3-/- but in WT mice on dpi 3. Spleens of
PbA-infected (3 and 6 dpi) and naive WT and Batf3-/- mice (n=3-6) were analyzed for CD11b+ cells by FACS (A),
after exclusion of other cell subsets and further differentiated into neutrophils (Ly6C+Ly6G+, B), Ly6C+ monocytes
(Ly6C+Ly6G−, C) or macrophages (Ly6C−Ly6G−, D). Values are presented as mean ± SEM. Differences were
tested with ANOVA followed by the Tukey post-test; p values below 0.05 were considered significant (* = p < 0.05,
** = p < 0.01, *** = p < 0.001).
162
Referring to Figure 3.21
Figure S14: IL-10 and IL-6 production from splenic CD11b+ cells was increased in PbA-infected
Batf3-/- mice. WT and Batf3-/- mice were infected with PbA (n=3-5) and spleens were analyzed 3 and 6 days
later. Naive mice (n=3) served as controls. IL-10 was measured in supernatant of 24h incubated splenocyte culture
with whole spleen cell suspension (A). Results from are presented as mean (±SEM). All differences were tested
with ANOVA followed by the Tukey post-test; p values below 0.05 were considered significant (* = p < 0.05, ** =
p < 0.01, *** = p < 0.001).
Referring to Figure 3.22
Figure S15: The total amount of Tregs was increased in PbA-infected Batf3
-/- mice on 6 dpi. WT and
Batf3-/- mice were infected with PbA (n=3-6) and spleens were analyzed at 3 and 6 dpi. Naive mice (n=3-4) were
used as controls. A: T cells were identified via FACS as described before and CD4+ cells were analyzed via flow
cytometry for CD25 and FoxP3 double positive cells (Tregs). Fractions were calculated to present the percentage of
Tregs from all T cells. Results are presented as mean (±SEM). All differences were tested with ANOVA followed by
the Tukey post-test; p values below 0.05 were considered significant (* = p < 0.05, ** = p < 0.01, *** = p < 0.001).
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Referring to Chapter 3.1.5.7
Figure S16: PD-1 and CTLA-4 were increased in PbA-infected Batf3-/- mice on 6 dpi. WT and Batf3-/-
mice were infected with PbA (n=3-6) and spleens were analyzed at 3 and 6 dpi. Naive mice (n=3-4) were used as
controls. NK cells were identified as described before and analyzed for expression of PD-1 (A) and CTLA-4 (B) by
flow cytometry. Results are presented as mean (±SEM). All differences were tested with ANOVA followed by the
Tukey post-test; p values below 0.05 were considered significant (* = p < 0.05, ** = p < 0.01, *** = p < 0.001).
Referring to Figure 3.32
Figure S17: CD4+ T cells in the brain were less activated after doxycycline treatment. CD4+ T cells
from brains of doxycycline treated (PbA 1e6 + DOX), untreated (PbA 5e4) and naive animals (n=4) were analyzed
for different activation markers by flow cytometry. A: intracellular granzyme B staining, B: surface staining for
ICAM-1. Statistics were performed with ANOVA and Tukey post-test with p < 0.05 considered significant.
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